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SUMMARY
DHA extracted from tumour biopsies obtained from 14 women 
undergoing radical surgery for cervical cancer, from 10 women 
undergoing surgery for vulval cancer and from internally matched 
control tissue from the myometrium in 8 cases of cervical cancer 
and from abdominal skin in 2 cases of vulval cancer was examined 
for the presence of HSV-2, HPV-6, 11, 16 and 18 DHA using 
Southern blot transfer and DHA-DHA hybridisation.
Sequences homologous with the MTRII region of herpes simplex 
virus type 2 were detected in one of nine invasive cervical 
cancers and in one of ten invasive vulval cancers. Ho tumour or 
normal tissue showed evidence of hybridisation to HPV-6 or 11 DHA 
and HPV-18 DHA was detected in only 2 of 22 tumours tested.
HPV-16 DHA was detected in 10 of 14 cervical tumours and in 8 of 
10 vulval tumours. The copy number and integration patterns in 
individual tumours varied widely. HPV-16 DHA was also detected 
in 7 of 10 internally matched control tissue biopsies. In one 
case the integration pattern differed between tumour and control 
tissue. Long term follow up of patients demonstrated no 
prognostic significance in the presence or absence of viral DHA 
in either tumour or normal tissue.
These studies did not support a definitive role for HPV-16 in 
either cervical or vulval cancer.
To determine the function of viral DHA in these cancers, 
attempts were made using these and 14 other tumours to derive new 
continuous cell lines by a primary explant technique. These cell 
lines, where the state of viral DHA in the original tumour and in 
internally matched normal control tissue would be available, 
could be valuable model systems for examination of cell-viral 
interaction.
Two continuous cervical cell lines, designated Tu 22-1 and Tu 
22-2 were derived from a biopsy of a squamous cancer. These cell 
lines differed in their requirement for epidermal growth factor, 
their ability for anchorage independent growth, their production 
of #-HCG and in their cytogenetic characteristics although they
17
were morphologically indistinguishable. Both cell lines 
contained detectable HPV-16 DNA in a similar complex pattern.
The original tumour also contained HPV-16 DNA but internally 
matched control tissue for this tumour did not contain such DNA.
One new cell line, Tu 31, was derived from a squamous cancer of 
the vulva following passage through an athymic mouse. This cell 
line fulfilled the requirements of an established human cell 
line. Single insert HPV-16 DNA was detectable in this line. The 
original tumour biopsy also contained HPV-16 DNA but in a complex 
configuration. Low copy single insert HPV-16 DNA was present in 
internally matched normal tissue from this patient.
As it was clear from the DNA studies that the presence of viral 
DNA alone was not sufficient to explain malignant change, 
complementary clinical studies of pre-invasive cervical cancer 
were undertaken to establish which other factors might be 
involved.
A cross-sectional study of 200 women with cervical intra- 
epithelial neoplasia (CIN), 36 women with cervical HPV infection 
and 100 normal control women from the same geographical area as 
the DNA study, demonstrated a relative risk for CIN of 2,0 for 
ever use of oral contraceptives and 2.57 for cigarette smoking 
with a trend towards a dosage effect and a possible relationship 
between number of cigarettes smoked and severity of histological 
change. Previous exposure to human cytomegalovirus imparted a 
small risk (1.57) for CIN in this population. A smaller 
prospective study of women presenting with overt genital warts 
confirmed that smoking was associated with an increased risk of 
histological cervical abnormality but contained insufficient 
numbers to determine if any one factor was associated with 
progression following exposure to HPV infection.
These studies urge caution in the assumption that HPV infection 
plays a major role in lower genital tract cancer and emphasise 
that other factors may be as important. Aetiological factors 
implicated in cervical and vulval cancer are reviewed and the 
evidence for a role for HPV critically assessed.
18
CHAPTER 1
THE AETIOLOGY QF CERVTCAT, A TO VULVAL CAlfCKR 
Section 1 : Epldeniological considerations
The observation that cervical cancer might be related to sexual 
behaviour was first made by Rigoni-Stern in 1842 1. In a study 
of mortality records, he concluded that uterine cancer was found 
more often in married women than unmarried women, and that it was 
almost absent in certain orders of nuns. He also observed an 
inverse incidence relationship of cancer of the breast to cancer 
of the uterus in these groups. Although no differentiation 
between cervical and endometrial cancer was made, it is likely 
that records referred to clinically overt tumours, more likely to 
be cervical in origin. However little attention was paid to this 
epidemiological information at the time.
Much of the epidemiological work in the early years of this 
century examined the effect of social class and race on cervical 
cancer. Kennaway (1948) 2 reviewed the existing epidemiological 
information on carcinoma of the cervix, crediting Braithwaite in 
1909 as being amongst the first to document the relative rarity of 
cervical cancer in Jewish women. Other groups confirmed an 
approximately three fold difference in cervical cancer rates 
between Jewish and Gentile populations. Similar differences were 
evident between Moslem and Hindu women, irrespective of social 
class. There was much discussion but no conclusion on the role of 
ritual behaviour related to vaginal bleeding and circumcision as 
potential aetiological factors.
He credited Theilhaber in 1909 in Bavaria as the first to show 
a consistent social class gradient in cervical cancer, with only 
3.7% of a group of women with cervical cancer from the highest 
three social class groups. He also suggested that low social 
class conferred a poorer prognosis for each stage of cancer.
Later data from the Registrar General's standardised mortality 
ratios for cervical cancer in the period 1930-2, showed a clear
19
social class gradient in the incidence of cervical cancer in both 
the 35-65 and the over 65 age groups. Detailed studies from 
Denmark and the U.S. demonstrated similar social class gradients
Stocks (1955) proposed a possible male factor based on an 
analysis of social and geographical distributions.
In 1950, Gagnon e in Canada repeated Rigoni-Stern's study of the 
incidence of cervical cancer in nuns. In a survey of 13,000 nuns 
over a 20 year period there were no cases of cervical cancer. A 
further review of 140,000 pathology reports of malignant uterine 
tumours only identified 3 cases of cervical cancer as nuns. 
Independent confirmation of the paucity of cervical cancer in nuns 
was provided by two other large studies 
The first specific studies to examine sexual behaviour in women 
with cervical cancer appeared in the 1950s. Lombard and Potter 
(1950) using case control data, found a significant excess of 
divorced or separated women, women who had married under 20 years 
of age and who had had their last child whilst under 25 in the 
cervical cancer group. The large study by Vynder et al (1954) 9 
examined the effect of marriage in both U.S. and Indian 
populations. They found that multiple marriages, early age at 
first marriage and early age at first coitus were significant 
factors. The relative risk of cervical cancer was 1.9-2.2 if 
first coitus was under 19 with one marriage, but was 3.1-5.3 if 
more than 2 marriages, suggesting a risk both with early 
intercourse and with increasing numbers of partners. All racial 
differences were explainable by differences in age at coitus and 
remarriage rates though much was made of the differences in 
circumcision rates between the case and control groups, as this 
was thought to link with the findings in Jewish and Moslem 
populations. Similar findings implicating early age at 1st 
marriage and 1st coitus, frequency of marriage and extramarital 
relationships were demonstrated by many groups in different 
populations *-.■»«>— p^g effects of race and social class 
tended to be dependent on these differences in sexual behaviour
1 O . 12, 1 A
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The case for early onset of coital activity was conclusively 
shown in the work of Rotkin 1 In a series of case-control
studies specifically designed to examine early coitus, he found a 
highly significant association with coitus before 20 years. This 
association was much stronger than that of early age at 1st 
marriage, and applied in both invasive disease and in carcinoma- 
in-situ. In the later studies he demonstrated that the total 
number of partners operated as an independent risk variable in 
both invasive and pre-invasive disease. Terris et al (1967) 1 ° 
independently demonstrated the association with 1st coitus and 
with multiple partners.
Although Terris and Dolman ( 1960) 1 1 had suggested an effect of 
frequency of coitus, later studies by that group were unable to 
confirm this ie. Most other groups could not demonstrate such an 
effect 1 °' 1 s .
By the late 1960s it was clear that early coitus and coitus with 
multiple consorts were major aetiological risk factors in cervical 
cancer irrespective of race or geography. These factors applied 
equally to invasive cancer and carcinoma-in-situ 13 * 1 :zo.
There was possibly some protection afforded by barrier 
contraception 11-1 3 . 1 e although this was controversial 
Most workers had concluded that some transmissible factor was 
involved. Martin (1967) 1 “*■ summed up the qualities of any 
proposed agent. The carrier should be largely asymptomatic and 
carriage should be possible by both sexes. It should primarily be 
transmitted by coitus. There would be an interval between 
infection and malignancy. To this we might add that other 
extraneous factors might modify the course of the progression from 
infection to malignancy. The most likely early candidates were 
smegma and syphilis, despite the often conflicting data.
Section 2 : Early candidates for sexual transmission of cervical
cancer
Syphilis had long been linked with a range of cancers, in 
particular oral cancer. A number of workers, however, had noted
21
that, although the exact proportion of cervical cancer patients 
with positive serology varied, in general the rate was three times 
that of the overall cancer population (see Rojel 1953)21. In 
these studies there had been little attempt to control for any 
likely confounding variables such as social class or occupation, 
nevertheless, both Levin (1942):2:z and Lombard and Potter (1950) e 
had shown an excess of syphilitic cases over controls. Vynder et 
al (1954) 9 also indicated that syphilis might be a risk factor, 
but were unable to comment further due to the inadequacy of the 
data. Jones et al ( 1958) 10 demonstrated a small but 
significant difference in the seropositivity rates for syphilis 
between cases and controls. Rajel (1953);zl , using the Danish 
Cancer Registry, specifically investigated this problem. He found 
a positive diagnosis of syphilis in 13.2% of cervical cancer women 
and a rate of 4.1% in controls matched for age, domicile and 
social level. He also found an increase in the proportion of 
prostitutes in the cancer group, though not of sufficient 
magnitude to alter his original conclusions. The demonstration 
that the syphilis rates in prostitutes were the same, whether they 
had cancer of the cervix or not, led him to propose that it was a 
factor other than syphilis that was responsible for cervical 
cancer.
Terris and Dolman (1960) 1 1 were unable to demonstrate any 
differences in syphilis serology and later studies controlling for 
social class and coital behaviour, have conclusively shown that 
syphilis is not an independent risk factor in cervical cancer.
The case for smegma as a carcinogen in cervical cancer had as its 
base the rarity of the tumour in circumcised races such as Jews or 
Moslems. A number of the early studies, in particular Vynder et 
al (1954)s , suggested differences in circumcision practice in the 
partners of cervical cancer patients. Experimental work with mice 
2:3':2'A demonstrated that prolonged exposure to human smegma could 
produce cervical cancer in these animals at low rates. However a 
number of different tumour types were produced and much of the 
effect was thought to be due to chronic inflammatory damage. The 
difficulty in obtaining reliable data on the circumcision state of
22
partners made it difficult to sustain the theory. Dunn and Buell 
(IDS?))2®, using a questionnaire approach, were unable to 
demonstrate any differences in circumcision rates between cases 
and controls. Martin (1967)1 ■*, whilst admitting the presence of 
seeming low incidence groups, described a study of Jewish women 
with cervical cancer compared with Jewish controls. He found that 
the same variables of age at 1st coitus, age at 1st marriage, 
multiple partners and marital infidelity in either partner were 
significantly different between these 2 groups as they were in all 
non-Jewish studies. In the same year Abou-Daoud (19§7'):ZG’ in the 
Lebanon showed that the cervical cancer rates in Lebanese Moslem 
and Christian populations were the same and that the same coital 
and marital differences were present in cancer patients 
irrespective of religion or circumcision practice.
It therefore became necessary to examine the role of other 
sexually transmitted diseases in cervical cancer. In the early 
1970s genital infection with herpes simplex virus became a major 
problem and seemed to co-incide with the increasing recognition of 
pre-malignant cervical disease.
Section 3 : Sero-epidemiological evidence implicating Herpes 
simplex virus (HSY) in cervical cancer.
3.1 : Early studies
Although Lewis et al (1965);z:7' were unable to demonstrate 
differences in complement fixing antibodies to HSV in women with 
cervical cancer and age, race matched controls, the following year 
Maib and colleagues demonstrated that 10 of 32 women with 
cytological evidence of HSV infection had histological features of 
cervical preneoplastic disease. Since that time, numerous studies 
have demonstrated an excess of previous HSV-2 infection in women 
with cervical neoplastic disease compared with control women.
23
Rawls et al <1968) 23initially showed an Increase in 
seropositivity in women with invasive cervical cancer over age and 
race matched control women and confirmed this relationship in the 
following year 30 for invasive disease but not for preinvasive 
lesions. JTaib et al (1969) 31 extended their series of biopsy 
data on women with cytological evidence of HSV to study the timing 
of infection relative to the diagnosis of cervical disease. They 
could not demonstrate any temporal relationship between infection 
with HSV and subsequent cervical neoplasia and questioned whether 
the association between HSV was due to differences in sexual 
epidemiology or whether factors other than HSV were involved.
Nevertheless the next few years saw a large accumulation of 
retrospective case-control data which concluded that previous 
exposure to HSV-2 was significantly more common in women with 
cervical neoplasia than in matched control women 32-3B, Of the 
early studies, only Royston and Aurelian 33 made any attempt to 
control for differences in sexual behaviour. The data supported a 
role for HSV-2 in cervical carcinoma but they commented that 
equally it could represent an independent relationship of HSV-2 
and cervical cancer to promiscuity or preferential growth of HSV-2 
in pre-malignant or malignant tissue.
Other early work was less convincingly supportive 3e— Adam 
et al (1971) 33 matched new cases of invasive cervical cancer 
with controls matched for age, race, class, parity, age at 1st 
intercourse and age at 1st pregnancy. They demonstrated elegantly 
that if matching was done only for age, race and class, as in 
previous studies, then there was an increase in HSV-2 
seropositivity in the cancer group, but, if matching included the 
sexual parameters then there were no significant differences 
between the groups.
The first prospective study was reported in 1973 33, following 
871 women with serological, cytological or virological evidence of 
HSV-2 infection and 562 control women matched for age and race. 
There was a consistent excess of cervical cancer cases in the
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HSV-2 group compared with the controls. This study, though not 
controlling for sexual variables did suggest strongly that 
previous exposure to HSV-2 was a major risk factor in the 
subsequent development of cervical neoplasia.
Later case-control studies indicated that the risk imparted by 
HSV also applied to pre-invasive disease tfahmias et al
(1974) controlled for age at 1st coitus, age at 1st pregnancy, 
oral contraceptive usage and number of sexual partners. 70% of 
women with carcinoma-in-situ had evidence of previous HSV-2 
infection compared with 34.5% of matched controls. The relative 
risk of in-situ cancer in the studies of Thomas and Rawls (1978) 
‘*3 was 2.28 and there was an attempt to control for sexual 
behaviour.
It seemed that by the end of the 1970s reasonable evidence 
existed that women previously exposed to HSV-2 were at 
increased risk of all types of cervical neoplasia. However, there 
were three serious reservations. The first was that very little 
of the evidence was prospective in nature although what was 
available supported the hypothesis. The second was that the data 
in general was poorly controlled for those parameters of sexual 
behaviour which had clearly been esta blished in the previous 
decade. Many studies which did control for sexual parameters were 
inconclusive.
The other major problem concerned the basis of distinguishing 
seropositivity to HSV-2 from that of HSV-1, In the 1970s it was 
believed that only 5-10% of genital herpesvirus infection was due 
to HSV-1 AA. No specific antibodies existed for routine use and 
the diagnosis of HSV-2 infection relied on complex relationships 
and differential reactivity of human serum with antigen raised 
from both viral types (see ref 45). All relied on determination 
of 'cut-off* ratios. The commonest test was a microneutralisation 
technique. Basically a comparison was made between the ability of 
the patient's serum to neutralise HSV-1 and HSV-2. The theory was 
that women with HSV-1 antibodies would neutralise HSV-1 and to a 
large extent HSV-2 because of cross-reactivity of antibodies. The 
relative ratio of HSV titres would therefore be low. In
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women with HSV-2 antibodies then HSV-2 virus would be neutralised 
but as anti-HSV-2 antibody is much less cross-reactive with HSV-1 
then these women would neutralise a much lower titre of HSV-1.
The resulting ratio of neutralised titres would be high. By 
comparing the ratios a K value was determined. In vitro work 
determined a value above which the ratio indicated likely HSV-2 
infection (see refs 31, 33 and 36 for details about exact 
determination of 'cut-off' values ). Alteration in the K value 
chosen would alter the apparent incidence of HSV-2 infection in 
the populations studied. As this was a very non-specific assay, 
many urged caution in the interpretation of data 
It was therefore felt that more detailed prospective studies with 
appropriate controls remained to be carried out and that studies 
looking at specific herpesvirus products in women with cervical 
cancer might be more appropriate.
3.2 Recent population studies
Larger case control studies have been reported recently 
Graham et al (1982) used a specific radioimmunoassay of HSV-2 
antibody to study 187 cases of invasive cancer or CUT 3 and 130 
controls matched for the appropriate sexual parameters. They 
concluded that the group of women with low number of sexual 
partners were at increased risk if HSV-2 positive. However the 
data is unclear and could be interpreted as merely showing an 
increase in HSV-2 positivity with increasing numbers of partners. 
Rawls et al (1986) looked at infection with HSV-2 in cases and 
controls in a number of different populations and found variation 
in HSV-2 seropositivity. In their own data the relative risk 
attributable to prior HSV-2 infection was 1.38, compared with a 
relative risk of 1.21 for early age at 1st coitus and 1.33 for 
multiple sexual partners. This still suggested a role for HSV-2. 
Luthra et al (1987) described 7 year data in an Indian 
population. They used non-specific antibody tests but looked at 
650 cases and 606 controls. As this was a less promiscuous 
population, age at consumation of marriage was taken as the
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controllable sexual variable. The relative risk for CIB was 1.3 
and for invasive disease, 2.9, suggesting that exposure to HSV-2 
might be required for the progression of CIN to invasive disease.
The largest and most detailed epidemiological data are from Prague 
AS>—S1. This study involved the screening initially of a 
population to acquire groups of women who had disease at 
enrolment, who would acquire disease during the study, or who 
would remain disease free at 4 years. Different antibody tests 
were performed and different 'cut-off' values examined. Cases 
were compared with disease free women at 2 and 4 years. Matching 
was for demographic and all recognised sexual variables. Initial 
analysis of the data prior to commencing prospective evaluation 
and at the time of matching confirmed that age at 1st coitus and 
number of sexual partners were significantly different in women 
with CIS compared with demographically matched control women. 
Interestingly the proportion of women smoking more than 10 
cigarettes per day increased from 15.4% in the control women to 
37.4% in women with or developing ClJf 3. Smoking was therefore 
used as an additional control variable. ITo differences in oral 
contraceptive usage were demonstrable between the groups. In the 
main prospective study so no significant differences were found 
in seropositivity between women with CIB at enrolment and women 
remaining disease free at 4 years using 2 different 
microneutralisation cut-off values or using HSV-2 type-specific 
antibody. Similar results were obtained comparing women 
developing CIB with disease free women over the 4 year period.
This large population based study would seem to conclusively 
refute the hypothesis that prior exposure to HSV-2 increases the 
risk of cervical pre-invasive disease. Further evidence from 
Kremar et al (1986) analysed the rates of conversion to 
seropositivity in women developing CIB and those remaining disease 
free. Bo differences were found suggesting that seroconversion to 
HSV-2 was not associated with the subsequent development of CIB. 
This extensive study would seem to demonstrate no relationship 
between HSV-2 and CIB in a population.
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nevertheless, the most recent study of Kjaer et al (1988) 
examining the population incidence of different human 
papillomavirus (HPV) types in areas of high and low cervical 
cancer incidence, found no relationship between the rates of HPV 
types and the cervical cancer rates, but found that there were 
differences in the seropositivity rates to HSV-2 infection 
between the high and low areas.
The precise epidemiological relationship between HSV and 
cervical cancer still remains unclear.
Section 4 : Scientific basis for a role for herpes simplex virus 
in genital cancer
4.1 Oncogenic potential of herpes simplex virus
It is not disputed that HSV is an oncogenic virus under 
laboratory conditions, inactivation of the normal lytic cycle 
resulting in persistent infection, biochemical or morphological 
transformation.
Following the first report of the potential of HSV-2 to 
morphologically transform diploid cells in vitro in 1971 e2> 
using UV-irradiated HSV-2, further reports indicated cell 
transformation by HSV-2 subjected to photodynamic inactivation 
s-t, by high temperature or by temperature sensitive viral 
mutants at non-permissive temperature Transformation of
cell morphology and behaviour in all types was associated with 
HSV-2 antigen expression in the transformed cells and often 
detectable antibodies in the sera of tumour bearing animals. 
Similar transformation properties were found for HSV-1
G-fl. . SG , BG
There were differences between the two viral types. HSV-1 
transformed cells tended to be epithelioid and produce 
adenocarcinomas in animals whereas HSV-2 transformed cells 
were fibroblastoid and produced fibrosarcomas in animals
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To some extent this suggested different pathways or different 
target cell types,
4,2 Transforming regions of herpes simplex virus
Although transformation of rodent and human cells was achievable 
by both virus types if appropiately inactivated, the precise role 
of viral nucleic acid remained unclear as conflicting reports on 
the stability and reproducibility of retention of transforming 
viral sequences accumulated The proportion of viral DNA
retained and the copy number varied in differing cell lines and 
even in parallel passages of the same cell line GO, There was 
controversy over sequential loss of sequences in successive cell 
passages
In the late 1970s experiments using cloned DNA fragments 
demonstrated the ability of specific regions of HSV DNA to 
mediate morphological transformation.
A single region of HSV-1 appeared to be associated with 
morphological transformation. Cloned DNA fragments from the Xbal 
f region (map units 0.29-0.45) and from the Bglll i region 
(0.311-0.415) of HSV-1 result in morphological
transformation. This region of HSV-1 was termed the MTRI region. 
The situation in HSV-2 was more complex. Two separate regions 
were identified as having transforming ability. The MTRII region 
was described by a number of groups as being associated
with the induction of morphological transformation. This region 
mapped within the Bglll n fragment (0.58-0.62). A second area 
within the Bglll c region (0.42-0.58) of HSV-2 also appeared to 
result in immortalisation of cultured cells e-7'-e-& . The 
conflicting data on transforming regions was studied by Jariwalla 
et al (1983) who found that the Bglll n region did not confer 
the ability to grow in long term culture using a serial passage 
assay; the Bglll c region did. Detailed analysis of subclones of 
the region suggested that the region 0.419-0.525 caused escape 
from senescence and that the region 0.525-0.585 was required for 
the tumorigenic state. These sequences were stably retained.
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Interestingly, the region 0.419-0.525 was homologous both to 
normal human DNA sequences which cross-hybridise with HSV DNA and 
with the transforming region of CMV type Towne (see below).
DNA fragments used to induce morphological transformation were 
however not necessarily retained in transformed cells 
Where these were retained, the pattern and amount varied widely 
and sequences could be lost by successive passage es.
The other major puzzle was that fragments of viral DNA too small 
to code for a transforming polypeptide were capable of initiating 
morphological transformation :7°»:;ri.
4.3.Herpes simplex expression in transformed cells.
Early studies using intact inactivated HSV-1 or 2 to transform 
cells in vitro consistently demonstrated detectable 
immunofluorescent antigen in transformed cells using antibody 
raised against infected cells Many of the cell
lines which produced tumours in susceptible rodents produced a 
neutralising antibody response to HSV. This demonstration of 
apparent viral expression in transformed cells gave support to 
the argument that the virus and its expression were part of the 
transformation process.
The majority of polypeptides coding within known transforming 
fragments were structural proteins and unlikely candidates for a 
transforming function e31 * . Subsequent analysis of a
number of transformed cell lines could not demonstrate any viral 
specific polypeptides ee. Antibodies raised against a 
polypeptide derived by in vitro translation from the MTRII region 
did not detect this polypeptide in cells transformed by this 
region
The most attractive candidate polypeptide was ribonucleotide 
reductase, consisting of two subunits, Vmwl40 (ICP10) and Vmw38 
The large subunit corresponded to AG4, described in human 
cervical carcinomas by Aurelian et al (1980) 7-e. The small 
subunit was completely encoded within the MTRI I region '7'7. The 
large subunit was mostly encoded by the Bglll c region with the
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carboxy terminus in the Bglll n region. However transformation 
experiments using DNA fragments from the MTRII region have failed 
to detect ribonucleotide reductase activity The small
fragments used by Galloway et al (1983) and Jones et al 
(1986) could not code for any complete subunit. Enzyme 
activity was detectable in cells transformed by the Bglll c 
region & 7 r although most cells transformed by fragments from 
within this region did not have such activity.
An explanation for the apparent expression of viral polypeptides 
in transformed cells might lie in the fact that most antisera 
were raised from infected cells. There was convincing evidence 
using monoclonal antibodies to HSV polypeptides that the 
polypeptides identified in these experiments were not virus-coded 
(see ref.80). It would appear that specific cellular 
polypeptides were up-regulated in infected cells and that some of 
these continued to be expressed at high levels in transformed 
cells ei being falsely labelled as virus-specific.
4.4.Animal models
Some experimental evidence exists demonstrating that cervical 
cancer can be produced in animals by exposure to HSV 
Formalin or UV inactivated HSV introduced into the vagina of 
inbred C3H mice using soaked cotton plegets produced both 
cervical dysplasia and invasive disease There was a
relatively long latent period before cytological or histological 
changes became apparent compared with similar experiments using 
chemical carcinogens. Prior immunisation of mice using HSV-1 or 
the HSV-2 subunit vaccine protected against the development of 
cancer
A major criticism of this elegant system was the preponderance 
of adenocarcinomas of the uterine body and cervix produced by 
exposure to HSV-2. Exposure to HSV-1 appeared to result largely 
in squamous tumours. In Man cervical carcinoma is predominantly 
of squamous origin.
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In an attempt to more closely mimic the human system, Palmer et 
al (1976) demonstrated the Cebus monkeys responded to genital 
HSV infection in a manner close to humans. There was a very low 
incidence of spontaneous cervical cancer in this species and it 
seemed ideal for prospective exposure and follow up. Initial 
follow up demonstrated that 8 animals developed cervical atypia 
at a mean of 20 months post exposure and 13 developed cervical 
dyplasia at a mean of 38 months post-exposure.
4.5 Putative mechanisms for oncogenesis by herpes simplex virus
There is no doubt that specific areas of the HSV genome are 
capable of initiating morphological transformation and that 
resulting transformed cells are tumorigenic. It is also clear 
that viral DNA is not necessarily retained within such cells and 
it is unlikely that there is a specific viral-coded transforming 
protein. How then might HSV initiate such morphological change ?
To include the phenomenon of transformation by very small DNA 
fragments it has been proposed that some specific DNA sequence 
arrangement might in itself initiate transformation or that 
integration or recombination of viral and cellular DITA might 
alter cellular gene expression to initiate change. Galloway et 
al (1984) proposed that the 737bp sequence found to be 
capable of morphological transformation could form a small 
stem/loop structure. This resembled the P elements of Drosophila 
although it was not large enough to encode a transposition 
function. The structure did not conform to the description of an 
insertion sequence. Jones et al (1986) ~7"1 in their analysis of 
the small fragment, BamHI e, derived from the Bglll c region, 
suggested the presence of insertion sequence-like sequences. 
Computer analysis of insertion sequence-like structures in HSV-2 
demonstrated the presence of such sequences within both the 
transformation regions and in other regions of HSV DNA (see 
ref.80). The significance of such DNA structures is unclear. No 
such structures have been proposed for HSV-1.
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Morphological transformation might be achieved by alterations or 
disruptions in cellular control mechanisms by insertion of DNA 
sequences by homologous recombination. Homology between HSV-1 
and HSV-2 DNA and human DNA has been consistently demonstrated 
predominantly within inverted repeat regions. Such a 
mechanism remains theoretical.
Another possible mechanism by which HSV DNA could induce 
morphological transformation was by biological carcinogenesis.
It has been demonstrated that mutagenesis could be effected by 
infection with both HSV-1 and HSV-2 s*0 -31. This effect, thought 
to be the result of point mutations, was comparable to the 
effects of chemical carcinogens. Introduction of HSV-2 DNA alone 
produced a similar effect Shillitoe et al (1986) 33 have
demonstrated that the BamHI g fragment of HSV-1 (situated 
within the MTRI region) increased the rate of frameshift 
mutations in an experimental system. Many mutagens were also 
carcinogens.
Similarly, gene an^lification might be an essential component of 
oncogenic change (see ref.94). HSV could induce such gene 
amplification 3S. The degree of amplification seen was 
comparable with chemical carcinogens 3e. Most interestingly, 
both HSV-1 and HSV-2 induced amplification of integrated HPV-18 
sequences in cervical tumour derived cell lines 37r raising the 
possibility of interaction between these viruses at the molecular 
level.
An interesting possibility was that HSV infection could produce 
up-regulation of specific cellular polypeptides 31. In 
transformed cells this up-regulation was maintained. If such 
changes occur in vivo, then cells could be altered in such a way 
as to make them more susceptible to later insults (e.g.specific 
HPV infection, nitrosamines, hormonal milieu), moving them 
further down the pathway to permanent oncological change.
In complex, multistage carcinogenesis, it was clear that the 
presence or absence of detectable viral information in 
established cancer tissue might not necessarily reflect the role 
of that virus in the oncogenic process.
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Section 5 : Herpes simplex virus information in human cervical
cancer
5,1 Herpes specific polypeptides in human cervical cancer patients
Vork on human systems has taken a similar pattern, looking 
initially for HSV gene products, RITA and ultimately DJFA in 
cervical tumour tissue and sera of cancer patients.
Initial studies identified a number of polypeptides in cervical 
cancer subjects using antibodies raised in infected cells 
101 . It is likely that some of these may be up-regulated 
cellular polypeptides equivalent to those found in transformed 
cells (see ref.80).
The antigen described by Aurelian's group, initially called Ag- 
4, is known to be equivalent to ICP 10 (Vmwl40), the large subunit 
of ribonucleotide reductase and has been extensively studied 7'& .
In cervical cancer patients the rate of seropositivity appeared to 
be related to disease severity. It was shown to be present in 
7.4% of treated cancers of the cervix and in 96% of recurrences 
but was also present in 7.7% of other cancers and in 11% of normal 
women 10:z. The proportion of positive sera decreased with 
increasing stage of cancer. In this regard it behaved much like a 
number of specific tumour markers. Its expression in transformed 
cells including those transformed by the Bglll c transforming 
region was controversial as ribonucleotide reductase activity has 
been detected in cells transformed by part of the Bglll c region 
incapable of coding for the entire subunit It would appear
that a HSV coded polypeptide was expressed in cancer cells and 
sera.
Other early antigens studied such as the HSV-TAA of Holinshead 
and associates 5,3 were present in a range of squamous tumours and 
in normal tissue 10:2 whereas others derived from infected cells 
reacted strongly with exfoliated cervical cancer cells, but the
34
difference was quantitative with high positivity rates in normal 
tissue 1 0 0 ' 1 0 1  .
Later studies used more specific antisera 1 0:3- 1 oe. 
Immunocytochemical staining of dysplastic but not normal cells in 
biopsies of premalignant cervical tissue occurred using antibodies 
to purified ICP 12 and 14 polypeptides 10:3, The DJfA binding 
protein VP 143 was demonstrable in biopsies from premalignant and 
malignant tissue and the staining appeared to be related
to disease severity. Dreesman's study 1OA also implicated the 
DBA binding protein ICSP 34/35. Using immunoprecipitation of 
control and cancer sera, Gilman et al (1981) 1 oe identified two 
polypeptides of molecular weights 38K and 118K precipitated more 
frequently from cancer than control sera which were col inear with 
polypeptides precipitated from HSV infected cells. This study 
attempted to control for previous exposure and other 
epidemiological variables. A 35K polypeptide indistinguishable 
from that found in transformed cells was identifiable in the human 
cervical carcinoma cell line C4II 10:?F.
Whilst these data were supportive of HSV expression in cervical 
cancer tissue, such expression might indicate growth advantage 
rather than direct involvement of HSV polypeptides in the 
initiaton and maintainance of morphological change.
5.2 Herpes specific RBA in cervical tumour tissue
McDougall et al (1980) 1 oe initially described the detection of 
HSV homologous RBA in biopsies of cervical carcinoma using 
radiolabelled DBA-mRBA in situ hybridisation. In the initial work 
25 of 61 biopsies of intra-epithelial neoplasia showed positive 
grain counts in a proportion of cells compared with 4 of 75 normal 
control biopsies. They could detect no hybridisation with human 
DBA, or with rodent or human cultured cells. Positive 
hybridisation was obtained in HSV infected cells and in HSV 
transformed cells. Analysis of the biopsies indicated that 
hybridisation was confined to the dyplastic cells. The same group 
1 oe used cloned HSV-2 DBA probes with variable results. Map
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regions 0.07-0.40, 0.58-0.63 and 0.82-0.85 all showed increasing 
grain counts in pre-invasive and invasive tissue compared with 
normal cervical tissue. However this was a clear qualitative 
difference and the proportion of cells positive by each probe 
varied from 8-30% for tumour tissue and from 2-8% for normal 
tissue.
Eglin et al (1981) 1 os* attempted to quantitate positivity using 
automated grain counting and also used normal internal control 
tissue in some cases. THey demonstrated a highly significant 
increase in grain count in pre-invasive and invasive tissue 
compared with normal control tissue and this was confirmed on 
comparison of neoplastic and non-neoplastic tissue from the same 
patients. Again direct examination of fixed tissue suggested that 
grains were situated in dysplastic cells. This group 110 also 
examined cloned DNA probes. Significantly increased grain counts 
were seen for the regions 0.07-0.11, 0.27-0.52 for CIN; and 0.07- 
0.21, 0.27-0.4, 0.85-0.87 and 0.93-0.98 for invasive cancer. No 
two individual biopsies produced the same pattern of in situ 
hybridisation with these probes and the MTRII region did not seem 
to be transcribed in any significant way.
Further doubt on the relevance of the initial findings was placed 
by Maitland et al (1981) 1 1 1. They used a similar DNA-mRNA in 
situ hybridisation technique and tested extensively for specious 
hybridisation to human DNA. They found 1.5% homology between 
adenovirus 2 and human placental DNA, and homology between the 
cloned HSV-2 DNA regions 0-0.05, 0.75-0.85 and 0.95-1.0 and normal 
human placental RNA. In formal in situ experiments using CIN 
tissue, there was 7% non-specific hybridisation to phage X, 39% 
hybridisation to adenovirus 2, and 67% hybridisation to HSV-2.
The mean grain count was always higher for HSV-2 but all Ad2 
positive biopsies were HSV-2 positive and examination of the 
stained sections indicated that it was the same cells or areas 
which were stained by both. They suggested that the finding of 
HSV-specific RNA in tissue biopsies was far from clear cut and 
suggested that hybridisation might be an unrelated phenomenon 
determined by the rate at which cells were dividing. This
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conclusion was reinforced by Eizuru et al (lQbS)112 who showed a 
similar qualitative difference in grain counts between normal and 
tumor tissue but who concluded that it was not possible to 
distinguish between non-specific binding to human RITA and HSV-2 
specific binding.
These findings would be consistent with the homology between HSV 
and human cellular DITA .
5.3 Herpes simplex virus homologous DNA in cervical tumour tissue
The most convincing evidence relating HSV to genital cancer would 
be the identification of HSV DNA from the known transforming 
regions in large numbers of tumours.
Frenkel et al (1975) 11:3 first described the identification of 
HSV homologous DNA in DNA extracted from a cervical tumour, 
demonstrating the presence of a complex fragment probably 
representing 39% of the viral genome at a copy number of 1-3.5 per 
diploid cell. This DNA seemed to be transcribed and HSV 
homologous RNA equivalent to 5% of viral transcripts from early 
infected cells was detectable,
Two subsequent studies 1 1 * 1 1 s looking at a total of 40
invasive tumours were unable to detect viral DNA. The study of 
Pagano 1 1 s stated a sensitivity of 0.125-0.25 genome copies per 
cell.
Using Southern blot transfer and DNA-DNA hybridisation 
techniques, Park et al (1983) 1 1 e identified the MTRII region, 
Bglll n ( 0.582-0.63) in one of nine invasive cervical carcinomas. 
This tumour was a cervical adenocarcinoma. Similarly, Galloway 
and McDougall (1983) demonstrated viral DNA in three of nine 
invasive tumours, again 2 of these were adenocarcinomas. In their 
study, the MTRII region was seen in one tumour, the Bglll j region 
(0.32-0.38) in one and one tumour had both DNA fragments. This 
study convincingly demonstrated the presence of viral DNA by the 
presence of known restriction enzyme sites and by the presence of 
fragments of definitive size. In a slightly larger study, Prakash 
et al (1986) 1 1 ~z found the Bglll j fragment in 2 of 13 invasive
37
cervical cancers and in 1 of 12 normal control DNAs. Rotola et al
(1986) 110 identified the Bglll n fragment in five of 69 cervical 
tumours although Manservigi et al (1986) 113 in a similar Italian 
population were unable to detect HSV DNA in cervical tumour 
biopsies. Macnab et al (1985) 120 demonstrated the presence of 
sequences homologous to the MTRII region in 1 of 15 squamous 
cervical cancers examined.
Although infrequently demonstrated, the consistent finding is of 
DNA from the MTRII region in DNA from a minority of tumours. The 
paucity of HSV DNA clearly militates against a major role, but as 
discussed in the previous section, HSV DNA is rarely retained in 
transformed cells clearly initiated by transfection with HSV DNA. 
Failure to demonstrate viral DNA does not rule out a role for HSV 
in cervical cancer.
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Section 6 : Scientific basis for a role for human papillomavirus 
in human genital cancer
6.1. Human papillomavirus as a sexually transmissable disease
The difficulties and controversies surrounding proof of a role 
for HSV in cervical cancer led to the extension of the search for 
an infective aetiological agent to another common genital 
infection, genital wart virus infection.
Genital warts are a very ancient disease, being recognised in 
Greco-Roman times. Initially genital warts were linked with other 
venereal diseases such as syphilis, and subsequently with 
gonorrhoea. It was believed that they were caused by vaginal 
discharge, poor hygiene and dirt. Vaelsch (1917) 121 first 
demonstrated transmission of warts by inoculation of human 
volunteers with unfiltered penile condylomata. Typical warty 
lesions developed in 3 to 9 months. Kegra (1924) 122 inoculated 
filtered penile condylomata material into volunteers. One 
volunteer developed a wart like lesion after 5 months.
Despite the long association with sexual activity, it took until 
1954 to conclusively demonstrate that human genital warts could be 
transmitted venereally in studies of servicemen returning
from the Korean war, having acquired penile warts. Vulvar warts 
developed at between 4 and 6 weeks after resumption of regular 
sexual intercourse with their partners. Particles similar to 
those identified in common hand and plantar warts were first 
identified in genital warts by Dunn and Ogilvie (1968) 12Jt.
Initial characterisation of HPVs was based on isolation of 
particles from clinical warts 1 2Ei or selective DNA extraction 
it was clear from the outset that different clinical 
lesions probably contained different viral types 12G. Rone of 
the common wart types seemed present in genital warts '2~z,
Gissman and zur Hausen ( 1980) 12& were able to isolate 
appropriately sized DHA from genital warts and demonstrate
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hybridisation with DNAs extracted from other non-genital warts. 
Restriction enzyme digest indicated that this was a different HPV 
type, designated HPV-6.
Nevertheless, detailed work on the virus was hampered by the 
small and variable quantities of virus or viral DNA obtainable 
from clinical samples until Israel et al (1979) 12:£> described a 
reproducible method of producing large quantities of viral DNA by 
cloning using E.coli plasmid vectors. Since then over 50 HPV 
types have been cloned and characterised.
It is not in doubt that these wart virus infections are 
venereally transmissible. The frequency with which genital wart 
virus infection was seen in sexually transmissible disease clinics 
rose dramatically in recent years. Recent specific studies 
demonstrating the transmission of particular papillomavirus types 
between infected sexual partners confirmed sexual transmission at 
the molecular level 1 3 0 • 1 31 .
Molecular biological methods have allowed detailed examination of 
viral DNA and viral products in vitro. More standard virological 
approaches to papillomaviruses remained hampered by the lack of a 
suitable in vitro culture system for propagating infectious virus. 
This was largely due to the fact that full expression of viral 
function only occurred in fully differentiated squamous epithelial 
cells. Productive viral DNA replication, capsid antigen 
production, and particle formation with full expression of late 
viral genes only occurred in the fully differentiated cells of the 
wart i.e. in cells either undergoing or which have undergone 
keratinisation. Vegetative DNA replication occurred in the cells 
of the stratum spinosum and granular layer of the epidermis.
Capsid protein production and virus particle assembly occurred in 
the upper stratum spinosum and in the granular layer where the 
cells were terminally differentiated. These functions were not 
detected in the basal layer epithelial cells. It was thought that 
viral DNA was present in these cells and that specific viral gene 
expression was responsible for cell proliferation characteristic 
of a papilloma. The factors controlling the changes to allow 
gradual onset of productive viral replication as the epithelial
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cells migrate through the epithelial layers are not yet 
understood.
Cells grown from papillomata appeared normal morphologically. 
Infectious virus was not produced. Initial attempts to insert 
viral genomes into normal cells were largely
unsuccessful. Viral genomes could be maintained in a vegetative 
state and there was some evidence of low level transcription 133. 
Many of the problems in successfully establishing tissue cell 
lines with infectious virus were outlined by Taichman et al (1984) 
13lA. Recently a system by which infectious HPV-11 could be 
propagated in vivo, allowing more detailed direct analysis of the 
intact functioning virion has been constructed 13S. Analysis of 
the attempts to transform rodent and human cells with HPV DNA will 
be discussed separately.
Characterisation of viral types was therefore made on the 
relationships a papillomaviral DNA has with other known types. 
Viral DNA should be in the size range of 7 to 8 kilobase pairs, 
persist in tissue as extrachromosomal circularly closed DNA, show 
partial sequence homology with other papillomavirus DNAs and have 
a genomic organisation comparable with other papillomaviruses. 
Viral DNAs were considered to be independent types if they showed 
less than 50% cross hybridisation with other types using 
reassociation kinetics of heterologous DNAs in the liquid phase. 
Values obtained did not necessarily represent sequence homology at 
the DNA level. Sequence analysis has shown that a high level of 
sequence homology could exist within conserved regions even 
between viruses which showed no cross hybridisation under 
stringent conditions. Viral types were grouped according to their 
cross hybridisation characteristics.
6.2 Oncogenic potential of papillomaviruses
Papillomaviruses are capable of inducing benign tumours in a wide 
range of animal species following infection of basal keratinocytes 
13&. A number of these benign papillomata will undergo malignant 
change in response to varying cofactors The most widely
41
studied animal papillomaviruses are the cottontail rabbit 
papillomavirus (CRPV) and bovine papillomavirus (BPV).
The ability of rabbit papillomas when experimentally transferred 
to undergo malignant change has been known since the 1930s 1=as. 
There appeared to be a lag or critical period following infection 
before the development of carcinomas and a number of chemical 
carcinogens could accelerate the rate and extent of malignant 
transformation Viral DNA was present in malignant tumours
and was maintained over a long time period in transplantable 
carcinoma lines 1 A°.
BPV was associated with tumours of the alimentary tract and 
bladder. In the U.K. approximately one half of all cattle will 
have tumours associated with BPV. Six different types of BPV have 
been identified subclassified into two major groups:- BPV-1,
2, and 5, which formed mixed fibropapillomata and could transform 
both epithelial and fibroblastic cells in vitro; and BPV-3, 4, and 
6, which formed squamous papillomata only and transformed only 
epithelial cells. BPV-2 and 4 have been associated with 
alimentary and bladder cancer in cattle. The association between 
BPV-4 and alimentary cancer is complex. Viral DNA was present at 
high copy number in benign papillomas yet was absent from invasive 
lesions 1A;2. Malignant change was dependent on environmental 
chemical cofactors, associated with a particular type of bracken 
and likely to involve naturally occurring immunosuppressants 
1 • 1 Analysis of both naturally occuring and experimental
bladder cancers showed the presence of multiple copies of BPV-2 
DNA 1 The finding of BPV-2 in the experimentally induced
cancers was interesting as only BPV-4 was inoculated into these 
animals. It remained unclear whether the virus was directly 
associated or whether malignant bladder epithelium was merely 
permissive to viral DNA replication.
There was a human model for considering HPV as an aetiological 
agent in genital cancer, the rare skin disease epidermodysplasia 
verruciformis (EV). First described in 1922, it consisted of 
disseminated flat warty lesions and red, pigmented, or achromic
42
macules. Lesions were usually multiple. In about one-third of 
individuals squamous carcinoma developed, normally at multiple 
sites and in the third or fourth decade of life. The disease had 
a strong genetic component, with more than one sib affected in 10% 
of families, and with consanguineous parents in 10% of cases.
Most affected individuals have impairment of cell mediated 
immunity. Ultraviolet light was also thought to play a 
significant role, as most lesions developed at sun exposed sites.
A number of papillomaviral types have been isolated from benign 
lesions 1Ae, and except for types 3 and 10, all appeared to be 
associated exclusively with EV 1AG. The most common types 
associated with EV were 5, 8, 17, and 20.
The onset of bowenoid carcinoma-in-situ or frank invasive 
squamous carcinoma occurred about 25 years after the initial onset 
of the benign lesions. Mot all HPV types found in benign lesions 
were identified in malignant tissue. HPV-5 was frequently 
associated with skin malignancy * HPV types 3, 8, 14, 17,
20 and 24 were identified in invasive lesions 1 1 1
DMA was present in high copy number (100 to 300) and there was 
some evidence of vegetative DMA replication in some tumours 
-i-*.<=». i e o t HPV types 5 and 8 were present as free monomers or 
oligomers but HPV-14b was probably integrated into cellular DMA. 
HPV-5 and 8 could contain small deletions
transcripts from the E6/E7 open reading frames (ORFs) have been 
identified in HPV-5 containing tumours 1 
EV is an excellent model to study the role of HPV in 
carcinogenesis in man. It involves interaction between virus, 
genetic predisposition, and immunocompetence. The virus type 
seems to be important, potentially analagous with its proposed 
role in genital cancer. There is a long latent time between 
primary lesion and malignant change suggesting a multistage 
process through benign to premalignant to invasive disease. Many 
factors may therefore be involved at different stages. UV light 
exposure is one such important external factor.
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6.3 Transformation system of bovine papillomavirus type 1
The mechanisms by which papillomaviruses are capable of inducing 
morphological transformation are best understood in BPV 1-rodent 
cell systems. BPV-1 was associated with benign cutaneous 
fibropapillomas in cattle but would induce fibroblastic tumours in 
a variety of foreign hosts 13e\
Its genomic organisation and the putative functions of the viral 
genes are shown in Fig.1
BPV-1 was initially shown to transform mouse cells in culture in 
1964 1S:Z. Morphological transformation of rodent cells by BPV-1 
was complex and appeared to be dependent on interactions between 
two physically separate areas of the viral genome. Transformation 
experiments involving cloned BPV-1 DMA fragments mapped 
transforming ability to the E5 region 1 s:3 and to the E6 region 
These regions could achieve morphological 
transformation individually 1 It appeared that mutations
affecting each of these regions had different effects on the 
transformation process. Mutations in the E5 region had a marked 
effect on the efficiency of transformation An intact E6/7
region was necessary to allow efficient tumorigenicity and 
anchorage independent growth One further ORF was involved
in the transformed phenotype, E2. This ORF had no transforming 
ability in isolation. Mutations at the 5' portion of this ORF 
resulted in a marked decrease in the efficiency of focus formation 
of transformed cells compared with those transformed by the intact 
BPV-1 genome 1EA. It was now clear that the E2 gene codes for a 
trans-acting factor which was required for initiation and 
maintainance of transformation and normal viral DMA replication
This polypeptide binded to specific sites in the ncr region 
and elsewhere, acting as a transcriptional activator There
was direct evidence that the E2 gene product was required for 
efficient expression of the E5 transforming gene The system
was complex, requiring trans-acting E2, a cis-acting ncr region 
which behaved as a transcriptional enhancer and a functional 
promoter.
6.3a Genomic organisation and gene function in HPV
The genomic organisation of HPV is similar to that of BPV-1. There 
is overlap between GRFs El and E2, and between LI and L2. The ORF E4 is 
included within the segment encoding the E2 gene product. The region 
between E2 and L2 is longer in genital papillomaviruses, altering the 
characteristics of the E5 gene product. The ncr region is shorter than 
in BPV-1.
Sequence analysis ~ 4* reveals a number of common characteristics 
amongst genital HPVs. These include a longer El ORF ( by 40 amino- 
acids>, the position of the E7 ORF immediately in front of El, a 
specific coding segment in the control region and a particular structure 
to the promoter region upstream from E6. Phylogenetically, HPV-6 and 11 
are closely related, with 58 - 92% amino-acid sequence homology, most 
marked in the E6/7, El, and Ll/2 regions. HPV-16 is more distantly 
related, the overall amino-acid homology being 25 - 69%. HPV-16 is more 
closely related to HPV-33 (see page 54). HPV-18 appears to link the two 
groups, with DMA sequence homology of 40 - 60% with HPV-6/11 and 50 - 
67% with HPV-16/33,
As in BPV-1, ORFs LI and L2 code for the major and minor capsid 
antigens. ORF El is involved in episomal DMA replication; the 3' end 
coding for a function involved in transient replication and the 5' end 
having a role as a negative modulator of viral replication®*. The ORF 
E2 has a transcriptional regulatory function e*. Full length E2 protein 
acts as a trans-activator; the carboxy terminal acts as a downstream 
repressor. Both bind directly to viral DMA and supress E6/E7 
transcription. The function of the E4 ORF is poorly understood. It may 
have a role in the onset of vegetative viral replication and may 
therefore interact with cellular functions to alter the pathway of 
differentiation to favour viral replication.
The E7 ORF, as discussed in 6.4, is capable of inducing 
morphological transformation. The protein demonstrates homology to 
adenovirus Ela polypeptide and other oncogene products 7’*, especially in 
the domains implicated in the induction of cellular DMA synthesis, 
cooperation with the ras oncogene for full oncogenic transformation and 
repression of transcription. It is a powerful trans-activator and, like 
the Ela polypeptide, binds to the retinoblastoma gene product s*. Its 
function may be to antagonise cell proteins, such as the retinoblastoma 
gene product, which may constrain cell proliferation.
44
Both ORFs implicated in transformation appeared to code for a
protein product. The E5 ORF was small and appeared to code for a
44 amino-acid, very hydrophobic, membrane associated polypeptide
ieo. The polypeptide encoded by the E6 ORF was detected in both
nucleus and non-nuclear membrane and might have zinc binding sites 
1 61
The complexity of the BPV-1 transformation of rodent cells acted 
as a model against which transformation by other papillomaviruses 
could be compared.
6.4. Morphological transformation by human papillomavirus
Chesters and McCance (1985) 1 were unable to transform either 
NIH3T3 cells or BSC1 monkey kidney cells using HPV-16. However, 
Tsunokawa et al (1986) 1 initially demonstrated that HPV-16 
sequences, cloned from a cervical cancer, were capable of 
transforming NIH3T3 cells. HPV-16 DNA was present, integrated 
into cellular DMA, in the transformed cell lines and RNA 
transcripts which hybridised with HPV-16 DNA were identified in 
the lines. Yasumoto et al (1986) 1 were able to transform 3T3 
cells using a head-to-tail HPV-16 dimer. Six transfected lines 
were generated, all containing multiple copies of HPV-16 DNA, 
integrated into cellular DNA. Transformation efficiencies were 
much reduced compared with those achievable with BPV-1 and foci 
took considerably longer to evolve than in the bovine system, a 
phenomenon also noted by Morgan et al (1988) 1 in the 
transformation of mouse C127 cells. They noted that HPV-16 
transformed cells did not exhibit the morphological alterations 
characteristic of transformed foci. As in earlier studies, HPV-16 
DNA was integrated into cellular DNA at multiple sites in contrast 
to the episomal nature of BPV-1 in transformed cells. Complex 
integration patterns were maintained through successive passages 
and in derived nude mouse tumours. Tumorigenicity of transformed 
cells with HPV-16 could arise as a two stage event in 3T3 cells 
1&e\ Altered growth potential with expression of a wide range of 
viral transcripts was seen in initially transformed cells which
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were not tumorigenic in nude mice. Cells which became tumorigenic 
expressed quantitatively less viral RITA, although the E6 and E7 
transcripts remained the predominant species.
Primary rodent cells can be transformed by HPV-16 linked to the 
EJ-ras oncogene 1 e-3r to a fully transformed tumorigenic phenotype. 
This ability appeared to be linked to the E6/E7 ORF. Confirmation 
that transforming ability was restricted to this region came from 
Bedell et al (1987) 1 et3 using different cloned viral expression 
plasmids. Transformation was achievable using only the E6/7 
region in both 3T3 and Rat-1 cells. The transforming region was 
further limited by Kanda et al (1988) 1 es* who transformed rat 3Y1 
cells using only the E7 ORF. Cells were morphologically different 
and were anchorage independent but were not tumorigenic.
Rodent cells were therefore capable of oncogenic
transformation by HPV-16 although this was more difficult to 
achieve than using BPV. Transforming ability appeared to lie in 
the E6/7 ORF and possibly within the E7 ORF alone. In some 
instances, using primary cells, a fully oncogenic phenotype was 
not achieved.
Successful transformation of human cells has now been reported 
1:70-1 using similar techniques. A number of differences are 
apparent between rodent and human transformants. Use of HPV-16 in 
an appropriate vector resulted only in immortalisation of human 
fibroblasts and keratinocytes. These cells were not oncogenically 
transformed in the way which BPV-1 or HPV-16 transformed rodent 
cells were transformed. Viral transcripts were identifiable in 
transformed cells. The molecular weight of the major transcript 
was similar to that identified in cell lines transformed by 
Yasumoto et al (1987) 1 and considered by them to be the E6/7 
transcript. Using the oncogene EJ-ras linked to HPV-16, 
Matleshewski et al (1988) 1:7:2 did achieve transformation of 
primary fibroblasts to cells which were highly aneuploid and 
exhibited reduced serum growth requirements. The cells were not 
tumorigenic in immunocompromised rodents. These transformed cells 
expressed E6 polypeptide.
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The tissue specificity of the human papillomavirus group has made 
extrapolation of findings in rodent and non-genital keratinocytes 
to genital tumours difficult. Woodworth et al (1988) 1:73 have 
immortalised keratinocytes derived from human exocervical 
epithelium using both HPV-16 and 18. In the case of HPV-16, a 
head-to-tail dimer was used, and in the case of HPV-18, single 
copy DNA was used. Immortalised cells continued to produce 
keratins. Viral DNA was present in transformed cells, integrated 
at multiple sites in the cellular genome, both as intact DNA and 
as rearranged DNA. This multiple integration arrangement occurred 
in the cell line derived from a single colony. HPV transcripts 
have been identified, including that associated with the E6/7 ORFs 
in transformed rodent lines. These cell lines did not produce 
tumours in nude mice demonstrating that the presence of integrated 
viral DNA and viral transcription did not alone confer a malignant 
phenotype on human cervical cells.
It is apparent from rodent, human non-genital and cervical 
epithelial transformation experiments that HPV-16 alone is not 
capable of inducing the full transformed phenotype. Co-operation 
with heterologous promoters is necessary even for immortalisation. 
Further co-operation with oncogenes may result in cells closer to 
a fully oncogenic phenotype, but other, as yet uncharacterised, 
extraneous factors must be involved in this complex multistep 
process. It is also clear that the system must differ from that 
of BPV, in that E5 and E2 ORFs are not involved in HPV mediated 
transformation. The story is further complicated by the finding 
that the E6 ORF of HPV-8, the putative oncogenic virus in EV, is 
alone sufficient to transform rodent cells 1 with E7 having 
perhaps a subsidiary role. Thus no two groups of 
papillomaviruses, despite their close genomic organisational 
similarities, appear to have the same major transforming region.
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Section 7 : Human papillomavirus in human genital cancer tissue
7.1 Cytological, histological and immunological evidence
The possibility of involvement of HPV in cervical cancer stemmed 
directly from the observations of Heisels and Fortin (1976) 1 
and Purola and Savia (1977) Independently, they described
epithelial changes in cytology and histology specimens of women 
reported to have cervical dysplasia identical to the cytological 
changes seen in condylomata acuminata. The most striking finding 
was of cells known as koilocytes, a term first used by Koss and 
Dufree (1956) 1'7:7. These cells were superficial or intermediate 
squamous cells with an enlarged, hyperchromatic nucleus, 
surrounded by a clear cytoplasmic halo. At the external margins 
of the halo, the cytoplasm was condensed and showed an ambophilic 
staining pattern. Cells could be bi- or multi-nucleated. These 
cells have been recognised for some time, and as early as 1960, it 
had been suggested that this type of cellular change might be a 
manifestation of viral infection.
The presence of papillomavirus particles and antigens in 
koilocytic cells has been confirmed by a number of ultrastructural 
17e'179 and immunohistochemical studies 1 e°— i&z. Initially in 
the absence of specific antigen for genital papillomaviruses, 
immunoperoxidase-Pap techniques using antisera raised against 
pooled plantar warts were used to identify expression of virion 
polypeptides in genital warts and in koilocytic cells. There was 
marked cross-reactivity amongst the capsid antigens of the 
different papillomavirus types (confirmed by the sequence 
conservation observed for the putative capsid protein in those 
papillomaviruses subjected to analysis thus far).
Both initial groups suggested that many women with ‘dysplasia’ 
probably had papillomavirus infection. Re-examination of cervical 
cytological and histological specimens indicated that a
high proportion of women with cervical intra-epithelial neoplasia
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had co-existent evidence of HPV infection. Since those initial 
reports, many have reported the co-existence of pre-malignant 
histological change and cytological and histological changes of 
HPV infection 1 The frequency with which HPV infection
was associated with CIN varies from 35-40% 1 to over 90% 1e” \ 
Viral capsid antigen expression has been demonstrated in areas of 
koilocytic change within all grades of CIN 1 e o • 1 1 3,2. Many
other studies did not specify precise histology when reporting 
antigen positivity in CIN, but antigen expression in CIN lesions 
without evidence of histological HPV infection was uncommon 13:z.
There is no controversy over the co-existence of HPV infection 
with pre-malignant cervical or vulval neoplasia. Whether this 
association is causal or reflects the sexual behaviour of this 
group of women remains in dispute.
7.2 Human papillomavirus DNA in cervical cancer tissue
Attention moved to trying to identify HPV DNA in genital cancer 
tissue and to determine the state of this DNA within the tumour 
cell.
Initial studies attempting to identify HPV types 6 and 11 were 
disappointing. Having established that the vast majority of 
genital warts contained HPV type 6 or 11 DNA, Gissman et al (1982, 
1983) 1 s:3 • 1 were unable to identify HPV-6 in any of 54 
invasive cervical cancers examined. Four of 24 cervical cancers ( 
invasive and carcinoma-in-situ) had evidence of HPV-11 DNA. Green 
et al (1982) 1 screened a number of genital tumours using a 
papillomaviral DNA derived from an EV lesion, HPV-10, and 
identified this DNA type in 2 of 31 invasive squamous cancers of 
the cervix.
In their screening of malignant tumours with HPV-11, Durst et 
al (1983) 1 identified DNA from one tumour biopsy which only 
hybridised under non-stringent conditions. Following isolation 
and cloning, stringent cross-hybridisation experiments with the 
available HPV types showed less than 0.1% hybridisation with all 
types except HPV-11, with which it demonstrated less than 50%
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hybridisation. This DNA was designated HPV-16. Eleven of 18 
invasive cervical cancers from Germany and 8 of 23 from Kenya and 
Brazil contained DNA homologous with HPV-16. Four of 29 
premalignant cervical lesions also contained HPV-16 type DNA.
Using stringent conditions, only 2 of 33 condylomata contained 
this DNA. This data opened the door to realistic speculation on 
the aetiological role of the papillomaviruses in invasive genital 
cancer.
The following year Boshart et (1984) in the same
laboratory, described a further HPV DNA isolated from malignant 
genital tissue. Hybridisation of this DNA with cloned DNA of 
other virus types revealed some relatedness with types 1-6 and 8- 
17 under low stringency conditions, with some hybridisation to 
HPV-2 even under high stringency. This new HPV DNA was designated 
HPV-18. The restriction digest data suggested a colinear DNA 
arrangement compatible with other HPVs. Analysis of tumour biopsy 
DNA indicated that 2 of 13 invasive cervical lesions from Germany 
and 9 of 36 tumours from Africa and Brazil contained homologous 
DNA to the new HPV-18. No condylomata contained HPV-18 homologous 
DNA.
A large number of studies then followed outlining the frequency 
with which HPV DNA was detectable in cervical neoplasia.
HP.V-.6/11 in cervical cancer
McCance et al (1983) 1590 extracted DNA from cervical biopsies 
from 22 women referred with abnormal cervical cytology, 19 of whom 
had histological abnormalities on directed colposcopic biopsy.
DNA homologous to HPV type 6 DNA was identifiable in 12 of these 
biopsies. Fifteen of the biopsies had histological evidence of 
papillomavirus infection and it could be inferred that viral DNA, 
detectable in 10 of these, was a result of active infection. 
However, 2 of 4 biopsies without histological evidence of HPV 
infection also had detectable HPV-6 DNA, including 1 case of CIN 
3. Crum and colleagues (1984) 1 examined 26 biopsy specimens 
from the cervix, all of which had Koilocytic atypia. Of the 13
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biopsies with evidence of condylomata, 5 had detectable HPV-6/11 
DFA and 1 had HPV 16-DFA. Of 10 biopsies with abnormal mitotic 
figures, identified by this group as being at high risk of 
progression, 7 had detectable HPV-16 D5A and none had HPV-6/11 
DM.
HPV-6/11 was rarely identified in invasive cervical cancer 
is»©.i3<=» was frequently identified in CIF 1 231 • 1
although HPV-6/11 was rarely identified in pre-malignant tissue 
from the Vest of Scotland :zos‘. The proportion of positive 
biopsies varied widely in the above studies and the frequency at 
which HPV-6 was detectable in CIF was generally higher in low 
grade CIF 1/2 biopsies than in CIF 3 1 31 * 200 • 201 • 2 0 ^- 2 0 ©
HPV-16 J.n-cgryical ..-cancar
HPV-16 was infrequently identified in genital warts 
117, 13! , 2 0 1  .2 0 s. 2 0 ©. 2 1 0 - 2 1  2  bu t was detectable in a high
proportion of both CIF and invasive cervical cancer.
The frequency at which HPV-16 homologous DFA was detectable in 
CIF was largely dependent on the grade of CIF; it was more 
frequently identified in CIF 3 1 31 * 2°i * • 21 3 • 21 "*■
although some studies did not demonstrate this =*<>2 . 2 0 & , 2 0 3 , 2 1  
The proportion of CIF biopsies having detectable HPV-16 DFA also 
varied geographically 19S.2°9 .
The precise significance of HPV-16 homologous DFA in CIF was 
unclear as many of these lesions had co-existing histological HPV 
infection (see ref.216). Although a number of studies gave data 
on the prevalence of actual HPV infection in their study 
populations 204,2o 5 12i7-22oj only in a few studies 
2 0 ©. 2 0 3 .2 1 © was possible to deduce that HPV-16 type D M  was 
present in the absence of active HPV infection.
More detailed information was available from in situ 
hybridisation studies. Crum et al (1986) 221 using biotinylated 
probes examined 10 cases of CIN, demonstrating, except for 2
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instances, positive hybridisation only in areas with evidence 
histologically of HPV infection. They concluded that 
extrachromosomal viral replication was preserved even within high 
grade CIN. Gupta et al (1987) 2:2:2 disputed this in a study of 
both CIN and VIN. Viral DNA localisation, if HPV-16, was within 
neoplastic cells. Schneider et al (1987) suggested that the
highest concentration of viral DNA was in areas of koilocytic 
atypia but that viral DNA content varied from cell to cell. Viral 
DNA was detectable in basal cells showing no histological evidence 
of viral infection. In CIN 3 biopsies,, viral DNA appeared to be 
uniformly distributed. This could reflect the inability of the 
virus to replicate in undifferentiated cells. From these studies 
it was not clear exactly where viral DNA resides within a given 
pre-neoplastic biopsy and there were data suggesting that the 
majority of viral DNA in these tissues might lie within 
recognisable infected cells. The assigment of an aetiological 
role for HPV in pre-invasive disease was not appropriate on this 
data alone.
Many groups have found that DNA extracted from squamous cervical 
cancer frequently contained DNA homologous to HPV-16 type DNA 
i * t . i 3 i , i 9 3 . 2 0 1  . 207, 2 o©. 3 . 22A-230 frequency with
which HPV-16 homologous DNA was detectable varies from 11% 2 0 2  to 
over 90% Z 0 1  . There appeared to be geographical differences in 
the prevalence of HPV-16 in invasive cancer. Studies from the 
U.K. generally reported high proportions of HPV-16 positive 
invasive lesions 2ro 1 . with 66-90% of invasive
tumours having detectable HPV-16 DNA. Reports from the U.S. 
tended to show intermediate levels of detection, around 40-60% 
i si . <=»<», isos. European studies showed a variable
proportion of positive tumours 1 » 1 * 2 0 7  * 2 1  ^  although the
rate of positivity was generally higher than in the U.S. The 
lowest rates of HPV-16 in cervical malignant disease were found in 
Japanese studies. Fukushima et al (1985) 2 0 : 2 only found 1 of 9 
invasive cancers contained HPV-16 homologous DNA. Other Japanese 
studies have confirmed similar low levels
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Interestingly, HPV-16 D M  was identified in 72% of cervical 
carcinoma samples from inland China 3 3 1  . Such geographical 
variation was evident in the initial report of HPV-16, with 
differences in the rates of HPV-16 identification evident between 
samples from Europe, Africa and Brazil 13JS. There was no 
relationship between HPV-16 rates and cancer incidence, elegantly 
demonstrated by Kjaer et al (1988)s:z in Scandinavian populations, 
and no obvious differences in tumour biology to account for the 
wide variety in detection rates.
HPV-16 type DNA was infrequently found in non-squamous cervical 
cancer. In those studies which describe the detailed histology 
HPV-16 DNA was detectable in only 9 of 27 such tumours 
1 , 2 0 2 ,217 ,2 2 s . 223 . 229. 2:32 0nly Tase et al (1988) 233
addressed the question directly. HPV-16 DNA was detectable in 
only 1 of 40 cases of adenocarcinoma of the cervix and in 8 of 44 
cases of adenosquamous carcinoma.
HPV-16 homologous DNA has been detected in secondary tumour 
deposits i *321 Lancaster et al (1986)
described 7 cases of squamous cervical cancer where pelvic lymph 
nodes were available for DNA analysis. In 6  of the 7, HPV DNA 
with a restriction enzyme profile identical to that of the HPV DNA 
found in the primary tumour was detected. Sutton et al (1987)
1 3 3  described one case where the tumour contained HPV DNA types 
6 , 16 and 18 and pelvic node contained HPV type 16 DNA. Six 
tumours were analysed in this way by Fuchs et al (1988):zo::;r. One
tumour contained both HPV- 6  and 16 DNA. The pelvic node also 
contained type 6  and 16 type DNA. All of the other 5 tumours and 
nodes contained HPV-16 DNA and in 3 where there was sufficient DNA 
for restriction enzyme analysis, the profiles were identical. In
Smotkin's study 2 3 2  ^ -^wo tumours positive for HPV-16 DNA had 
omental and pulmonary tumour deposits available for DNA analysis. 
Both contained HPV type 16 DNA.
The evidence supporting a role for HPV-16 in squamous cervical 
cancer is therefore substantial. It appears that this type is 
very frequently identified in high grade pre-invasive and invasive
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disease. It is identified in distant metastatic tissue suggesting 
that it is present within malignant cells.
HPV-18 in cervical cancer
In the initial report of Boshart et al (1985) 13e a much lesser 
proportion of cervical tumours contained HPV-18 homologous DM. 
This was generally confirmed by other studies.
Sutton et al (1987) 1 3 3  described HPV-18 homologous D M  as 
present in vulval warts and HPV-18 D M  was described in cervical 
wart virus infection without CIN peid eb al (1987) 1 3 1
and Schneider et al (1987) 2°e described genital warts which 
contained D M  homologous to a combined HPV-16/18 D M  probe,
HPV-18 was detected in CIN 2 0 ^- 2 0 3 .2 1 ^.2 2 © Toon et al <1 9 3 7 ) 
2 0 3  were unable to detect HPV-18 in 27 cases of CIN. No study 
using HPV-18 D M  as probe has described more than 20% of CIN 
biopsies positive for HPV-18. There did not appear to be the same 
relationship of increasing prevalence with increasing severity of 
CIN with HPV-18 as in HPV-16 2 o^. 2 0 0 . 2 1  
In most studies invasive squamous cancers contained HPV-18 
homologous DNA infrequently 1 3 3  * 207r * 22^ . 2 2 ^. 2 2 © Reid et al
(1987) 1 3 1  found this type in 25% of their tumours and 13 of 58 
invasive cancers examined by Kurman et al (1988) 20,31 contained 
HPV-18 DNA. This group suggested an association between
poorly differentiated carcinomas and HPV-18 although histochemical 
staining to exclude glandular elements was not performed 23E>. A 
number of studies were unable to detect HPV-18 DNA in any squamous 
tumours 2 3 2 . 2 3 3  
HPV-18 was found in non-squamous cancers of the cervix 
2 0 2 .2 2 ^ . 2 3 2  In the study of Tase et al (1988) 2 3 3  HPV-18 was 
found in 24 of 84 adeno and adeno-squamous cervical carcinomas.
HPV-18 is less frequently identified in squamous cervical cancer 
and its aetiological role is therefore less clear. The finding of 
this type in adenocarcinomas of the cervix in higher frequency 
warrants further investigation of this cancer to determine 
differences between HPV-16 and 18 in different target cells.
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Other HFV type.a. in cervical cancer
Two other viral types, 31 and 33, identified in human neoplastic 
cervical tissue, could be involved in cervical carcinogenesis.
Lorincz and co-workers (1986) 3 3 3  noted in a number of ano­
genital neoplasms screened by hybridisation to HPV-6/11, a 
consistent but different Pst 1 restriction enzyme digest pattern. 
DFA of this type was cloned from one lesion. Detailed analysis 
indicated some cross hybridisation at low stringency with a number 
of HPV types but no cross-hybridisation at high stringency.
Genome organisation was similar to other papillomaviruses and 
initial saturation hybridisation suggested 35-40% sequence 
homology with HPV-16, with limited sequence analysis showing 70% 
homology in the LI region and 50% in the E6 . This DFA has been 
designated HPV-31. In their series this DFA was detectable in 9 
of 44 CIF biopsies, in 2 of 62 invasive cancers but in none of 6  
genital warts. Subsequently, this type was identified in 7-15% of 
CIF biopsies and in 5% of invasive biopsies 1 3 1  • 2 0 , 7 * zze. 
Stoler and Broker (1986) using single strand RFA in situ
hybridisation detected HPV-31 in malignant cells from a cervical 
cancer,
Beaudenon et al (1986) identified DFA in one invasive
cervical cancer which only hybridised to HPV-16 DFA under low 
stringency conditions. This DFA has been designated HPV-33. It 
showed 7% sequence homology with HPV-16 at high stringency. 
Evaluation of genomic organisation and sequencing 2 3 3  have shown 
a structure similar to other HPVs. There was a close relationship 
with HPV-16, with between 65 and 75% sequence homology in the 
El,2,6,7, LI and L2 regions, and 50% homology in the E4 and 5 
regions. Allowing for conservative substitutions, LI polypeptides 
of these two types showed around 90% homology, suggesting possible 
sharing of antigenic properties. The original study demonstrated 
this type in 2 of 29 CIS biopsies, and in 1 of 53 invasive 
biopsies but in none of 33 genital warts. A similar low frequency 
for this viral type in CIF and malignant tumours was confirmed by 
Fuchs et al (1988) :zov'.
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Section 8 : Other sexually transmitted diseases implicated in the 
aetiology of cervical cancer
8 . 1 Human Cytomegalovirus (CMV)
Cytomegalovirus is the largest member of the Herpesviridae 
family, the genome being 150xl0G daltons. It is known to exist as 
a persistent infection of the genital tract and has been
isolated from the cervix and from semen 1. It can be
sexually transmitted and causes cervicitis and urethritis
It is frequently isolated at genito-urinary medicine 
clinics, in some cases more frequently than HSV 
Human CMV will induce morphological change in cells in vitro
Albrecht and Rapp (1973) demonstrated the presence
of CMV specific antigens in the cytoplasm and cell membrane of 
transformed cells and in sera from tumour bearing animals.
Two regions of the CMV genome will bring about morphological 
transformation. A 481bp fragment of the Hind III E region of the 
strain AD169 will transform both rat embryo and NIH 3T3 cells
Transformation of Rat-1 cells or hamster embryo cells was 
localised to the BamHI M and J fragments of the Xbal E region
these two regions being adjacent on the genome. Viral DMA 
was not retained in AD169 transformed cells but was retained in 
cells transformed by the strain Towne 2SO,
The precise mechanism of transformation was unclear but 
proposals similar to those for HSV have been suggested. There 
were some structural similarities between the transforming regions 
of CMV and HSV-2 Galloway et al (1984) proposed
that the small transforming fragment might form a stem/loop 
structure similar to that proposed for HSV-2. It has also been 
proposed that these sequences acted as enhancer sequences of 
specific cellular genes. CMV codes for a protein kinase 
compatible with putative oncogene products. A gene coding for a 
phosphorylated protein was mapped to the long unique region of the 
CMV genome CMV exhibited homology with human DNA
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The association between CMV and genital cancer has not been as 
extensively examined as that of HSV. Helnick et al (1976) 
described the isolation of infectious CMV from explant cultures of 
cervical tumours. Sero-epidemiological studies of CMV in cervical 
cancer have been contradictory. Vestergaard et al (1972) 
reported significantly higher levels of complement fixing 
antibodies in cervical cancer patients compared with controls 
matched for age and social status. However the seropositivity 
rate in the control group was 65X. Pasca et al (1975) 
detected neutralising antibodies more frequently in women with 
cervical atypia than in controls but the control group was 1 0  
years younger. Kumar et al (1960) 2SS in a better matched study, 
although studying both invasive and pre-invasive disease, found a 
significant increase in seropositivity using complement fixing 
antibodies. Stoian et al (1982) found that 20% of invasive
cervical cancer patients had detectable complement fixing 
antibodies to CMV.
In contrast, better matched studies have demonstrated no 
difference in seropositivity between women with cervical intra- 
epithelial neoplasia and matched control populations :zse* :2SS,( 
although Valkinshaw et al (1987) 2eo did find increased 
seropositivity in women with CIF compared with a well matched 
control group.
There has been little investigation of the presence of CMV 
hoiiologous DFA in cervical cancer, the major problem being the 
size of the viral genome. zur Hausen (1975) failed to
detect viral DFA in transformed cells at a sensitivity of 0.2 
genome copies per diploid cell but this would miss viral DMA of 
20-25x1 (F’. Huang et al (1984) reported the detection of CMV
DFA In normal and neoplastic cervical tissue using DMA-DMA 
reassociation kinetics. Fletcher et al (1986) 2 e 3  detected DMA 
homologous to the Hind III E region of CMV in 2 of 43 biopsies of 
cervical intra-epithelial neoplasia. In both of these biopsies 
the DFA was thought to be integrated into cellular DMA. This DNA 
region includes the known transformation region of this viral 
strain.
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There is therefore some evidence for the presence of the virus in 
cervical disease, but its role - causative or casual - is not 
clear.
8.2 Chlamydia Trachomatis
C. trachomatis is a common isolate from the cervix 'ZG,A % 
particularly in younger women it is often asymptomatic.
Suggestions that C. trachomatis might be involved in cervical 
intra-epithelial neoplasia have been present for some time. 
Schachter et al (1975) isolated the organism from 4.1% of
women with CIN compared with an overall 0.8% in their cervical 
screening programme. Paavonen et al (1979) isolated
chlamydia from 17% of women with dysplasia and 25% of women with 
invasive cancer. This group also described significantly higher 
titres of antibody compared with a control group, although there 
was no matching for sexual activity or other factors known to be 
associated with cervical cancer. However the restrictive age 
range of chlamydial isolation shown by Roberts et al (1987) 
suggests that age matching would be a critical variable in such 
comparisons.
The strongest evidence supporting a role for chlamydial infection 
in cervical cancer came from the study of Schachter et al (1982)
In a matched pair analysis of 149 patients with CIN, there 
were no differences in the seropositivity to HSV but a significant 
excess of seropositivity to chlamydia using the micro- 
immunofluorescent technique. These analyses were controlled for 
those sexual variables known to be involved in cervical cancer.
The relative risk was 2 for previous infection, rising to 3.37 in 
the group where there were few other risk factors. More recently, 
Allerding et al (1985) =es*, examining the previous cytological 
histories of women developing in-situ or invasive cancer, found a 
rate of past chlamydial infection on cytology as often as previous 
evidence of HPV infection.
Although some cases of intra-epithelial neoplasia might be 
influenced by chlamydial infection, there was no experimental
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evidence suggesting any oncogenic potential for this organism. 
However, studies into the aetiology of CIF must take infection 
with chlamydia into account as a confounding variable.
Section 9 : Fon-infective factors associated with cervical cancer
Current concepts of human carcinogenesis make it unlikely that 
single agents promote cancer. In the case of papillomavirus in 
particular, animal model systems where the virus is involved in 
malignant change and in the model of epidermodysplasia 
verruciformis, external co-factors play an essential role 
i43, i a s ,27o therefore important to examine the evidence
that non-virological factors may play a part in the multistep 
hypothesis of genital cancer.
9.1 Oral contraceptive steroids
The theory that hormones contained in oral contraceptive steroids 
could have a role to play in cervical carcinogenesis was not new.
Overholser and Allen (1935) 2 : 7 1 showed that squamous metaplasia 
could be produced in experimental rodents by injection of 
oestrogen when combined with cervical trauma over a varying time 
scale. Loeb et al (1936) were able to produce invasive
carcinomas in the vagina and cervix of experimental mice by direct 
application of oestrogens, and Hisaw and Lendrum (1936) 
demonstrated that these changes could be prevented by addition of 
progestins.
Experimental evidence that oestrogens might actually directly 
cause cervical cancer in laboratory animals came from Allen and 
Gardner (1941) Continuous oestrogen administration resulted
in an observed increase in in-situ and invasive cancer in the 
treated group. In 1959, Gardner was able to produce cervical
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and .vaginal malignant tumours by local application of oestrogens 
to the cervix and vagina in mice.
The possibility of an interaction between oestrogens and other 
carcinogens was raised by Murphy (1961) =J7re\ Mice whose 
cervices had been exposed to the chemical carcinogen, 3 - 
methylcholanthrene, were then given escalating doses of 
diethylstilboestrol (DES). The incidence of tumour formation and 
the time of development of tumours were both found to be related 
to the dose of DES. DES used alone was also associated with an 
increase in the rate of tumour formation. Similar results were 
obtained by Kaminetsky (1966) This study was the first to
propose that progesterone alone was capable of producing an 
increase in cervical dysplasia, mainly mild. This was at odds 
with the accepted protective effect of progesterone in oestrogen 
induced tumorigenesis 
Early work on the effect of steroids used in oral contraceptive 
pills confirmed the known effect of oestrogens on the cervix of 
experimental rodents Again it was felt that
progesterones (dihydroprogesterone, norethisterone) prevented the 
development of oestrogen induced genital tumours :z:7e.
Oral contraceptive steroids produced marked morphological 
effects on the cervix which could potentially predispose the 
critical cervical transformation zone to infection or alter the 
characteristics of that infection. They produced oedema, 
softening, increase in Nabothian follicles, increase in secretion 
and eversion. Histologically they produced increased vascularity 
in the squamous epithelium, increased numbers of endocervical 
glands with marked epidermidisation, stromal oedema, and 
increased neutrophils and plasma cells 2:eo. Reserve cell 
hyperplasia was frequently described 2eo<201, Apart from these 
fairly general changes, squamous metaplasia with persistence of 
the mucin secreting endocervical glands commonly occurred .
A more specific abnormality has been noted. Taylor et al (1967) 
first described a form of atypical endocervical hyperplasia
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associated with pill usage. Others have described a 
microglandular hyperplasia in which glands arose and proliferated 
within metaplastic epithelium 2 S 1  .2s:3.
The first clinical and epidemiological data suggesting a role 
for oral contraceptive steroids was the study of Melamed and 
colleagues (1969) In a large study comparing the incidence
of cervical disease in women using oral contraception with those 
using barrier contraception they found a small but significant 
increase in the rate of cervical carcinoma-in-situ. Early 
studies into the role of oral contraceptive steroids in cervical 
cancer were conflicting and many failed to control for the 
appropriate variables in sexual behaviour known to be factors in 
the epidemiology of cervical cancer (see ref,285). Thomas (1972) 
concluded, in his own case-control study, that short term 
use was not associated with an increased risk of premalignant or 
malignant disease. Similarly Vorth and Boyes (1972) 
controlling for some of the sexual parameters, were unable to 
demonstrate any significant difference in contraceptive usage or 
duration of oral contraceptive use in a case-control study. The 
large case-control study of Boyce (1977) controlling for
most of the sexual variables, found no differences in either 
overall use or duration of use between women with cervical cancer 
and control women.
Interesting studies by Stern et al (1970) and by Ory et al
(1976) suggested that much of the increased risk attributed
to oral contraceptives was a function of preselection. Both 
groups found that women commencing oral contraceptives were more 
likely to have abnormal cervical cytology at commencement than 
women choosing other forms of contraception. Thus women on oral 
contraceptives had an increased incidence of cervical 
premalignant disease prior to exposure to the pill.
However, prospective studies have shown an increased relative 
risk of cervical cancer associated with contraceptive pill use. 
Peritz (1977) followed women who were either pill users or
never users prospectively and found an increased relative risk
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for cervical cancer in pill users which seemed related to 
duration of use, although there was no attempt to control for 
sexual behaviour. Swan and Brown (1981) 3 3 1  later analysed a 
small subset of women used in this study with case controls for a 
number of sexual variables. They were able to show that there 
were significant differences between cases and controls for age 
at first intercourse, age at regular intercourse, and number of 
sexual partners. They concluded that the relative risk findings 
from the original study could be accounted for by the observed 
differences in sexual behaviour. Stern et al (1977) 2:3:2 
suggested that long term usage (more than 7 years) was associated 
with an increased risk of progression from mild to severe pre- 
invasive disease but found no increase in relative risk of 
developing CI IT de novo in pill users. Harris and colleagues 
(1980) in a well controlled study, indicated that pill
usage for over 5 years was associated with a relative risk of 2 
for the development of cervical precancer, independent of other 
variables.
Much of the recent concern over the role of the pill in cervical 
cancer stemmed from the large bank of data from the Oxford Family 
Planning study. This group demonstrated an increased risk
associated with use in excess of 4 years for premalignant 
cervical disease. There was no formal attempt to control for 
sexual behaviour but a small subgroup were compared for age at 
first intercourse and number of partners. Patterns for this 
large study cannot be inferred from this subgroup. Kay (1983)
23E also indicated an increased risk but felt that the 
confounding variables were likely to result in an overestimate of 
pill risk. Andolsek et al (1983) 23G showed a small increase in 
risk for malignant disease but with numbers similar to the Oxford 
group, were unable to show any substantive difference for CIN 3. 
Further concern arose following the preliminary results of the 
VHO collaborative study 2S9'7' examining invasive cancer only, 
there appeared to be little risk (relative risk 1 .1 1 ) 
attributable to pill use when other confounding factors such as 
age at first intercourse and number of partners were taken into
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account. However, even controlling for such factors, a relative 
risk of 1.37 was demonstrable with 5 or more years of use.
The precise role of oral contraceptive steroids remains obscure 
but there is sufficient theoretical and epidemiological evidence 
to consider that such steroids may have a substantive cofactor 
role.
9.2 Cigarette smoking
A link between tobacco smoking and cervical cancer was initially 
hypothesised by Vinkelstein in 1977 based on the
observation of a high correlation in the geographic incidence of 
squamous carcinoma of the lung and cancer of the uterine cervix 
seen in the Third National Cancer Survey Extrapolating
from the data collated in this extensive survey, he argued that 
major human cancers of squamous origin, in particular lung and 
bladder cancers, seemed to show cigarette smoking as a major 
independent risk factor.
In fact, a number of authors had previously drawn attention to 
smoking as a potential risk factor in cervical cancer. Naguib et 
al (1966) 3 0 0  initially demonstrated a positive, graded 
association in relative risk of cervical cancer between non- 
smokers, ex-smokers and current smokers, although the authors 
felt that socio-economic confounding might account for this risk. 
Tokuhata (1967) 3 0 1  , in a case-control study of invasive 
cervical cancer, indicated that there was increased tobacco 
consumption among cases compared with controls, although this 
seemed restricted to tobacco consumed by means other than 
inhalation. Thomas (1973) 3 0 : 2 in a complex study of factors 
associated with cervical carcinoma-in-situ and cervical squamous 
cell dysplasia, showed an increased relative risk in smokers for 
carcinoma-in-situ which was weakly statistically significant. In 
a large follow up study between 1963 and 1972 in Sweden, Cederlof 
(quoted in ref.298) indicated a 7 year incidence of cervical 
cancer of 28.7 per 1000 in women smoking more than 15 cigarettes 
per day compared with a rate of 4 per 1000 for non-smokers, a
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relative risk of 7.2. In the same study, the relative risk for 
lung cancer was 8.5, and for bladder cancer 2.2.
Detailed analysis of the Third National Cancer Survey by 
Villiams and Horn (1977) 3°:3) in which lifetime exposure to 
cigarettes was calculated, showed that there was a strong 
positive correlation between exposure to cigarettes and carcinoma 
of the cervix even after multiple regression analysis had 
controlled for a number of potential confounding social 
variables. The relative odds ratio also seemed to increase with 
increasing cigarette exposure, suggesting a dosage phenomenon. 
Preliminary data from the long term surveillance of the Oxford 
Family Planning Study unexpectedly indicated a small but
independent risk associated with smoking. This was the only 
study in which some account of the sexual behaviour variables had 
been taken.
Some dissension from the general view was proposed by Stellman 
et al (1980) who argued that almost all of the increased
relative risk associated with smoking could be accounted by 
confounding of socio-economic factors. However, even this data 
showed an increased risk associated with smoking over 1 0  
cigarettes per day after adjusting for the various socio-economic 
factors.
Since then better controlled data have emerged. Vigle and Mao 
(1980) demonstrated relative risks of 3.8 for smokers for
carcinoma-in-situ and 2.0 for invasive cancer. The risk for ex­
smokers was similar to non-smokers, a situation analogous to the 
risks of ex-smokers in lung cancer. They were able to show an 
almost linear increase in relative risk with increasing exposure 
in both premalignant and malignant disease. Harris et al (1980) 
:2S*:3, showed a clear increased relative risk for cervical 
dysplasia in smokers after controlling for sexual behaviour, this 
risk being just over 2. They also indicated that there seemed to 
be a dosage relationship between total exposure to cigarettes and 
risk. A similar relative risk was demonstrated by Clarke et al 
(1982) In this study the relative risk was also related to
the amount of smoking.
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In 1983 two studies were published which were specifically- 
designed to test the hypothesis that cigarette smoking was a 
major independent risk factor in cervical cancer. Lyon et al 
<1983) 3 0 3  demonstrated a relative risk of 3 for carcinoma-in- 
situ in women who smoked. Their analysis controlled for known 
confounding variables such as social class and sexual behaviour. 
So dosage phenomenon was demonstrated. Trevathan et al (1983) 
3°3 , allowing for socio-economic status, oral contraceptive use, 
number of sexual partners, and age at first intercourse, clearly 
showed an increased relative risk of 2.4-3. 6 for the various 
grades of cervical premalignant disease. Cumulative exposure to 
cigarettes was strongly related to risk. Women with 12 or more 
pack-years exposure had a relative risk of 12.7 for carcinoma-in- 
situ and 4.3 for mild dysplasia.
There could be little doubt that cigarette consumption was a 
major independent risk factor in cervical cancer and the 
possibility existed of a dosage phenomenon. How this might come 
about was less clear.
The cervix was remote from the source of inhaled mutagens. 
However inhaled mutagens were known to be concentrated in distal 
body fluids such as breast milk, urine and saliva 3 1 °- 3 1 =2 .
Sasson et al (1985) 3,1:3 demonstrated that nicotine and cotidine 
were concentrated in the cervical mucus of smokers to a much 
greater extent than in any other body fluid. Similar 
concentration of these products has been demonstrated in mucus 
obtained from the cervices of women with CIN 3,1 There are no 
studies comparing the women with and without CIN under standard 
conditions. The study of Hellberg et al (1988) 3 1  raises a 
further problem, that of passive smoking. Non-smokers had 
detectable nicotine and cotidine in cervical mucus though not in 
serum. If this was confirmed then it could suggest that 
epidemiological data has underestimated the risks of smoking.
Nicotine itself is not carcinogenic although it has been shown 
to result in a reduction in local immune response if present in 
high concentrations in cervical mucus =,1=*.31E\ Other tobacco 
products could be present in cervical mucus. One group 3 1  & have
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shown that the cervical mucus of smokers was highly mutagenic 
under experimental conditions. Polyaromatic hydrocarbons found 
in tobacco were carcinogenic to the cervix of experimental 
animals. ITitrosamines are the major carcinogen present in 
tobacco smoke. There are no data on their presence in cervical 
mucus although they are concentrated in urine 
There is therefore considerable epidemiological and experimental 
data which suggest a direct or indirect role for cigarette 
smoking in cervical cancer.
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Section 10 : Aetiology of vulval cancer
10. 1 Epidemiological considerations
Vulval cancer accounts for around 5% of female genital 
malignancy. It differs from cancer of the cervix in being largely 
a tumour associated with old age. The mean age at diagnosis is 
generally reported as over 60 years and a substantial proportion 
of cases are over 70. The vast majority of tumours are squamous 
in origin, with the documented existence of a pre-invasive intra- 
epithelial lesion, including carcinoma-in-situ, the mean age of 
which precedes the invasive form by 15 to 25 years 3 *2 ,3 1 * 3  
Much of the early epidemiological data centred on the 
relationship between vulval dystrophies, in particular 
leucoplakia, and invasive cancer. Bonney was one of the earliest 
authorities suggesting such a relatonship, although he attributed 
Sir Henry Morris in the 1880s as being the first to demonstrate an 
association between vulval dystrophy and carcinoma on the same 
site 3,1 Taussig (1940) 3 : 2 0  reported
that almost 50% of women with invasive disease had a history of 
leukoplakic vulvitis. On this basis, he recommended aggressive 
surgical management of established leukoplakia. Although others 
321.322: confirmed the high proportion of pre-existing 
leukoplakia in women with vulval cancer, McAdam and Kistner's 
(1958) 3 : 2 1 detailed histological study of vulval dystrophies, in 
which women with such lesions were followed closely, demonstrated 
that there was minimal risk attached to most vulval dermatoses. 
Jeffcoate (1966) 3 2 3  in prospective studies indicated that women 
with leukoplakia rarely progressed to malignancy, and gave a risk 
of 4 -5 % progression for leukoplakia, increasing to 1 0 % if 
hyperplasia and atypia were present. Similar risk estimates were 
argued by Underwood and Hester (1971) in prospective data.
Early studies had also highlighted a number of other interesting 
findings. Vomen with vulval cancer were more likely to be
67
nulliparous and more likely to have undergone early menopause 
3 1 ^ , 3 2 2  There was an apparent association with co-existent 
medical diseases such as diabetes, hypertension, atherosclerosis 
and obesity 3 1  ^  • 3 1 3 . 3 2 2  but this data was not well controlled. 
Others ^ ^ s . 3 2 3  Were unable to substantiate these findings and it 
would appear that these associations were more related to the age 
of the patient population than to the epidemiology of the cancer,
A number of studies have looked at the role of specific local 
lesions in vulval cancer. Taussig (1940) 3 2 : 0 commented on the 
frequent finding of syphilitic or post-syphilitic ulcers in women 
with invasive vulval cancer. Hahn (1956) 32rsfound 8 of 131 
invasive tumours had positive serology for syphylis. This excess 
of previous exposure to syphilis has been noted by others 
3 i &. 3 2 2 . 327- Green et al (1958) 3=2:2 reported that women with 
positive serology were younger and had poorly differentiated 
tumours, a finding confirmed by Franklin and Rutledge (1972) 3 1  '7. 
Age differences were also described in post-granulomatous cancers 
32s. 3 2 3  One of these studies 3 2 3  identified two distinct 
groups. The first group had co-existing carcinoma-in-situ. These 
women rarely developed secondary spread and had a high 5 year 
survival rate. The second group had no evidence of pre-malignant 
disease and had tumours characterised by rapid growth and 
metastasis. Ho obvious conventional histological differences were 
evident between these tumours. As all these tumours were of 
squamous origin, this argued for a subset of at risk women exposed 
to particular sexually transmissable agents who were younger and 
had more aggressive disease. Japaze et al (1977) 3 1 3  found a 
syphylis seropositivity rate of 26% in their group of invasive and 
in-situ cancers.
These granulomatous lesions have been observed to undergo 
malignant transforraation 32'a.
The other major observation of the early studies was the marked 
excess of other lower genital cancers in women with vulval cancer 
3 i 7-. 3 i 3 , 3 2 2 . 3 3 0  ^ reported incidence being as high as 65%
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31 3 . These initial impressions have been subsequently confirmed 
and applied to both pre-invasive and invasive vulval cancer 
sze, 3 3 1 — stsrn jke concept of multicentric disease, where women 
with vulval carcinoma were found to have or have had cervical or 
vaginal carcinoma, was fully established in the late 1960s and 
there had been speculation on a common aetiology.
In the 1970s the numbers of women with detectable pre-invasive 
disease of the vulva appeared to rise and the age of detection 
fell 311B4 Woodruff et al (1973) 3:3:2 calculated that only 20% of 
the vulval tumours seen in the period 1936-50 had been in-situ 
cancer, compared with 47% in the period 1966-72. 41% of these 
women were under 40 years of age. Buscema et al (1980) 32& 
indicated that the proportion of in-situ lesions in the 21-40 age 
group increased from 28.5% to 37.2% between 1958 and 1978 and 
Friedrich et al (1980) 333 stated the modal age at diagnosis of 
vulval carcinoma-in-situ to be 30.
The association with sexually transmissible granulomatous 
disease, the apparent link with cervical carcinoma which had been 
established as a likely sexually linked cancer and the increasing 
numbers of young women with in-situ carcinoma suggested a possible 
infective aetiology for vulval cancer, despite the generally 
elderly age group to which the vast majority of vulval cancer 
patients still belonged.
It was therefore not unrealistic to attempt to link genital 
herpesvirus infection with vulval cancer, especially as the vulva 
was the commonest site of infection with this virus. .
10.2 Herpes simplex virus in vulval cancer
The rising incidence of genital herpes infection seemed co­
incident with the rising incidence of vulval carcinoma-in-situ in 
younger women. Freidrich et al (1980) 333 found that 5 of 53 
women with in-situ carcinoma had a history of previous HSV 
infection, including a previously described case of a young girl 
who developed in-situ cancer of the vulva following severe
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herpetic vulvitis in pregnancy. This lesion regressed 
spontaneously. The relative rarity of vulval carcinoma made it 
virtually impossible to mount meaningful sero-epidemiological 
studies.
Kaufman et al (1981) 333 expanded their group's work on the 
expression of HSV specific polypeptides in cervical tumour 
biopsies to examine a number of vulval biopsies. Seven of 8 
vulval carcinoma-in-situ biopsies examined had immunohistological 
evidence of expression of ICSP 34/35 protein, 5 of 8 had evidence 
of ICP 11/12, and 6 of 8 evidence of VP 143 protein. Two 
additional vulval dysplasias had evidence of expression of both 
ICSP 34/35 and VP 143. In 4 of the cases of in-situ carcinoma, 
adjacent histologically normal tissue was examined and found not 
to express any of these specific products. Detailed examination 
of the tissue biopsies suggested expression of HSV related 
polypeptides in the superficial layers, in contrast to the 
cervical biopsy results. Reaction was exclusively cytoplasmic, 
despite the demonstration that these polypeptides are associated 
with the nuclei of infected cells. A more recent larger study 
33e demonstrated the presence of the HSV-2 related antigen, ICSP 
34/35, in 50% of biopsies from vulval carcinoma-in-situ by 
immunocytochemical techniques. In a similar study, Cabral et al 
(1982) 3:3:7 used indirect tissue immunoperoxidase staining to 
demonstrate the presence of the HSV-2 antigen designated VP 143 in 
1 of 3 severe vulval dysplasias, three of 7 in-situ carcinomas, 
and 1 of 3 invasive tumours. Staining was confined to the basal 
cell layers in the non-malignant tissue. Internally matched 
normal vulval tissue showed no evidence of staining. Staining for 
the glycoprotein VP 119 was also in positive biopsies. In this 
study, staining occurred in the perinuclear area as was seen in 
infected cells.
There was little work on the detection of HSV specific nucleic 
acid in vulval cancer. McDougall et al (1980) 100 did detect HSV 
specific RNA in a biopsy from a pre-neoplastic vulval biopsy by 
DNA-R5A in situ hybridisation and Eglin et al (1984) 330 
described HSV RNA in biopsies from malignant vulval tissue. Only
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2 studies were described which examined the detectability of HSV 
D M  in vulval cancer tissue in any detail. Macnab et al (1985) 
120 examined 11 invasive tumours of the vulva and found D M  
homologous with the Hindlll a region of HSV-2 in D M  extracted 
from one tumour. Manservigi et al (1986) 1 1 s examined 4 invasive 
vulval tumours and 2 in-situ carcinomas for HSV sequences. D M  
homologous to Bglll n and o regions was detected in 2 of the 4 
invasive tumours, in a rearranged fashion. One of the in situ 
cancers also contained detectable Bglll n DNA and a fragment of 
the Bglll o area. DNA from the MTRII region of HSV-2 had 
therefore been identified in both malignant and pre-malignant 
vulval tissue.
There was therefore some evidence that HSV information is present 
in vulval neoplastic tissue, although there were insufficient data 
from which to draw any meaningful conclusion.
10.3 Human papillomavirus in vulval cancer
Genital condylomata had long been associated with vulval 
malignancy. A number of studies had shown a striking proportion 
of vulval cancers co-existing with large condylomata, with rates 
of 7-20% being quoted 31 7’* • 33:2• 333. Franklin and Eutledge
(1972) 31 ^  stated that in a number of cases, histological 
evidence of condyloma, in-situ cancer and invasive cancer could be 
found in the same specimen. There were many case reports of 
malignant transformation of genital warts * 32:e* 339"342.
Viral particles were identified in Bowenoid papulosis, a variant 
of in-situ carcinoma 3^3 and histological koilocytic atypia, 
characteristic of HPV infection, could be found in 69% of cases of 
in-situ carcinoma However, evidence of viral antigen
expression in in-situ cancer has been conflicting , 3-o.c
HPV.-6/n
Genital warts were commonly due to HPV types 6 or 11 
HPV-6 could be identified in giant condylomata of Buschke-
71
Lowenstein, which were slow growing locally invasive tumours which 
could affect the vulva An unusual HPV type 6 was also
described in an unusually aggressive vulval verrucous carcinoma 
HPV- 6  was identified in pre-neoplastic vulval disease 
i3 i . 1 3 ^. 3 3 5 ,3 ^ 3  McCance et al (1985) 3 3 0  found HPV- 6  
frequently in association with HPV-16 in all grades of vulval 
intra-epithelial neoplasia (VIN) although a number of biopsies had 
histological evidence of HPV infection. Sutton et al (1987) 1 3 3  
similarly identified HPV- 6  in in situ lesions in higher copy 
number than HPV-16. In the largest study HPV- 6  or 11 was
identified as the sole viral type in 26% of cases and in 
association with other types in 1 1 % of cases.
The finding of HPV- 6  in invasive cancer varied. Some groups had 
been unable to demonstrate HPV- 6  DNA in invasive vulval cancer 
1 3 1  - 194'227, However Sutton et al (1987) 1 3 3  indicated that 
HPV- 6  was the sole HPV DNA identified in 4 of 9 invasive lesions 
and was found in association with other types in 2 others. HPV- 6  
DNA was also identified in DNA extracted from lymph node 
metastases, HPV- 6  was present as frequently as HPV-16 in 
condylomatous cancers 3 3 1  and was identified as the sole DNA type 
in 1 of 5 HPV positive squamous cancers by Carson et al (1988)
3 5 2
Other HPV types
HPV-10 was implicated in some vulval lesions. Green et al 
(1982) 1AG identified HPV-10 in a vulval carcinoma-in-situ and in 
2 other invasive cancers of the vulva. They also showed its 
presence in 2 genital condylomata. Zachow et al (1982) 
identified similar viral DNA in bowenoid papulosis, verrucous 
carcinoma and carcinoma-in-situ of the vulva. In both these 
studies the viral DNA was present in a free, unintegrated form.
HPV-31 was not detected in 21 biopsies of VIN or in 5 invasive 
specimens 1 3 1  but was identified in 9% of in situ lesions by 
Kaufman et al (1988) 33&. Beaudenon et al (1986) 2 2 3  found HPV- 
33 DNA in 4 of 54 VIN biopsies.
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Hpy-16-
HPV-16 was identified infrequently in genital condylomata
1 17. 131 . 199.201 ,203. 20<E>. 21 0-21 2. 3AG I t  bas been
identified more frequently in pre-invasive disease ^ii,a&o.3 3 3  ^
though often in association with HPV- 6  an(i often where
there was histological evidence of viral infection 2 1  , Both 
Beaudenon et al (1986) 2 2 3  and Reid et al (1987) 1 3 1  described 
the identification of HPV-16 DHA as sole viral DHA in over 2/3 of 
VIH biopsies but Kaufman et al (1988) 3 3 3  found HPV-16 as the 
sole type in only 11% of biopsies. Ho histological information on 
the presence of koilocytic atypia was presented in these studies. 
Only Gupta et al (1987) using in situ hybridisation
techniques, have convincingly demonstrated the presence of HPV-16 
DHA in vulval in situ cancer in the absence of histological wart 
infection.
The frequency with which HPV-16 was identified in invasive 
disease also varied widely 1 3 1  . 1 3 3 ,2 1 7 , 2 2 7 , 3 3 2  with this type 
being present in 15-90% of samples.
HPV-18
In the initial studies of Boshart et al (1984) 13e, describing 
HPV-18, this viral type was not found in any condylomata or vulval 
cancer. HPV-18 DHA has been identified rarely in vulval 
condylomata ■» =*■»,■»»=* an(j vulval carcinoma in situ :z;z'7 by most 
groups. However the large study of in situ vulval cancer by 
Kaufman et al (1988) 33& found HPV-18 to be common in carcinoma- 
in-situ of the vulva ( 11/46).
HPV-18 DHA has only been identified infrequently (2/31 tested) 
in invasive tumours 1 3 1  • 1 3 3 . ^ 2 7  both cases in
association with HPV- 6  or 16. HPV-18 was present in a lymph node 
secondary deposit in one tumour 1 3 3  but in association with both 
HPV- 6  and 16.
Viral DHA has been found in a substantial proportion of both pre- 
invasive and invasive vulval cancers. The position is less clear
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cut than in cervical cancer and there is considerably more 
variability in the viral type found. HPV-6/11, rarely found in 
invasive cervical cancer, is frequently associated with invasive 
vulval cancer. Although it is attractive to suggest that viruses 
of similar oncogenic potential, present in the genital tract, are 
closely involved in two related malignancies, the natural 
histories of the two cancers urge caution to this approach.
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CHAPTER 2
HUKAN PAPILLOMAVIRUS A HD HERPES SIMPLEX VIRUS TW 
IffVASIYB -GEBIIAL MAIiTOWAWCY ARP MATCHED CQRTRQL TISSUE
Section 1 : Introduction
Although there are considerable data on the prevalence of HPV 
D5A and HSV D M  in genital malignancy, few studies systematically 
examine a single group of cervical and vulval cancers for both
HPV and HSV D M  group has
examined a range of invasive genital tumours with all probes from 
both viruses implicated in their aetiology.
There are now data on the presence of HPV D M  in histologically 
normal tissue 1 31 • 203 • 207r * 212 * • 230 * However
there is little information on the presence or absence of HPV D M  
in normal tissue from women with invasive genital malignancy 
containing detectable HPV D M  21 
To examine these two problems the D M  extracted from 15 invasive 
cervical cancers and 11 invasive vulval cancers was probed for
the presence of HPV-6, 11, 16 or 18 and for HSV-2 Hind III a, e,
h, and i DM. D M  extracted from internally matched normal 
tissue from 8 cervical and 3 vulval tumours was similarly probed 
for the presence of sequences homologous to these DMs. By this 
approach it should be possible to determine the prevalence of 
each viral D M  in malignant tissue, the possible presence of more 
than one viral type in tumour DM, and the frequency with which 
viral D M  was present in normal tissue in women with malignant 
disease.
It was hoped that such detailed analysis would lay a foundation 
for tissue culture and cell line studies of tumours found to 
contain D M  homologous to viral D M  and that it would be possible 
to clone such homologous sequences from tumour or cell line DMs 
for analysis.
TABLE-1
SPURGE OP TUMOURS USED IF PEA AJtALYSBS
Camtal tumour. Age. Sourie. Hisioloay.
l 36 RHND Poorly differentiated squamous
2 34 RHND Squamous
5 - RHND Squamous
8 44 RHND Poorly differentiated squamous
16 42 Staging biopsy Squamous
17 32 RHND Poorly differentiated squamous
20 32 RHND Squamous
22 30 RHND Moderate/poorly diff, squamous
23 50 RHND Well differentiated squamous
24 26 RHND Moderately well differentiated squamous
29 35 RHND Poorly differentiated squamous
30 25 RHND Squamous
35 37 RHND Squamous
38 46 RHND Squamous
39 32 RHND Papillary adenocarcinoma
Vulval tumour
3 70 Radical vulvectomy Well differentiated squamous
9 29 Radical vulvectomy Moderately well diff, squamous
12 87 Excision biopsy Squamous
15 66 Radical vulvectomy Squamous
18 92 Simple vulvectomy Squamous
19 90 Excision recurrence Squamous
21 81 Radical vulvectomy Squamous
27 60 Radical vulvectomy Well differentiated squamous
28 75 Simple vulvectomy Carcinoma-in-situ
32 73 Excision recurrence Poorly differentiated squamous
34 76 Radical vulvectomy Squamous
Endometrial tumour
6 60 TAH Adenocarcinoma
7 27 TAH Adenocarcinoma
Vaginal tumour
13 60 Anterior exenteration Well differentiated squamous
Nude mouse tufflour
41 54 Staging biopsy Well differentiated squamous
RHND Radical hysterectomy and node dissection 
TAH Total abdominal hysterectomy
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Section 2 : Materials and methods
2.1 Collection of tissue specimens 
Uormal control tissue
Histologically normal ectocervical tissue was obtained from 9 
patients undergoing hysterectomy for benign uterine pathology.
All had normal cervical cytology in the preceding 12 months and 
had no history of cervical surgery or history of malignant 
disease at other sites. The age range of these women was 39 to 
77 years of age.
Following removal of the uterus, strips of ectocervical 
epithelium were dissected under sterile conditions in the 
operating theatre. These were placed on ice in tissue culture 
medium (see Chapter 3, section 2.2) and transported to the 
laboratory for DHA extraction. Strips were taken at intervals 
from the cervix and histology of the adjacent areas obtained. In 
all specimens used as normal controls, histology was normal. It 
was assumed that these control biopsies were histologically 
similar.
Histologically normal vulval skin was obtained from 2 women 
undergoing autopsy for non-malignant disease. Heither of these 
women had evidence of vulval pathology and adjacent skin was 
reported as histologically normal. These skin biopsies were 
stored on ice in culture medium and extracted immediately.
Cervical tumour tissue
Tumour tissue was obtained from 14 radical hysterectomy and 1 
wedge biopsy specimen of invasive cancer of the cervix for DHA 
extraction.
The clinical details of these women are shown in Table 1.
Viable tumour tissue was dissected in theatre from the radical 
hysterectomy specimen. Care was taken to avoid necrotic areas or
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stromal tissue. Tissue was washed in culture medium and then 
either placed in culture medium on ice for immediate extraction 
or snap frozen in liquid nitrogen for late extraction.
Vulval tumour tissue
Tumour tissue was obtained from 7 radical vulvectomy specimens,
1 simple vulvectomy and 3 vulval biopsy specimens. The patient 
details of these tumours are shown in Table 1.
Tumour tissue from viable tumour areas was dissected from the 
surgical specimens in theatre. It was washed in culture medium 
and either placed in medium on ice or was snap frozen in liquid 
nitrogen. The decision to snap freeze tumour tissue was dependent 
on both the original biopsy histology and the time to D M  
extraction, with those tumours where a clear histological 
diagnosis was not available being frozen until it was established 
that further samples were not required. Those tumours from the 
Regional Gynaecological Oncology Unit, Queen Elizabeth Hospital, 
Gateshead were frozen as the minimum transit time was 4 hours.
Hatched control tissue
Paired matched internal control tissue was obtained in 8 cases 
of carcinoma of the cervix and 3 cases of carcinoma of the vulva.
Using a fresh scalpel, a block of tissue was dissected from the 
uterine fundus of radical hysterectomy specimens. Tissue was 
largely myometrium with serosal tissue. Care was taken not to 
enter the endometrial cavity to avoid potential contamination 
with tumour tissue. This tissue was snap frozen in liquid 
nitrogen. Tissue taken was in the order of 1 cm3 in volume.
In 3 women undergoing radical vulvectomy, a strip of abdominal 
skin immediately superior to the tranverse abdominal incision of 
the radical procedure was excised and snap frozen in liquid 
nitrogen. The skin samples were at least 2cm. from the nearest 
tumour margin on gross inspection. A fresh scalpel was used for 
this dissection.
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Samples were stored until full histological examination of the 
surgical specimen was completed. Samples were only regarded as 
histologically normal if the tissue immediately adjacent to the 
matched control tissue was reported as histologically normal.
D M  was then extracted.
Other tumour tissue
Tissue was dissected from 2 hysterectomy specimens from women 
with endometrial adenocarcinoma following bisection of the uterus 
in the operating theatre. Tissue was obtained from a single case 
of squamous carcinoma of the vagina. Tissue was obtained from a 
subcutaneous tumour produced in a athymic nude mouse by injection 
of a suspension of cells obtained from a biopsy of a squamous 
carcinoma of the cervix prior to radiotherapy. Details are shown 
in Table 1.
2.2 D M  extraction
Fresh tissue to be extracted was finely minced using a sterile 
scalpel or scissors. Total cellular D M  was isolated by 
proteinase K digestion and phenol extraction Minced
samples were incubated for 3 to 24 hours at 37°C in 50mM 
trometamol-HCl (TRIS-HC1), 10mM edetic acid (EDTA), lOOmM NaCl, 
and 0.4% sodium dodecyl sulphate (SDS) lysis buffer containing 
200pg/ml proteinase K ( Boehringer, Mannheim), all at pH 8.0. 
Nucleic acids were extracted twice with phenol equilibrated with 
TE buffer (0.001M edetic acid, 0.01M TRIS-HC1 pH 8.0 ), once with 
chloroform (to remove the phenol), dialysed extensively against 
lxSSC (150mM NaCl, 15mM sodium citrate, pH 7.2) and precipitated 
in absolute alcohol containing 0.2M sodium acetate at -20e*C 
overnight. The nucleic acid pellet was collected by 
centrifugation, washed in absolute alcohol, re-pelleted, and air 
dried. The total nucleic acid pellet was redigested with 
lOOpg/ml RHase A (Sigma, Poole, England) in lOmM TRIS-HC1, lOmM 
EDTA pH 7.5 for 3 hours at 37°C. This digest was re-extracted,
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twice in phenol and once in chloroform. The resultant DBA 
solution was extensively dialysed against 1 x SSC at 4°C, 
precipitated in Burrough's absolute alcohol and resuspended at 
appropriate concentration in TE buffer.
Prior to usage the DHA concentration of each sample was 
determined by comparison of band intensities visualised by 
ethidium bromide with those of standard X DBA (Gibco, Paisley, 
Scotland) on a short gel.
Snap frozen samples were extracted in a similar manner except 
that the samples were crushed in dry ice prior to digestion.
2.3 Gel electrophoresis and Southern blot transfer
Restriction enzyme digest
The relevant DBAs for each Southern blot transfer were first 
digested with the appropriate restriction enzyme; Hind III,
Bam HI, or Pst I (BRL, Glasgow, Scotland). Restriction digests 
were carried out to the manufacturers specifications using 30 pg 
rat embryo DBA for reconstruction tracks and 10-20pg total 
cellular DBA. Digests were carried out using excess enzyme, 
normally 40 units for 20-3Opg DBA. Digests were carried out at 
37°C for a minimum of 18 hours. The reaction was stopped by 
freezing on stop buffer containing bromophenol blue dye.
Gel electrophoresis
Products of digestion were separated on full length 0.6% agarose 
gels. Agarose was dissolved in electrophoresis buffer (one litre 
of buffer contained 43.625g TRIS, 46.875g sodium dihydrophosphate 
and 3.7g EDTA; 0.05ml of ethidium bromide stock solution was 
added to each litre). DBAs were run in buffer at 10V, minimum 
current for 6-8 hours and at 20V, minimum current for 24-36 
hours.
Gels were examined under UV light to confirm adequate fragment 
separation and were trimmed to minimum size.
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Southern blot transfer
DNA fragments were transferred onto nitrocellulose membranes 
(Schleicher and Schuell) using the method of Southern (1975) 3SS» 
or onto nylon membranes ( Biodyne, Pall; Genescreen plus, New 
England Nuclear ) using the manufacturers methods.
Gels were washed in 0.2H HC1 for 30 minutes; in 0.2M NaOH, 0.6M 
NaCl for 30 minutes and in 1M TRIS pH 7.5, 0.6M NaCl for 30 
minutes. Transfer was acheived in 10 x SSC overnight.
The transfer membrane was washed twice in 2 x SSC for 30 
minutes, air dried, and baked at 70-80°C in a vacuum oven to 
immobilise the DNA fragments.
2.4. Preparation of viral DNA probes
HSV-2 probes were derived from the HSV-2 strain HG52, cloned 
into the plasmid vector pAT153 3eo. The probes used and the 
genomic map positions are shown in Fig 2. These probes cover 42% 
of the HSV-2 genome. Viral DNA was released from the vector by 
appropriate restriction endonuclease digestion and purification 
twice by agarose gel electrophoresis.
HPV probes were kindly provided by Drs. zur Hausen and Gissmann 
and colleagues. HPV-6 , 11 and 16 are cloned into the Bam HI site 
of pBR322, and HPV-18 is cloned into the EcoRI site of the same 
vector. Purification of the viral probes was carried out as 
described above.
Radiolabelling of viral probes
Nick translation of viral probes was carried out using the 
technique described by Rigby et al (1977) 3ei . Probes were 
labelled with 3 ;zP-orthophosphates (Amersham International, 
England); a-deoxy-t3 2 P]-adenosine triphosphate and a-deoxy-[3 3 P]- 
thymidine triphosphate for HPV and with a-deoxy-[ 3 :2P]-cytosine 
triphosphate and a-deoxy-[3 2 P]-guanosine triphosphate for HSV.
The difference in labelling reflected the differing nucleotide
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proportions in each viral probe and allowed maximalisation of the 
specific activities of the probes.
For HSV, 0.25pg of probe DNA in buffer solution [50mM TRIS-HC1 
pH 8.0, 5mM magnesium chloride, 50pg/ml bovine serum albumin 
(BSA), and lmM DDT], 0.02mM Adenosine triphosphate, 0.02mM 
thymidine triphosphate, and 1% BSA was digested with a lxlO~e 
dilution of DNase for 2 minutes at 37°C. Radioactive 
triphosphates were then added and 1 unit of DNA polymerase-1 
added to the solution . This was incubated at 15,=,C for 90 
minutes, with counting to check incorporation at 30 minutes, and 
the reaction stopped on ice.
Incorporation was checked by spotting lpl of the reaction mix 
onto two filter papers and comparing the scintillation counts 
following washing of one filter. Incorporations of between 25 
and 40% were accepted.
Labelled probe was purified from non-specific label by passing 
the remaining solution down a Sephadex column (Sephadex in TE 
buffer) and collecting the maximal fraction peak only. Only nick 
translations which achieved a specific activity of labelling of 
greater than lxl0ecpm//ig DNA were used in hybridisations.
2.5 Hybridisation procedure
Prehybridisation
Filters to be probed with HSV probes were prehybridised with 3 x 
SSC, 50pg salmon sperm DNA/ml., 0.2% Ficoll, 0.02% 
polyvinylpyrrolidone, 0.02% BSA, 0.1% SDS in aqueous solution at 
72°C overnight. Filters to be probed with HPV probes were 
prehybridised with 50% formamide (Fluka), 5 x SSC, 50mX Hepes pH
7.0, 0.01% Ficoll, 0.01% polyvinylpyrrolidone, 0.01% BSA,
50pg/ml, salmon sperm DNA at 42°C for 4 to 24 hours.
Conditions of stringency
Hybridisations were carried out under stringent or non-stringent
81
conditions. Stringency was determined by the relationship of the 
hybridisation conditions to the normal melting temperature of the 
probe DNA, i.e. the temperature at which exact complementary DNA 
strands will separate. Under conditions close to the melting 
temperature, DNA will re-anneal with DNA containing a high 
proportion of sequence homology. These were high stringency 
conditions indicating a high likelihood of sequence homology 
between probe and source DNA. The further from the melting 
temperature, the more likely probe DNA was to re-anneal with DNA 
with less sequence homology. It has usually been assumed that 
positive hybridisation under stringent conditions indicated that 
the source DNA contains the probe DNA sequences.
Melting temperature (Tm) was calculated using the formula of 
Schildkraut and Lifson (1965) :3e;2. This temperature is 
dependent on the relative proportions of purine and pyrimidine 
bases in each virus and was influenced by the salt concentration. 
Hybridisation with HSV probes was always carried out under 
stringent conditions (T™-10). Hybridisation with HPV probes was 
carried out at non-stringent conditions (Tm- 40) and the filters 
washed at stringent or non-stringent temperatures. By exposing 
filters for autoradiography at each stage cellular sequences 
showing some homology with the HPV probe could be detected at 
non-stringent washing. Specific DNA homology could be confirmed 
at high stringency washing.
Hybridisation procedure
HSV DNA probes were denatured in 0.2M NaOH on a heating block, 
neutralised and the filters hybridised in 6 x SSC, 0.02% 
respectively of Ficoll, polyvinylpyrrolidone (PVP), and BSA, 0.1% 
SDS, and 10% dextran sulphate in aqueous solution for 20 hours at 
72c;,C. Filters were then washed in stepwise decreasing washes of 
3 x -0.2 x SSC plus 0.1% SDS and lOmM sodium pyrophosphate.
Filters were air dried and exposed for autoradiography (Kodak) 
with Dupont lighting plus intensifier screens for 2-7 days.
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HPV probes were similarly heat and alkali denatured before 
hybridisation in 50% formamide, 5 x SSC, 50pg/ml salmon sperm 
DNA, 0,01% Ficoll, PVP and BSA in Hepes buffer pH 7.0 at 42°C for 
48 hours. For stringent conditions the filters were washed at 
6 8 °C and for non-stringent conditions filters were washed at 48°C 
prior to exposure for autoradiography. The use of formamide 
allowed hybridisations to be carried out at lower temperatures 
(1% formamide allows reduction by 0.75°C).
Biodyne filters could be re-probed following washing of 
hybridised DNA from the filter. This was achieved by washing in 
50% formamide and lOmM sodium pyrophosphate buffered to pH 6.5 
for 1 hour at 65°C, followed by vigorous washing at room 
temperature in 2 x SSC and 0. 1% SDS for 15 minutes. Washing at 
this temperature in formamide was effectively above the T™ for 
HPV and should remove all hybridised sequences. Filters were air 
dried and re-exposed for autoradiography for 21 days. Providing 
no hybridisation was evident after this time span, the filters 
were re-probed as appropriate.
Hybridisation with undigested DNA
To determine the state of the viral DNA in the tumour DNA, 
undigested DNA was hybridised with HPV probes under non-stringent 
conditions. The procedure, other than the absence of restriction 
enzyme digestion, was identical to that described above.
Reconstruction (positive control) experiments
All gels examined contained a standard reconstruction assay 
containing known quantities of the viral DNA to be probed. The 
amount of viral DNA required for each reconstruction was 
expressed in genome copies per diploid cell. This was calculated 
from the relative weights of viral and human cellular DNA. These 
tracks acted as positive control markers for each experiment, and 
as size markers for the viral DNA. RC1 would denote 1 genome
TABLE ,2
PEA PROBES Iff IHVASIVE TUMDUR BIOPSIES
Cervical
tumour
1
2
5 
8 
16
17 
20 
22
23
24
29
30 
35
38
39 
Vulval
tumour
3
9
12
15
18 
19 
21
27
28 
32 
34
Other
tumours
6 
7
13
41
Hindi 11 a Hindlll h Hindlll e Hindlll 1 HPV 6/11 HPV 16 HPV 18
+
+
+
+
+
+
+
+
+
+
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copy of viral DNA per diploid cell and would act as a sensitivity 
marker for that hybridisation.
Vhere the viral probe has not been excised from the plasmid 
vector, plasmid DNA was included in the gel run as control 
against non-specific hybridisation to vector sequences.
Figure 3, a - c and figure 4 demonstrate typical reconstruction 
experiments for Hind a, e and h, and HPV-16, showing the 
characteristic fragment pattern on digestion of these probe DNAs 
with Bam HI. Fragment size markers are shown.
Section 3 : Results
3.1. Hybridisation with herpes simplex type 2 probes
Table 2 lists the DNA probes used for each tumour biopsy.
Two tumour DNAs showed evidence of hybridisation to the Hindlll 
a probe under stringent conditions. Figure 5 shows a Bam HI 
digest of DNA extracted from the cervical tumours 8 and 17, the 
endometrial cancer 7, and the vulval cancers 9, 18 and 19, probed 
with Hindlll a (map units 0.512-718). Hybridisation was seen in 
the track containing Tu 8 , a poorly differentiated squamous 
carcinoma of the cervix, with a fragment at around 8 kb, the copy 
number being about 10 genome copies per cell. This band was not 
colinear with HSV-2 virion DNA, and might represent HSV-2 
homologous sequences integrated into cellular DNA.
No other cervical tumour sample showed evidence of hybridisation 
to Hindlll a or any other HSV cloned probe.
Figure 6 is a Bam HI digest of DNA extracted from cervical 
tumours 2 and 5, and vulval tumour 3, probed with Hindlll a DNA. 
Hybridisation to a fragment, approximately lOkb in size, was seen 
in vulval Tu 3. This did not co-migrate with virion DNA and was 
presumed to represent HSV-DNA integrated into high molecular 
weight cellular DNA. No hybridisation of any other vulval tumour 
DNAs was seen with Hindlll a or any other HSV probe.
FIGURE 3
a. Reconstruction hybridisation for Hindlll a. Lanes 1, 2 and 3 
contain 1, 5 and 10 copies per cell Hindlll a DHA, digested with 
Bam HI, and probed with Hindlll a. The character! si tic 
hybridisation pattern of 7 bands is seen, due to the cleavage 
pattern of Bam HI with this DHA. Size markers are shown on the 
right and lane 4 contains plasmid vector DHA as probe DHA was not 
excised from its vector in this case.
b. Reconstruction hybridisation for Hind III e. Lanes 1, 2 and 3 
contain 1, 5 and 10 copies per cell Hindlll e DHA, digested with 
Bam HI, and probed with Hindlll e. Size markers are on the 
right. The hybridisation pattern shows 4 bands, typical of this 
digest. Two other bands, one of high molecular weight, and one 
of lower molecular weight are not demonstrated on this 
autoradiograph.
1 2 3
FIGURE 3c
Reconstruction hybridisation of Hindlll h DHA, Lanes 1, 2 and 3 
contain 1, 5 and 10 copies per cell Hindlll h DHA, digested by 
Bam HI, and probed with Hindlll h. A typical 3 band digest 
pattern is seen, the size markers indicated on the right.
8FIGURE 4
Reconstruction hybridisation of HPV-16 DHA. Lanes 1, 2, 3, and 4 
contain 20, 10, 5 and 1 copies per cell HPV-16 DHA, digested with 
Bam HI and probed with HPV-16 DHA under stringent conditions. A 
typical single band at 8 kb is seen in lanes 1-3, and faintly in 
lane 4. Lane 5 contains plasmid DHA
FIGURE 5
Bam HI digest of tumour DNAs probed with HSV-2 cloned probe 
Hindlll a under stringent conditions.
Lanes 1, 3 and 4 contain DNA from vulval tumours 18, 19 and 9; 
Lanes 2 and 6  DNA from cervical tumours 17 and 8 ; lane 8  DNA from 
the endometrial cancer Tu 7. The reconstruction tracks are in 
lanes 5 and 7, showing 10 and 1 copy per cell respectively. The 
size markers are indicated on the right. Hybridisation is 
demonstrated in lane 6  (cervical tumour 8 ) with a single band of 
approximately 10 copies per cell at around 8 kb. The RC1 track in 
lane 7 is faintly seen.
FIGURE 6
Bam HI digest of tumour DHAs hybridised with cloned probe Hindlll
a.
Lane 1 contains DHA from vulval tumour 3, lanes 3 and 5 DHA from 
cervical tumours 2 and 5. The reconstruction tracks, one and 5 
copies per cell, are shown in lanes 2 and 4. Size markers are 
shown on the left and the band nomenclature on the right. 
Hybridisation is seen in both reconstruction tracks. In addition 
hybridisation is seen to a band in lane 1 (vulval tumour 3) at 
approximately lOkb (as indicated).
TABLE 3
HYBRIDISATION TO HPV 16 DHA QF TUMOUR AND MATCHED CQJTTRQL
T1SSQE-DBA
Tumour Control
Stringent Ion-stringent Stringent Ion-stringent
Tu 20 + + + +
Tu 22 + +
Tu 23 + + + +
Tu 24 + +
Tu 29 + + + +
Tu 30 + +
Tu 38 + + + +
Tu 39 + + + +
Tu 27 + + + +
Tu 34 + + + +
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Hybridisation to Hindlll a DHA was therefore seen in 1 of 9 
cervical and 1 of 1 0  vulval tumours tested.
3.2 Hybridisation with human papillomavirus types 6  and 11 probes
Ho evidence of hybridisation to these probes was seen under 
stringent conditions to any tumour DHA although even under 
stringent conditions, cross-hybridisation between HPV-11 and HPV- 
16 DHA was noted.
Figure 7 demonstrates cross-hybridisation under non-stringent 
conditions. This experiment shows DHA from vulval tumour 27 and 
its derived cell line Tu 31 hybridised with HPV-11. Tracks 1 and 
2 contain HPV-16 reconstructions at 1 and lOcopy per cell; 
tracks 5 and 6  HPV-11 reconstructions. Clear hybridisation of 
HPV-11 probe DHA to linear 8 kb HPV-16 DHA is seen.
3.3 Hybridisation with human papillomavirus type 16 probe
Tumours and matched control tissue
The results from those tumours from which matched control tissue 
was available are shown in Table 3. All cervical and vulval 
tumours tested demonstrated the presence of DHA homologous to 
HPV-16 DHA under stringent hybridisation conditions. Figure 8  
represents a Bam HI digest of tumours 24 and 39, probed with HPV- 
16 DHA under stringent conditions. Tumour 39 showed 
hybridisation of a single band, migrating at less than 8 kb, 
suggesting that only part of the viral genome was present in this 
tumour. Tumour 24 demonstrated hybridisation to 3 fragments, one 
of which was col inear with the reconstruction tracks, 
representing a linear insert of intact viral DHA. The additional 
non-col inear fragments were presumed to represent viral DHA 
integrated into different sites within cellular DHA.
Figure 9 represents undigested tumour and matched control DHA 
probed with HPV-16 under stringent conditions. The tumour and 
control pairs 20, 23, 24, and 39 are shown. In addition internal
1 2 3 4 5 6 7
m0 8k b
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FIGURE 7
Bam HI digest probed with HPV-11 under non-stringent conditions. 
Lanes 1 and 2 contain HPV-16 DHA at 1 and 10 copies per cell. 
Lanes 3 and 4 contain DHA from vulval tumour 27 and vulval cell 
line 31 respectively. Lanes 5 and 6  contain HPV-11 DHA at 1 and 
5 copies per cell, and lane 7 contains plasmid DHA.
Hybridisation is seen with the HPV-11 reconstruction in lane 6 . 
Cross-hybridisation is also clearly seen to unit length HPV-16 
DHA in both lanes 1 and 2. There is no hybridisation to either 
tumour or plasmid DHA.
FIGURE 8
Bam HI digest of cervical tumour DNA probed with HPV-16 under 
stringent conditions.
The reconstruction experiments are in lanes 1 and 2 at 1 and 10 
copies per cell. Lane 3 contains DNA from cervical tumour 24 and 
lane 4 D M  from cervical tumour 39.
Hybridisation to the reconstruction tracks is seen at one copy 
per cell (lane 1), Both tumour D M s  hybridise to HPV-16 D M  at a 
level of about 10 copies per cell. Tumour 24 exhibits 3 bands, 
one of which is colinear with the reconstruction band in lane 2. 
Additional, lower molecular weight bands are also seen. Tumour 
39 exhibits a single band, not comigrating with the 
reconstruction track D M .
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FIGURE 9
Undigested tumour and internal control DNA probed with HPV-16 DNA 
under stringent conditions.
DNA from tumour and control pairs 23, 24, 39, and 20 are shown in 
lanes 1+2, 3+4, 6+7, and 10+9 respectively. Control DNA only 
from tumours 27, 29 and 22 are also demonstrated in lanes 5, 8  
and 12. Lane 11 contains DNA extracted from a normal external 
control cervix and lanes 13-15 contain the reconstruction tracks 
with 1, 5 and 10 copies per cell. Lane 16 contains plasmid DNA. 
Hybridisation to all samples except controls 2 2  and 24 (lanes 1 2  
and 4) is seen under stringent conditions. No hybridisation to 
external control cervix is seen in this sample.
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controls 27, 29 and 22, and a normal external control cervix are 
demonstrated. Hybridisation of matched control tissue was 
clearly seen in 3 of the 4 matched pairs and in control 29. In 
all, 5 of 8 cervical control tissues demonstrated hybridisation 
under stringent conditions. Both vulval control tissues showed 
evidence of hybridisation. Hybridisation of Bam HI digested DNA 
from vulval Tu 34 and its matched control normal skin is shown in 
Figure 10. Tu 34 had a single 8 kb band, present at approximately 
5 copies per cell, which co-migrated with the reconstruction
track. The matched control tissue also demonstrated a single 
comigrating band, at lower copy number. Comparison of Bam HI 
digests of the other vulval tumour, Tu 27 and its matched control 
will be described more fully in Chapter 4.
Hybridisable sequences comigrated with high molecular weight 
cellular DNA in both tumour and control DNAs, suggesting that HPV 
DNA was present either in concatemeric form or integrated into 
cellular DNA. The complex patterns seen, for example in Tu 24 
and 27, suggest that integration was more likely.
Unmatched tumours
Cervical tumours 1, 2, 5, 8 , 17 and 35 were probed with HPV-16 
DNA. There was insufficient DITA for analysis of tumour 16.
Figure 11 shows Bam HI digested DUA from the cervical tumours 2, 
17, 23 and 35 and the vulval tumour 28 probed with HPV-16 under 
stringent conditions. Ho hybridisation was demonstrable in Tu 2. 
Tu 23 DNA demonstrated faint bands on this exposure which did not 
co-migrate with virion DNA. Tu 17 DNA clearly demonstrated an 
8 kb band, at more than 10 copies per cell and Tu 35 had a single 
band at similar copy number, but migrating more slowly than the 
8 kb virion band. Neither Tu 1, 5 (see figure 12) or 8 showed 
evidence of hybridisation with HPV-16 under stringent or non- 
stringent conditions. The nude mouse tumour 41, derived from a 
squamous carcinoma of the cervix, did show evidence of 
hybridisation to an 8 kb fragment on long autoradiographic 
exposures.
FIGURE 10
Hybridisation of Bam HI digest of vulval tumour 34 and internal 
control tissue with HPV-16.
Lanes 1 and 2 contain HPV-16 DBA reconstructions at 1 and 10 
copies per cell. Lane 3 contains DBA from vulval tumour 34 and 
lane 4, DBA from control skin from this patient. Size markers 
(kb) are indicated on the left.
Hybridisation to the reconstruction tracks is seen, faintly on 
this exposure at a level of one copy per cell. There is 
hybridisation to vulval tumour 34 DBA at a level of 5 copies per 
cell which comigrates with the reconstruction tracks at 8 kb, 
suggesting the presence of unit length HPV-16 DBA in this tumour. 
In lane 4 a faint band is seen at a level of 1 - 2 copies per 
cell, also comigrating with the reconstruction track DBA. This 
suggest that the control DBA also contains unit length HPV-16 
DBA.
FIGURE 11
Bam HI digest of tumour DMs probed with HPV-16 under stringent 
conditions.
The reconstruction tracks, at 10 and 1 copies per cell, are shown 
in lanes 2 and 3. D M  from cervical tumours 23, 17, 35 and 2 is 
present in lanes 1, 4, 6  and 7 respectively. Lane 5 contains D M  
from the vulval carcinoma-in-situ 28 and lane 8  contains D M  from 
the nude mouse tumour 41, derived following injection of cells 
from a cervical squamous carcinoma. In this exposure 
hybridisation at 10 copies is clearly seen (lane 2). Tumour 17 
(lane 4) shows hybridisation which comigrates with the 
reconstruction track at 8 kb. Tumour 41 (lane 8 ) also has a faint 
band at 8 kb on this exposure, confirmed on longer exposures. 
Tumours 23 and 3 5  (lanes 1 and 6 ) also show hybridisation to 
single but differing bands (the band in lane 1 is indicated). 
Tumour 2 (lane 7) does not hybridise to HPV-16 DM. The vulval 
tumour 28 (lane 5 ) has multiple bands at high copy number (see 
text for details).
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Vulval tumours 3, 9, 12, 15, 18, 21, 28,and 32 were probed with 
HPV-16. Only tumour 3, which contained DNA homologous to HSV-2 
Hindi 11 a DNA, and tumour 18 did not show hybridisation to HPV-16 
DNA under stringent conditions. Figure 12 shows HPV-16 probing 
of undigested DNA from tumours 9, 18, 21, 27 and 34 under 
stringent conditions. Cervical tumour 5 and the two endometrial 
tumours 6  and 7 are also shown on this figure. Figure 11 
has already demonstrated the in situ carcinoma, Tu 28, 
hybridising to HPV-16 DNA. This tumour contained very high copy 
number viral DNA in an apparent complex integration pattern. The 
precise configuration of the viral DNA in this tumour will be 
discussed later.
Analysis of both endometrial carcinomas under stringent 
conditions revealed that HPV-16 homologous DNA was present. The 
vaginal carcinoma, tumour 13 did not contain such sequences.
Normal control tissue (unmatched)
Nine samples of normal ectocervix and 2 samples of normal vulval 
skin were probed with HPV-16 DNA. An example of normal cervical 
tissue is included in Figure 9 and an example of vulval skin is 
shown in chapter 4. One of the cervical samples did show 
evidence of hybridisation to HPV-16 DNA under stringent 
conditions.
3.4. Hybridisation with human papillomavirus type 18 probe
The tumour DNAs probed with HPV-18 DNA are listed in Table 2.
None of the matched tumour-control pairs exhibited evidence of 
hybridisation to HPV-18. Two tumours, vulval tumour 28 and 
cervical tumour 35, did hybridise to HPV-18 DNA under stringent 
conditions. Fig 13a shows these 2 tumours probed with HPV-18 
after Bam HI digestion. Both tumours also hybridised to HPV-16. 
Reconstruction experiments indicated that even under stringent 
hybridisation conditions there was some weak cross-hybridisation 
between HPV-16 and 18. Figure 13b shows HPV-16 DNA
«  * TtTJ
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FIGURE 12
Undigested tumour DNAs probed with HPV-16 under stringent 
conditions.
Lanes 1 to 5 contain DNA from the vulval tumours 9, 18, 21, 27 
and 34 respectively. Lane 6  contains DNA from cervical tumour 5 
and lanes 7 and 8 , DNA from the endometrial tumours 6  and 7. 
Lanes 9 to 11 contain reconstructions at 1 , 5 and 10 copies per 
cell. Lane 12 contains plasmid DNA.
Hybridisation is seen to all samples except vulval tumour 18 
(lane 2) and cervical tumour 5 (lane 6 ).
a. b.
FIGURE 13
a. Bam HI digest of tumour DBAs probed with HPV-18 under 
stringent conditions. Lanes 1, 3 and 4 contain the cervical 
tumours 2, 35 and 17. Lane 2 contains DBA from the vulval 
carcinoma-in-situ 28. Size markers (kb) are shown on the left. 
Bo hybridisation is seen in lanes 1 and 4. Tumour 35 (lane 3) 
shows hybridisation at high copy number, with multiple bands.
The low molecular weight band in this lane is consistent with 
hybridisation to HPV-18, confirmed by the hybridisation pattern 
seen on Pst I digest of this tumour DBA (see text for details). 
The hybridisation seen in lane 2 (tumour 28) also shows multiple 
bands. The band pattern is however similar to that seen on 
probing of this tumour with HPV-16 (see lane 5, figure 11) and 
could represent cross-hybridisation at high copy number.
b. Bam HI digest of HPV-16 DBA probed with HPV-18 DBA under 
stringent conditions. Lane 1 contains 10 copies per cell and 
lane 2, 1 copy per cell. Hybridisation is seen in lane 1.
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reconstructions probed by HPV-18 DNA under stringent conditions, 
demonstrating the degree of cross hybridisation evident. Tumour 
35 showed the characteristic Bam HI digestion pattern of HPV-18 
with the low molecular weight band, obtained as the HPV-18 genome 
is cut twice by this enzyme. Tumour 28 did not exhibit this 
band. Pst I digest of these tumour DNAs confirmed that the HPV- 
18 homologous DNA in tumour 35 had the characteristic pattern of 
HPV-18, whereas the relative digestion pattern of tumour 28, 
although showing hybridisation to HPV-18, was similar to that of 
HPV-16. The precise significance of these findings was unclear. 
It could be due to cross-hybridisation between the two viral 
types when viral DNA was present in high copy number.
3.5. Summary of results
HSV-2
Hindi 11 a sequences (which span the MTRII region of HSV-2, see 
figure 2 ) were detected in one of nine invasive cervical and in 
one of ten invasive vulval cancers. Hybridisation to other 
probes spanning the putative mtr regions of the HSV genome was 
not seen in any specimen.
HPV- 6  and 1 1
Hybridisation to these probes was not detected in any specimen. 
HPV-16
HPV-16 DNA appeared to be ubiquitous in cervical and vulval 
invasive cancers in this study. Hybridisation to HPV-16 DNA 
under stringent hybridisation conditions occurred in 10 of 14 
cervical tumours and 8  of 1 0 vulval tumours examined.
However, HPV-16 DNA was frequently identified in non-malignant 
genital tract tissue in these women. Where internally matched 
normal tissue was available, 7 of 10 samples demonstrated
TABLE 4
PROGNOSIS OF TOME If VITH I EVASIVE CAECER AFP PEA STATUS
Tumour tissue Matched control
HSV-2 HPV 16 HPV 18 HPV 16 Months
followed
Status
Cervix
Tu 1 n/d - - N/A 18 Died of disease
Tu 5 - - - N/A 35 Disease free
Tu 8 + - n/d N/A 12 Died of disease
Tu 16 - n/d n/d N/A 34 Alive,recurrence
Tu 17 - + - N/A 14 Died of disease
Tu 20 n/d + - + 42 Disease free
Tu 22 - + - - 48 Alive,recurrence
Tu 23 n/d + - + 42 Alive,local recurrence
Tu 24 - + - - 24 Died of disease
Tu 29 n/d + - + 37 Disease free
Tu 30 - + - - 18 Died of disease
Tu 35 - + + N/A 30 Died of disease
Tu 38 - + - + 30 Disease free
Tu 39 n/d + - + 30 Disease free
Vulva
Tu 3 + - - N/A 48 Died of disease
Tu 9 - + - N/A 48 Alive,recurrence
Tu 15 - + - N/A 40 Disease free
Tu 18 - - N/A 40 Died;not tumour
Tu 21 - + - N/A 19 Died of disease
Tu 27 - + - + 12 Died of disease
Tu 28 - + + N/A 36 Disease free
Tu 32 - + - N/A 32 Disease free
Tu 34 - + - + 33 Disease free
n/d, insufficient DNA for full analysis 
N/A, not available
- , no detectable DNA at stringent conditions 
+ , hybridisation at stringent conditions
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hybridisation to HPV-16 under stringent conditions. Ho 
significant difference in the prevalence of HPV-16 genomes in 
malignant and non-malignant tissue in women with invasive genital 
cancer was demonstrable (y2 = 0.28, not significant).
HPV-16 DITA was also identified in 2 biopsies from endometrial 
adenocarci noma.
HPV-18
HPV-18 DUA was rarely identified in this population. Of 22 
tumours probed with HPV-18, only 2 demostrated the presence of 
HPV-18 homologous DNA, Both of these tumours also hybridised to 
HPV-16 DNA probes, with one tumour demonstrating the restriction 
pattern of HPV-16 rather than HPV-18.
Section 4 : Prognosis of women with and without detectable human
papillomavirus genomes in genital cancer tissue.
The ubiquity with which HPV-16 genomes were detectable in both 
tumour groups make comparisons of prognosis in these small 
numbers difficult.
Follow up data on the outcome of 14 cervical and 9 vulval 
tumours were available. The outcome and DNA status is shown in 
Table 4 .
Of three HPV-16 DNA negative cervical tumours, including the 
HSV-2 DNA containing tumour, two have died of secondary disease 
and one was disease free at 40 months post treatment.
Of ten HPV-16 DNA positive tumours reviewed, 4 have died from 
disease at between 14 and 30 months following surgery. Two have 
evidence of recurrent disease but were alive at the time of
review. Four women remain alive and disease free.
The two patients whose vulval tumours did not contain HPV-16 
homologous DNA have died, one from recurrent disease and one from 
unrelated causes. This latter patient's tumour contained Hindlll
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a homologous DNA. Of the 7 tumours which contained DNA 
homologous to HPV-16 DNA, 4 were disease free, 2 have died of 
recurrent disease and one was alive but had received treatment 
for recurrent disease. This latter patient was the youngest 
patient with vulval disease and had local excision of a vulval 
recurrence. Since then she has successfully completed a 
pregnancy and remained disease free at time of review.
Analysis of the outcome of patients with cervical cancer where 
matched control tissue distant to the primary tumour was 
available, showed that of the 3 women without evidence of HPV DNA 
distal to the tumour, 2 were dead from disease. One was alive 
but has had recurrent disease. This patient, from whom the cell 
lines Tu 22-1 and 22-2 are derived, will be described in detail 
in chapter 4. Of the 5 women in whom HPV-16 DNA was detected in 
distal tissue, 4 were disease free, and one was alive with 
recurrent disease. There was no apparent relationship between 
disease free survival and HPV-16 status in either tumour or 
distal tissue. Indeed it appeared that HPV-16 DNA in distal 
tissue imparts a better prognosis in this small group.
The overall survival for the cervical cancers in this study, 
considering that all but one sample was obtained from women with 
early disease, suitable for surgical treatment, was poor.
Patient selection is discussed in the next section and the 
possible implications of using atypical tumours to demonstrate 
viral oncogenesis will be discussed more fully in chapter 4 and 
in the discussion in chapter 6 .
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Section 5 : Discussion of methodology
5.1 Selection of patients
Selection of patients used in this and in the culture studies 
described in chapter 3 was arbitrary. The decision to utilise a 
particular tumour was dependent on availability and tumour size 
as sufficient tumour tissue was required for DNA extraction, 
tissue culture and for adequate histological study. Cervical 
cancer patients were therefore a selected group of women with 
early disease, suitable for radical surgery, but with relatively 
large tumours. The mean age (35,8±7.4 years) of such patients 
was lower than that normally ascribed to cervical cancer for 
these reasons. Selection bias could therefore have influenced 
the results.
However, the prevalence of HPV-16 DNA was high in this younger 
population, contrary to what might have been expected based on 
the age progression seen by Meanwell et al (1987) It was
not thought that these women represented an atypical sample for 
viral DNA prevalence studies. There was less selection for 
vulval tumours as most of these were sufficiently large and all 
women fit for anaesthesia underwent radical surgery. The wide 
age range (up to 92 years) reflected the aggressive surgical 
policy of the Northern Regional Gynaecological Oncology Unit and 
the high standard of available anaesthesia.
Both tumour groups were small and it was difficult to draw 
major inferences on population prevalence on small samples. 
Nevertheless the data from this were consistent with other U.K. 
studies 2 0 1  . and were consistent with local studies which 
indicated that HPV-16 was present in a very high proportion of 
pre-malignant genital tissue * ^ os\
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5.2 Control tissue
In the latter half of the study, it was appreciated that there 
was little data on normal internal control tissue in women with 
malignant genital cancer. Previous work within the laboratory 
with in situ hybridisation using HSV probes 3 3 6 3 had demonstrated 
the value of such comparisons. Control tissue was therefore 
collected from 9 cervical and 5 vulval tumours. Initial 
difficulties with DNA extraction of large biopsies of frozen 
tissue resulted in very poor yields from the extraction process 
and insufficient quantities for analysis in 1 cervical and 3 
vulval samples (tumours 19,21,32,38). Prior pulverisation of 
these large samples in dry ice as suggested by Green et al (1979) 
3e3, resulted in the extraction of large quantities of control 
DNA.
The choice of tissue site was a clinical one. For cervical 
tumour specimens, a section from the uterine fundus was chosen as 
it represented genital tract tissue, was far distant from the 
primary site ( at least 5cm.), and was non-epithelial tissue not 
thought to be permissive for HPV. Great care was taken not to 
include endometrial tissue in the sample and a fresh scalpel was
utilised for the control sample. I was therefore confident that 
no contamination of the control tissue with tumour tissue 
occurred in the sampling process. To ensure that the tissue used 
was histologically normal, samples for extraction were snap 
frozen. DNA was not extracted until histological examination of 
the surgical specimen was complete. In the event, no 
histological evidence of tumour was found within 5cm of the 
control sampling area. This tissue was therefore uncontaminated 
internal control tissue.
The choice of control tissue for vulval cancer was more 
difficult. The idea of using DNA extracted from blood taken 
during the procedure was dismissed as impractical and possibly 
dangerous for older women undergoing radical surgery. It was 
decided to use abdominal skin from the uppermost part of the 
radical surgical specimen. Skin removed during radical
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vulvectomy was taken as a butterfly shaped excision. The upper 
edge of this excision was normally several centimetres from the 
vulval tumour. The same sampling precautions were taken. Such 
tissue was less satisfactory than myometrium as control tissue as 
it was squamous epithelium, and was closer to the tumour. 
Microscopic subepithelial invasion has been described for vulval 
cancer, making it difficult to decide the minimum distance at 
which one could be confident that epithelium would be normal. 
Ferenczy et al (1985) 2 1  1 demonstrated the presence of viral 
genomes up to 15mm from the nearest histological evidence of 
condylomata and possibly HPV-16 DMA 15mm from one case of VIM 3. 
Our control tissue was a minimum of 20mm from the nearest 
histological evidence of tumour.
5.3 Hybridisation techniques
Southern blot hybridisation techniques were complex and time 
consuming. They still represented the best method for the 
detection of HPV DMA in human cells. The technique was 
sensitive, detecting down to 1 genome copies per cell. They 
allowed positive identification of the viral DMA involved by use 
of restriction enzyme pattern analysis. Thus any variants would 
be detectable. They were the only method which could tell 
whether viral DMA was free or integrated into cellular DMA,
However they relied on total tissue DMA. This had two major 
drawbacks. Firstly, a tumour biopsy will consistofra minority of 
malignant cells. Viral DMA present in these cells would be 
diluted by normal cellular DMA. Southern blot hybridisation did 
not distinguish between 10 cells with 100 copies of viral DMA and 
1000 cells with one copy. In histological terms, this type of 
analysis did not give any information on the type of cells 
containing viral DMA or their distribution within the tumour.
Other techniques have been utilised in the analysis of viral DNA 
in genital tumours. Filter hybridisation bypasses the tissue 
digestion and DMA extraction required for Southern blot analysis 
3 S ‘<1 as cells are disrupted, DMA immobilised and rendered single
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stranded on the hybridisation filter. Such a technique could 
more readily allow analysis of large numbers of samples as could 
dot blot hybridisation techniques 2 0 *5 . 2 0 7  These techniques 
might not be as sensitive as conventional hybridisation and still 
relied on total tissue DNA. In addition, problems with cross 
hybridisation of probe DITA with normal human DNA could arise.
HSV DNA contains sequences which readily hybridise with human DNA 
and these regions have been identified. HPV DNA cross 
hybridises with Alu sequences =3e-A and it has been suggested that 
part of the highly conserved E6 region of the HPV-16 and 18 types 
could be present and transcribed in normal human DNA 3es 
In situ hybridisation of tissue sections using biotin-avidin 
labelling tritiated thymidine or 3 SS-thionucleoside
triphosphates2 2 2  has been applied to genital tissue. This has 
allowed study of stored tissue and historical comparisons. It 
has also allowed accurate delineation of the cell type containing 
viral DNA. This was particularly applicable to the study of pre- 
malignant tissue where the presence of a limited number of cells 
with high copy number viral DNA allowed positive hybridisation 
using these techniques. Biotin-avidin hybridisation has a 
sensitivity of over 100 copies per cell, 3 SS-labelling 10-30 
copies per cell and tritium labelling 1-3 copies per cell. Such 
techniques might therefore not be sensitive enough for use in 
invasive tissue in which most cells contained low copy viral DNA 
(e.g. SiHa cell line). The application of single stranded RNA 
probes 2 3 : 7  which are as sensitive as southern blot techniques 
and allow cellular and intracellular localisation of DNA and RNA 
could prove valuable.
The recent introduction of polymerase chain reaction techniques 
3&e, which are capable of detection of target DNA sequences at a 
sensitivity of 1 0 s fold that of southern blotting and could 
therefore be applicable to small samples such as cervical smears, 
could allow more representative ascertainment of the prevalence 
of HPV both in neoplastic and in normal tissue. This technique 
is very sensitive and there are reservations regarding false
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positivity 3es? especially in view of the known cross­
hybridisation with specific HPV DNA sequences
Nevertheless, none of the other techniques offer any information 
on the pattern of viral DNA within tumour DNA or whether or not 
viral DNA is integrated into cellular DNA.
5.4 Cross-hybridisation
In the reconstruction experiments, cross-hybridisation between 
HPV-11 and HPV-16, and between HPV-16 and HPV-18 was noted. This 
was apparent under non-stringent conditions (as in Figure 7) and 
was consistent with similar cross-hybridisation described under 
non-stringent conditions in early studies 1S,S. 1 Of more
concern was the cross-hybridisation noted even under stringent 
hybridisation conditions (as in Figure 13b for HPV-18).
No tumour DNA hybridised to HPV-11 under stringent or non- 
stringent conditions, and therefore in terms of the prevalence of 
particular viral types in tumour tissue, the cross-hybridisation 
noted might not be of direct relevance. However, both tumour 
DNAs hybridising to HPV-18 DNA also hybridised to HPV-16. In the 
case of Tumour 35, given the restriction patterns, it appeared 
likely that the tumour contained both viral types. Such mixed 
infections have been described by others in both premalignant and 
malignant tissue 1 3 3  • zos In t^e case 0f tumour 28, it would 
appear that cross-hybridisation had occurred, the Pst I digestion
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THe HPV-18 DNA probe was kindly supplied by Drs zur Hausen and 
Gissmann. Reconstruction experiments with HPV-18 indicated 
sensitivities of detection down to 1 genome copy per cell. Under 
stringent hybridisation conditions, weak cross-hybridisation was 
observed between HPV-18 and 16. The HPV-18 used did not cross-hybridise 
with HPV-1 1 , Exposure times to demonstrate the cross-hybridisation with 
HPV-16 were usually in excess of 1 0 days. In two instances (e.g.see 
figure 13b) cross-hybridisation was detected on normal exposure times 
(2-7 days), and to a more marked degree. Contamination of the probe 
preparation was excluded as no hybridisation to known HPV-16 containing 
tumours was demonstrated in these particular experiments. The 
possioility of inadvertant lower stringency conditions was considered.
CULTURE QF BIOPSY TISSUE FROM IlTVAfiTVK CANCERS OF 
IHE_LQVER GENITAL TRACT
Section 1 : Intrcxiuction
A major problem in the study of the putative role of HPV in 
genital cancer has been the lack of a suitable in vitro model 
system in which the expression of the virus can be observed under 
experimental conditions. Most information on viral organisation, 
expression and oncogenesis had until recently come from 
extrapolation of work carried out in bovine papillomavirus.
Viral types 16, 18 and 31, those most frequently associated with 
malignant genital tumours, could not be maintained in cell 
culture. Therefore to examine the action of these viral types in 
human cell systems it was necessary to either morphologically 
transform cells in vitro or to find a natural model system where 
HPV genetic information was already present in transformed cells.
Transformation of rodent cells has been achieved using 
transfection of HPV-16 DNA 1 &3_ 1 65-3. These cells retain HPV DNA 
and transcribe RNA. Such cells exhibited some oncogenic 
properties'. As described in chapter 1, transformation of human 
keratinocytes by HPV-16 was feasible and established
long term epithelial cultures have been described from 
transfection of ectocervical cultures by HPV 17'3 , Such cells 
did not exhibit the full oncogenic range, and as such might not 
resemble in any way the situation in vivo.
An alternative approach would be to study those cell lines 
derived from genital tumours in which viral DNA was identifiable. 
Under these circumstances viral DNA has been introduced into 
cells under natural conditions and thus examination of the 
function of such DNA might be more representative of the true
96
role of HPV in these cancers. A number of studies examining old 
and newly established cervical cell lines have been carried out 
i s*e, as©, 3 7 0 - 3 7 a which have identified DNA homologous to HPV- 
16 or 18 DNA in cell line DNA. The only vulval cell line studied 
is the A431 line 3 : 7 1 and viral DNA was not detectable. There 
were a number of important reservations in extrapolating such 
data to the clinical situation,
The relative proportions of HPV-16 and 18 in established cell 
lines contrasted strongly with the distribution of these viral 
types in tumour biopsies (see chapter 1). This dissociation made 
it difficult to extrapolate findings from these lines to an in 
vivo situation.
The role of a sexually transmissable factor in the genesis of 
cervical cancer and to a lesser extent vulval cancer, applied to 
squamous carcinomas which undergo a premalignant phase. Many of 
the cell lines studied were poorly classified in histological 
terms and could be adenocarcinomas or mixed tumours, again 
raising doubts regarding their usefulness in elucidating the 
precise nature of the role of HPV in cancer. These older lines 
have also been extensively passaged and this could result in cell 
selection or DNA rearrangements far removed from the original 
tumour.
Two other reservations were impossible to assess in existing 
cell lines. There was always selection in attempting to obtain 
continuous cell lines from tumour biopsies and therefore 
reservation on the ability of a given cell line to reflect the 
behaviour of tumour cells in vivo. Comparison of the state of 
viral information in biopsy material and in derived cell lines 
could allow better utilisation of the cell line. Similarly if 
the presence of viral information in cells of a derived 
continuous line was to be regarded as meaningful then it must be 
clear that such viral information was not present in that 
patient's normal tissue. These questions have not been addressed 
to date.
Attempts were therefore made to derive continuous cell lines 
where DNA analysis of the original tumours was available and
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where, in a proportion of cases, normal tissue from the same 
patient was available as internal control. Conservation of copy 
number and arrangement of sequences would be strong evidence that 
such cell lines would be accurate tools for the study of the 
mechanisms of carcinogenesis in genital malignancy.
Section 2 : Tissue culture methods
2.1 Primary explant culture
Culture of tumour biopsy material was largely carried out using 
a primary explant technique modified from Vesterinen et al (1981) 
3'7S which had been successfully used in cervical tumour explant 
culture by Kitchener (1985) 37'e
Tissue was obtained from the following sources:-
: hysterectomy specimens from women without malignant disease 
with a recent history of normal cervical cytology
.•cervical tumour biopsies obtained from either punch biopsy, 
wedge biopsy, or radical hysterectomy for invasive 
cervical cancer
:vulval tumour biopsies obtained from either excision biopsy 
simple or radical vulvectomy for invasive vulval cancer.
For normal cervical tissue, strips of ectocervix were dissected 
aseptically in the operating theatre from hysterectomy specimens. 
Care was taken to remove as much stromal tissue as possible at 
the time of the initial dissection. Tissue strips were 
immediately placed in culture medium, stored on ice and taken to 
the laboratory. For tumour tissue, areas of viable tumour were 
aseptically dissected in theatre from the surgical specimen,
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taking care to avoid areas of stroma and necrosis. This tissue 
was similarly placed in culture medium and transported on ice. 
Tissue was washed extensively in Hank's Balanced Salt Solution 
(BSS)at 4°C and minced into 2 to 3mm fragments. Four to six 
explant fragments were seeded onto 50mm plastic petri dishes and 
overlayed with 1.5 ml, of medium. Plates were incubated 
overnight at 37°C in 5% C0S. The following day a further 3.5ml of 
medium was added and the plates reincubated. Medium was changed 
every 4 days and non-adherent explants removed.
2.2 Culture medium
Primary culture was carried out in a 1:1 mixture of Ham's F12 
medium and Dulbecco's MEM (Flow laboratories, Irvine, Scotland) 
supplemented with 20% fetal calf serum (Gibco), 2mM L-glutamine, 
lOOu/ml penicillin, 100/ig/ml streptomycin and lOng/ml epidermal 
growth factor (Boehringer, Mannheim).
Initial subcultures of some tumour explants were carried out in 
a 2 : 1  mixture of fresh medium and spent medium obtained from 
established, growing primary cultures of normal cervical 
epithelium. The spent medium was filtered through a 20/i 
Millipore filter and stored at -20°C. Prior to use each batch 
was thawed and an aliquot plated onto blood agar. Provided no 
bacterial or fungal growth ensued in 1 0 days, then the batch was 
used in explant culture. All other subcultures were carried out 
in fresh medium.
2.3 Subculture of explant cultures
Vhen it was felt that there was sufficient explant growth 
(usually >60% of plate), then attempts were made to disaggregate 
and subculture the primary culture.
Medium was removed and the cultures washed twice in 0.02% EDTA 
in phosphate buffered saline (PBS) at room temperature. Cultures 
were overlayed with 1ml of 0.0625% trypsin in 0.02% EDTA for 5 
minutes at room temperature and 10-15 minutes at 37‘‘C. Plates
99
were directly observed during this time for evidence of 
disaggregation. Plates were then washed with 1-2 ml. of fresh 
medium and the plates inspected for completeness of 
disaggregation. If the majority of the cells were still 
adherent, the process was repeated. The resultant cell 
suspension was centrifuged at 2000rpm for 5 minutes at 4°C and 
the pellet suspended in fresh medium or a mixture of fresh and 
spent medium. Cell viability after this procedure in normal 
cells was 65-80% by trypan blue exclusion.
2.4 Management of fibroblast contamination
Fibroblastic contamination was not a major problem in normal 
cervical cultures, but was a persistent problem in tumour explant 
culture.
Great care was taken to try to dissect stromal tissue from 
epithelial or tumour tissue both at the time of the initial 
dissection and when mincing tissue into small explants. However 
as tumour tissue was rarely a pure cell type, fibroblasts 
persistently grew in epithelial cultures.
Isolated fibroblast colonies were removed under direct vision by 
scraping with a sterile heated Pasteur pipette at regular 
intervals. If this was insufficient or if the colonies of tumour 
and fibroblasts were too closely interspersed, then fibroblasts 
were removed by partial disaggregation. Medium was removed and 
the plate washed as above. 1.5ml of 0.02% EDTA in PBS was 
overlayed and the plate incubated at 37°C for 2 minutes. The 
plate was washed with 2ml of fresh medium. Generally this 
removed human fibroblasts without disaggregating epithelial 
tumour cells.
2.5 Culture of cervical and vulval tumours in athymic nude 
outbred mice.
The high failure rate (see results) in establishing primary 
growth from tumours in explant culture led to an attempt to
100
establish cell lines following passage of tumour biopsy material 
through laboratory rodents. This work was carried out in the 
Department of Experimental Tumour Research, Royal Hospital for 
Sick Children, Glasgow in collaboration with Dr. Tariq Ali.
Tumour tissue was collected as before and stored in normal 
medium on ice. The biopsy was then washed extensively in ice 
cold PBS and minced in a hand grinder. The resultant preparation 
was passed through a series of needles to gauge size 23 under 
strict aseptic conditions. The resultant suspension was checked 
for cell viability by trypan blue exclusion. The cell suspension 
was centrifuged at 2 0 0 0 rpm for 1 0  minutes and the cell pellet 
reconstituted with fresh PBS to give a cell concentration of 
approximately 1 x1 0 s viable cells/ml.
Outbred athymic, nude mice were used as the vector for these 
experiments. One milliliter of cell suspension was injected 
either subcutaneously in the subscapular region (4 cases) or 1ml 
of cell suspension was injected intra-peritoneally under light 
general anaesthesia (1 case). The mice were observed for 
evidence of tumour growth or metastasis for 16 weeks.
Once the presence of a discrete tumour was noted this was 
excised under general anaesthesia. The animals were observed 
further and sacrificed at a later date.
TABLE 5
PRIMARY EXPLAJT CULTURE QF CERVICAL CARCIIQKA
TUMOUR HISTOLOGY AGE SOURCE DAYS IN 
CULTURE
SUBCULTURE REASON FAILED
1 Poorly 
diff, sq,
36 RHND 0 No Technical- 
incubator C02
2 Squamous 34 RHND 0 No Technical- 
incubator C02
4a Squamous 77 Staging biopsy 24 No Bacterial
contamination
4b Poorly 
diff, sq,
42 Biopsy pre­
radiotherapy
18 Yes •
5 Squamous
'
RHND 20 No Bacterial
contamination
8 Poorly 
diff,sq,
44 RHND 0 No Prior radio­
therapy
10 Squamous 31 RHND 0 No No growth
11 Moderately 
d i f f ,s q ,
33 RHND 0 No Bacterial
contamination
14 Squamous 46 Staging biopsy 0 No Bacterial
contamination
16 Squamous 42 Staging biopsy 41 No Fibroblastic
overgrowth
17 Poorly 
diff.sq,
32 RHND 34 No Fibroblastic
overgrowth
20 Squamous 32 RHND 0 No Prior RT
22 Moderate/ 30 
poorly d i f f .s q ,
RHND 28 Yes
23 Well
d i f f .s q ,
50 RHND 19 No Fibroblastic
overgrowth
24 Moderately 
diff. sq,
26 RHND 0 No Prior radio­
therapy
25 Squamous 60 Staging biopsy 0 No Fibroblastic
overgrowth
29 Poorly 
d i f f ,s q .
35 RHND 36 Yes
30 Squamous 25 RHND 25 Yes -
35 Squamous 37 RHND 19 No Fibroblastic
overgrowth
36 Squamous 36 RHND 0 No Prior RT
38 Squamous 46 RHND 0 No Prior RT
39 Papillary
adeno-ca,
32 RHND 0 No Fibroblastic
overgrowth
40 Adeno­
carcinoma "
Nude mouse 
tumour(Tu 39)
0 No No growth
41 Squamous — Nude mouse 
tumour
0 No No growth
RHED-Radical Hysterectomy and pelvic lymph node dissection 
sq.- squamous; diff.- differentiated; RT - radiotherapy
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Section 3 : Results of explant culture
3.1 Primary explant culture of normal cervical ectothelium
Cultures were attempted from eight normal cervices. In all but 
one, adequate epithelial growth occurred and confluent cultures of 
squamous keratinocytes were obtained after 2 1  to 42 days. 
Generally, two to three explants showed evidence of outgrowth. 
Fibroblastic contamination was rarely a problem with normal 
cultures. Cells showed evidence of differentiation and 
keratinisation. Figure 14 demonstrates primary explant growth of 
normal epithelium with evidence of stratification.
Attempts were made from all cultures to subculture, but this was 
not successful in any case.
3.2 Primary explant culture of invasive cervical cancer
Sustained epithelial cell growth was obtained in 10 of 24 
invasive cervical carcinomas. Full details of the patients, 
duration of primary culture, and reason for failed culture are 
shown in Table 5.
Early epithelial outgrowth occurred at 3-4 days. Figure 15 shows 
an explant of Tu 35 surrounded by radiating growth of rather 
pleomorphic tumour cells at around day 15. If there was 
reasonable growth from more than one explant then epithelial 
growth from these could coalesce. This is demonstrated in Tu 30 
(Figure 16). Ultimately solid monolayers of epitheloid tumour 
cells may form as shown in Figures 17 and 18.
The problems of fibroblast contamination are demonstrated in 
Figures 19 and 20. Figure 19 shows a confluent monolayer of cells 
derived from explants of Tu 30, Epitheloid and fibroblastic cells 
intermingle. This culture was eventually overwhelmed by 
fibroblasts despite selective disaggregation. Figure 20, of a
FIGURE 14
High power view of growing edge of primary explant culture of 
normal cervical ectothelium. Rote stratified nature of cultured 
cells.
(x 40)
FIGURE 15
Low power view <x 25) of epithelioid cells growing from a primary 
explant culture of cervical tumour 35, examined at day 15.
FIGURE 16
View of cells growing from 2 explants of cervical tumour 30 at 
day 26. Tumour cells from the two explants have almost merged on 
the right hand edge of the figure.
(x 25)
FIGURE 17
Low power view <x 25) of monolayer primary culture derived from 
explants of cervical tumour 29 prior to disaggregation at day 36.
I
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FIGURE 18
High power view (x 40) of primary monolayer culture of cells 
derived from cervical tumour 30.
FIGURE 19
High, power (x 40) view of explant growth from a different plate 
of tumour 30, There is intermingling of epithelial and 
fibroblastic cells (at day 2 2 ), the culture being eventually 
overwhelmed by fibroblast contamination.
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FIGURE 20
View (x 25) of primary culture of tumour 35. The culture is 
largely fibroblastic. Isolated tumour cells can be seen in the 
centre of the picture and compression of edge of the epithelial 
culture is seen on the right.
FIGURE 21
Low power view (x 25) of another primary culture of tumour 30, 
In the growing edge of the epithelial culture on the left there 
is patchy degeneration of cells.
FIGURE 22
View (x 40) of edge of primary explant culture of tumour 35. 
Fibroblastic overgrowth is seen on the right of the picture.
Some cells at the edge of the culture have become elongated with 
a slightly granular internal appearance.
TABLE 6
PRIMARY EXPLAJTT CULTURE II VULVAL Ti
TUMOUR HISTOLOGY AGE
3 Veil
diff,sq,
70
9 Moderately 
well diff.sq.
29
12 Squamous 87
15 Squamous 66
18 Squamous 92
19 Squamous 90
21 Squamous 81
26 Squamous 
/VIN 3
77
27 Well
d i f f .s q .
60
28 Carcinoma-in-
situ
75
32 Poorly 
d i f f ,s q ,
73
33 Veil
d i f f ,s q ,
82
34 Squamous 76
SOURCE DAYS IN
CULTURE
Radical 23
vulvectomy
Radical 11
vulvectomy
Excision biopsy 0
Radical 29
vulvectomy
Simple 0
vulvectomy
Excision biopsy 26
recurrenc
Radical 0
vulvectomy
Excision biopsy 21
Radical 0
vulvectomy
Simple 0
vulvectomy
Excision biopsy 33
recurrence
Excision biopsy 19
recurrence
Radical 0
vulvectomy
SUBCULTURE REASON FAILED
No Fibroblastic
overgrowth
No Fibroblastic
overgrowth
No No growth
Yes -
No Bacterial
contamination
No Bacterial
contamination
No Bacterial
contamination
No Fibroblastic
overgrowth
No Bacterial
contamination
No No growth
No Cell death
No Fungal
contamination
No No growth
TABLE 7
PRIMARY EXPLAJTT CULTURE-OTHER TUMOURS
TUMOUR HISTOLOGY AGE SOURCE DAYS IN SUBCULTURE REASON FAILED
6 Adenoca. 60 T.A.H.
CULTURE
18 No Cell death
7
uterine body 
Adenoca. 27 T.A.H. 17 No Cell death
13
uterine body 
Well 60 Anterior 0 No No growth
diff,sq, 
vagina
exenteration
TAH-Total abdominal hysterectomy
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different plate of Tu 35, demonstrates the compression of the 
growing epithelial edge by fibroblasts.
Uncontrollable fibroblast contamination was responsible for the 
failure of 4 of 1 0  primary cultures. Bacterial contamination 
resulted in the loss of 2 other established primary cultures.
Other plates initially grew epithelial outbuds but these failed to 
continue to grow, ultimately showing patchy disintegration, as in 
Figure 21 of Tu 30, or elongation and vacuolation, as in Figure 22 
of Tu 35.
Fourteen sets of explant cultures failed to exhibit any 
epithelial growth. Two did not establish due to early bacterial
contamination, and 2  failed for technical problems with the COz
concentration in the incubator. Two others resulted in a pure 
fibroblast culture. The remainder did not exhibit growth of any 
kind despite prolonged culture.
3.3 Primary explant culture of invasive vulval cancer
Sustained epithelial growth was obtained in 7 of 13 vulval 
invasive cancers. Table 6 shows comparable data on histology and 
days in culture.
Tumour explants behaved in a similar fashion to cervical 
explants. Figure 23 shows early epithelial tumour growth from an 
explant of Tu 33 at day 5. Figure 24 demonstrates continuing 
epithelial growth from Tu 33. Similar problems with fibroblast 
contamination and cell death were encountered and are demonstrated 
in Fig 25, which shows a higher power view containing epithelial 
tumour cells, fibroblasts and degenerating cells.
Bacterial contamination was a more serious problem in vulval 
explant culture, being responsible for the failure of culture 
initiation in 3 instances and failure of growing cultures in 1. 
Three cultures failed due to uncontrollable fibroblast 
contami nat i on.
FIGURE 23
Early epithelial outgrowth (day 5) from explant of vulval tumour 
33. Growth is largely epithelial but a few fibroblastic cells 
can be seen.
(x 1 0 )
FIGURE 24
Continuing epithelial growth from explant of tumour 33 at day 1 0 . 
Cells are pleomorphic and fibroblastic elements are irare 
pronounced than in figure 23.
(x 25)
FIGURE 25
High power view (x 40) of cells from primary explant culture of 
tumour 32. Some cells have degenerated, and some show evidence 
of intracellular vesiculation which appeared to be a precursor of 
degeneration.
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3.4 Primary explant culture of other tumours
Three other tumours were cultured as shown in Table 7. Fone was 
successfully subcultured.
3.5 Subculture of primary explant cultures
Attempted subculture was carried as described in all established 
primary cultures not grossly overwhelmed by fibroblasts as soon as 
approximately 50% of the dish contained confluent epithelial 
cells. This was carried out in 5 instances and 4 are described in 
detail below. The subculture of Tu 22 will be described in detail 
in chapter 4.
a. Tu 4b
Two of 3 plates obtained from this squamous carcinoma of the 
cervix exhibited good epithelial growth by 6  days. By day 15 
epithelioid cells covered about 50% of one plate although there 
were numerous fibroblast colonies. These were removed by scraping 
and on day 18 the epithelioid cells were disaggregated as 
described. Cells proved very adherent and 2 treatments were 
required to remove most cells. The resultant cell suspension was 
replated into a 50ml flat flask with 10ml fresh medium.
Vithin 48 hours there was adherence of some pleomorphic cells 
and a number of fibroblasts. Despite attempts to remove these, 
the few epithelial colonies were overwhelmed by confluent 
fibroblastic growth in 96 hours.
b. Tu 29
Fifteen plates were obtained for culture from this poorly 
differentiated squamous carcinoma of the cervix. After 12 days 
one plate showed reasonable epithelial growth. By day 29 there 
were large epithelial colonies interspersed with fibroblasts.
These were removed by treatment with EDTA and on day 36 the 
epithelial cells were disaggregated and re-seeded. Although small
TABLE 8
TUMOUR GROWTH II ATHYMIC IUDE MICE
TUMOUR HISTOLOGY IIJECTIOI SITE TIME TO II VITRO
EXCISIOI CULTURE
27 Veil diff. Intra-peritonea1/ 42 days Yes
sq. vulva subcutaneous
30 Sq.cervix Subcutaneous lo Vo
35 Sq.cervix Subcutaneous Vo Vo
39 Adenoca. Subcutaneous 21 days Vo
cervix
41 Sq.cervix Subcutaneous 84 days Vo
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epithelial colonies did form they were replaced by a pure
fibroblast culture by 5 days.
c. Tu 30
nineteen plates were obtained for culture of this carcinoma. 
Good epithelial growth was seen in 9 (see Figures 16 and 18). On 
day 25 a number of large colonies were disaggregated within 
cloning rings and reseeded into another 50mm dish. Figure 26 
shows cell growth at day 12. This plate was subcultured but 
fibroblast contamination was a major problem requiring repeated 
treatment and ultimately the culture became contaminated with 
bacteria.
d. Tu 15
Eight plates were obtained for Tu 15. Good epithelial growth
was seen in 7 of these initially but 5 subsequently succumbed to
fibroblastic over growth. By day 22, 2 plates had grown to 
virtual confluence and were disaggregated and reseeded into an 
80ml flask with fresh medium. A mixed epithelial and fibroblast 
culture resulted which, despite treatment with EDTA, persisted 
until confluence. Subsequent subculture resulted in a 
predominately fibroblastic growth.
3.6 Growth of tumours in athymic nude mice
Five tumours were injected into laboratory rodents as described,
4 by the subcutaneous route and 1 by both subcutaneous and intra- 
peritoneal routes. The results are summarised in Table 8 . Two 
tumours failed to establish detectable subcutaneous tumours after 
16 weeks, Autopsy of the animals showed no evidence of tumour.
Two tumours did establish discrete tumours in the animals which 
were excised. Explant cultures were established as for the 
primary tumours but there was no evidence of epithelial cell 
growth after 14 days observation. The tumour Tu 41 was derived 
from biopsy material from a patient undergoing radiotherapy. 
Original tumour tissue was not available.
amam
FIGURE 26
Low power view (x 25) of cells of passage 1 subculture derived 
from cervical tumour 30. Cells have been 12 days in culture.
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The tumour Tu 27 did result in successful in vitro culture and 
this will be described in detail in chapter 4 ,
Section 4 : Discussion of culture techniques
4.1 Culture techniques
There are many different methods described for culture of human
cervical epithelium. The method used here was based on the
primary explant technique of Vesterinen et al (1980) and was
used successfully in the same laboratory in primary growth of 
normal cervical explants and cervical carcinoma explants and
to develop the cervical carcinoma cell line Cxl06 The
technique resulted in good explant growth in almost all normal 
cervical explants cultured.
The culture medium used was complex, though few additional growth 
factors were utilised. Vilbanks (1975) x*~7~7 utilised numerous 
combinations of culture media and additional hormones, but 
concluded that the culture medium made little difference.
Addition of oestrogen, progesterone or insulin did not affect 
growth of normal cells. Others found that high serum 
concentrations are necessary in primary epithelial culture 37's , 
Rheinwald and Green (1977) 37re described the effect of epidermal 
growth factor of cultured keratinocytes. They suggested that this 
polypeptide growth factor increased the number of cell generations 
and delayed senescence. Subculture of normal cells was enhanced. 
Stanley and Parkinson (1979) found that EGF increased colony
size in cervical epithelial cultures. The basic medium was 
therefore supplemented with EGF. Hydrocortisone has also been 
implicated as a necessary growth factor in cervical cell culture 
byt experiments with normal explant culture showed no 
difference in the time to confluence over a 50mm culture plate 
with or without hydrocortisone. I was unable to subculture normal
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cervical ectothelial cells under any conditions, including 
cultures carried out with added hydrocortisone. This was 
therefore not added to the culture medium for growth of tumour 
explants.
Feeder fibroblast layers have been suggested as essential for 
culture and passage of normal cervical cells 3:?rs* but Vesterinen's 
method demonstrated that culture and subculture were
achievable without this refinement. Feeder layers were not used 
in these cultures.
In a number of tumour explant cultures, including that of the 
successful Tu 22 culture, conditioned medium from normally growing 
normal ectocervical explants was added. It is assumed that such 
conditioned medium contains small growth factors and hormomes 
specific to squamous epithelium and that this might enhance tumour 
cell growth.
4.2 Success rate of explant culture
Existing cervical cell lines have been achieved using a range of 
culture techniques and culture media 374.38°-33’, Essentially 
the culture methods fall into two main groups, explant technique 
. 303. see, Qr mince(} tissue/disaggregation technique
301,382,388,390,391  ^have resulted in successful cell
lines. Few data were available on the relative success rates of 
the different methods or what might influence this. Friedl et al 
(1970) 3S3, in establishing the SiHa cell line, stated that this 
was the only success in 1 0  attempts, although epithelial outgrowth 
was noted in 4 other explant cultures. Fjelde (1955) 
demonstrated good growth in primary culture in 8 of 36 epidermoid 
cancers and 1 0  of 40 squamous cancers, although only one 
established cell line resulted from these cultures. Giard et al 
(1973) established 7 cell lines from 116 carcinomas. In the
same laboratory in which these studies were performed, Kitchener 
(1985) established one cervical line from 56 primary explant
cultures. Using more complex disaggregation, media supplements and
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feeder layers, Kelland et al (1987) 3 3 1  established 4 cell 
lines from 15 cervical biopsies.
Primary cervical culture was attempted in 24 biopsies and primary 
growth was established in 10, a success rate of 42%. Growth was 
adequate enough for attempted subculture in only 4 of these. Two 
related cell lines (see chapter 4) resulted from these cultures.
The reasons for growth failure were outlined in the tables. 
Essentially, no tumour which underwent pre-operative radiotherapy 
established primary growth in explant culture. Other reasons for 
failure were either infection or fibroblast overgrowth. Despite 
careful dissection and aggressive removal of fibroblastic growth 
by scraping or disaggregation, this remained the major limiting 
factor in attempts to establish subcultured tumour cells. Similar 
limitations are described by others * 3 3 1  .
A standard antibiotic combination was used throughout. Other 
antibiotics, in particular cephalosporins, were used in attempts 
to clear infection from some plates, as were antifungal 
preparations such as amphotericin; all unsuccessfully. More 
aggressive prophylactic additives, such as aminoglycoside 
antibiotics, might have been useful, particularly in cultures of 
vulval tumours (see below).
4.3 Vulval tumour culture
The difficulty in establishing vulval tumour cells in tissue 
culture is exemplified by the relative sparsity of established 
cell lines. Only 3 have been described 3ee» 333. 3 =*.* The line 
LT-2 was established from a nodal metastasis from a vulval 
squamous carcinoma . The line A431 3GG was established by 
explant culture of a primary vulval epidermoid tumour. Details of 
the other line, SV-962, described by Fogh et al (1977) 333, are 
not given.
Primary vulval tumours were often gross exophytic growths, more 
often than not infected. It was very difficult to establish 
primary growth in vulval squamous tumours and infection played a 
larger role in these cultures than in cervical cultures. This
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difficulty led us to collaborate with the existing experimental 
tumour group in the Department of Child Health. They had 
considerable experience in mouse xenografts with a range of rare 
childhood solid tumours. This was more successful, in terms of 
primary growth, but the excised tumours had similar problems with 
fibroblast contamination. Only the tumour injected 
intraperitoneally resulted in an established cell line.
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CHAPTER 4
DEVELOPMENT AFP CHARACTER I SAT I OF OF CONTINUOUS CELL 
T.T1TES DERIVED PROM I EYAS I YE TUMOURS QF THE CERVIX AFP
YULYA
Section 1 : Introduction
The rationale behind the attempts to derive fresh cell lines, 
rather than rely on existing lines was described in the 
introduction to chapter 3.
Given the reservations regarding extrapolation of results from 
old established cell lines to in vivo tumours, it was felt 
essential to derive cell lines where the state of viral DMA in 
both tumour and internally matched normal tissue was known. With 
this information, such cell lines could offer a unique model 
system for the examination of viral-tumour cell interactions.
Section 2 : Establishment of continuous cell lines.
2.1 Establishment of cell lines Tu 22-1 and Tu 22-2, derived from 
a squamous carcinoma of the uterine cervix.
A 30 year old nulliparous woman was referred to gynaecological 
outpatients following the finding of a clinically suspicious 
cervix at routine cervical cytological screening. Malignancy was 
suspected at the outpatient visit and arrangements were made for 
examination and biopsy. A wedge biopsy of the cervix from a 
clinical stage 1 invasive carcinoma demonstrated moderately to 
poorly differentiated squamous carcinoma of the cervix (Fig. 27). 
She underwent radical hysterectomy and pelvic lymph node
^  ,y.-.v {JL w  .
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FIGURE 27
View showing histology of tumour 22. This is a moderate to 
poorly differentiated squamous carcinoma; there being little 
evidence of cell differentiation or keratin formation.
(x 50)
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dissection with conservation of both ovaries on 29th April 1983. 
Following surgery she remained well but subsequently developed a 
pelvic mass. At laparotomy this was found to be a recurrence of 
tumour in her right ovary. Both ovaries were removed and she 
underwent a course of radiotherapy 
A segment of viable tumour tissue was dissected from the surgical 
specimen in theatre and placed in normal medium on ice. One piece 
of this biopsy was processed for DBA extraction and the remainder 
utilised for culture. A section of myometrial tissue was removed 
from the uterine fundus and snap frozen in liquid nitrogen as 
described in chapter 2.
Twenty plates were initially set up from this tumour, the 
remainder of the biopsy being utilised for DBA extraction. The 
medium used for these plates was a 2:1 mixture of fresh and spent 
medium (as described in chapter 3, section 2.2). By day 14 most 
plates had been overwhelmed by fibroblast overgrowth but 2 plates 
showed good epithelial cell growth. At day 29, cells on one plate 
were disaggregated and seeded into an 80 ml. flask containing 
fresh 2:1 medium mixture. The cells were very difficult to 
disaggregate and fresh medium was added to the initial plate.
After a further 4 days the cells on this plate were subcultured. 
Serial subculture of the first disaggregation indicated that an 
increasing proportion of the cells were fibroblastic and by 
passage 4 the majority were fibroblasts. In contrast, the cells 
from the second disaggregation remained epithelial in appearance. 
These cells were serially subcultured successfully in normal fresh 
medium and represent the continuous cell line Tu 22-1.
From passage 6 attempts were made with random flasks from each 
passage to grow cells in medium lacking EGF. One flask at passage 
9 demonstrated normal growth of cells in the absence of EGF. This 
flask was serially subcultured in the absence of EGF and these 
cells are the subline Tu 22-2. Further attempts to subculture 
cells without EGF at later passage failed.
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Section 2.2 : Establishment of the cell line Tu 31, derived from
a squamous carcinoma of the vulva.
A 60 year old woman presented with an obvious vulval tumour and 
underwent wedge biopsy. This demonstrated a well differentiated 
squamous carcinoma of the vulva (Figure 28). She underwent 
radical vulvectomy with inguinal node dissection. Bodes were 
negative for tumour and she recovered well. She remained well 
until 9 months later when she developed a lesion on her right 
forearm. This was excised and proved to be squamous carcinoma 
indistinguishable from the parent vulval tumour. She developed 
recurrent disease and died from secondary groin recurrences which 
ulcerated through to the femoral vessels 12 months after primary 
surgery.
A large biopsy was removed from the vulvectomy specimen in the 
operating theatre and placed in culture medium. A strip of skin 
from the distal superior abdominal edge of the specimen was 
excised and snap frozen in liquid nitrogen.
Explant culture of the tumour was prepared in the standard way. 
All plates were grossly infected within 48 hours with Pseudomonas 
aeruginosa. The patient had problems with suture line breakdown 
also associated with Pseudomonas infection.
In vivo culture in athymic nude mice was attempted in this case 
in parallel with explant culture. A cell suspension was prepared 
from a small biopsy as previously described. Cell viability prior 
to injection was 60%. One millilitre of this suspension was 
injected intraperitoneally into an anaesthetised athymic nude 
mouse. The animal remained well for 4 weeks with no evidence of 
tumour formation, but thereafter developed increasing abdominal 
ascites. At 6 weeks, under general anaesthetic, a peritoneal 
lavage was performed with a 19 gauge needle using PBS at 37°C.
The ascitic fluid obtained was centrifuged at 3000rpm for 10 
minutes and the cell pellet resuspended in fresh culture medium. 
The total cell count was 1.8 x 10e viable cells and these were 
seeded at high density ( 4.5x10s cells per 50mm dish) in fresh 
medium.
FIGURE 28
Histology of vulval tumour 27. This shows a well differentiated 
squamous carcinoma with evidence of keratin 'nests' (as seen 
centrally in this picture).
(x 50)
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Confluent monolayers of apparent epithelial cells developed 
within 48 hours. Cells were subcultured, but by passage 3 it 
appeared that the predominant cell type was fibroblastic. A large 
number of highly pleomorphic viable cells were noted to be present 
in suspension. Pooled medium from all passage 4 flasks was 
centrifuged and the cell pellet resuspended in fresh medium 
without EGF. Numerous small colonies developed, becoming 
confluent in 14 days. Successful subculture of these cells 
resulted in the continuous vulval cell line Tu 31.
Section 3 : Methods for characterisation of cell lines
3.1 Storage of cells.
Subconfluent monolayers of cells were harvested as previously 
described. Cells were pelleted by centrifugation at 3000rpm for 
10 minutes at 4°C and resuspended in fresh medium with 10% fetal 
calf serum and 10% glycerol. Cells were aliquoted into sterile 
plastic 1ml vials, placed at -20°C for 6 hours, and then 
transferred to storage in liquid nitrogen. Forty-eight hours 
after any single batch was frozen, one vial was gently thawed, 5ml 
fresh normal medium added and the cells replated to check that 
growth characteristics and viability remained normal.
3.2 Cell morphology
Subconfluent and confluent cell monolayers were grown on glass 
coverslips. After removal of the medium cells were fixed and 
stained with haematoxylin and eosin or with Masson stain. Cells 
were examined by standard light microscopy. Cells were also 
examined directly in growing cultures following removal of most of 
the culture medium.
Ultrastructural analysis was also carried out on cells grown on 
coverslips. Thereafter cells were fixed in 2% gluteraldehyde and 
osmic acid, dehydrated in methanol and embedded in Epon-Araldite.
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Thin sections were cut and stained with uranyl acetate and lead 
citrate.
3.3 Growth kinetics
Cells at varying passage numbers were disaggregated, counted and 
cell viability checked by trypan blue exclusion. Cell suspensions 
were prepared and equal numbers of viable cells seeded into fresh 
medium in 50 mm plates. The experiment was carried out in 
quadruplicate. At each 24 hour time point, the cells were 
harvested and counted. The number of cell doublings was 
calculated from the cell counts at 2 time points a and b as 
follows :
D (doubling time) =_________ b-a (hours)_________________
log2(count at time b) - log2(count at time a). 
The doubling times quoted in these experiments were an average of 
2 separate values ( i.e.using 2 sets of time points within the 
same experiment).
3.4 Anchorage independent growth
2 ml. of single cell suspension containing 5x10*, 1x10s, 2x10s 
and 5x10s cells/ml in complete medium containing 0.3% agar (Difco, 
Noble) were plated over 2 ml. complete medium containing 0.6% 
agar. Plates were incubated at 37°C in 5% COz and 0.5 ml. of 
fresh medium added at 3 day intervals. Plates were inspected 
regularly for the presence of discrete colonies,
3.5 Tumorigenicity in athymic nude mice
Single cell suspensions of 1 x 107 viable cells/ml were 
prepared. lOOpl of this suspension was injected into the 
subscapular area of oubred athymic nude mice (by Dr.Raza as 
described in chapter 3). At least three attempts from three 
different late passage numbers were undertaken for each cell line. 
Animals were inspected for evidence of discrete tumour growth or 
metastatic tumour over a 16 week period. The animals were then 
sacrificed and examined for evidence of tumour. Discrete tumours 
were excised under general anaesthesia.
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3.6 Cytogenetic analysis
Subconfluent monolayers in the logarithmic growth phase were 
incubated with Colcemid solution at 37°C for 2 hours. Stock 
solution was N-deacetyl-N-methylcolchicine lOOmg, 95% ethanol 
(5.3g), lOg propylene glycol in phosphate buffer made up to 100 ml 
with distilled water. Cells were incubated in a 1 in 25 dilution 
using Hank's BSS. Cells were disaggregated, pelleted by 
centrifugation and resuspended in 75mM KC1 solution for 25 
minutes. Cells were fixed by the addition of absolute 
methanol/glacial acetic acid ( 3:1). Slide preparations were made 
by droplet technique and air drying. Giemsa-trypsin banding of 
chromosomes preparations was carried out using the technique of 
Seabright (1971) 33e. Essentially the slides were passed through 
sequential solutions of 0. 15M NaCI, 0. 15M NaCI containing crude 
trypsin solution, NaCl, Giemsa stain in phosphate buffer and 
distilled water. Slides were air dried and then examined.
3.7 Assays for oncofetal products and steroid receptors.
Medium from subconfluent monolayers was assayed for the presence 
of a number of known oncofetal antigens; namely, a-fetoprotein 
(AFP), j3-sub-unit Qf human chorionic gonadotrophin (£-HCG), 
carcino-embryonic antigen (CEA), human placental lactogen (HPL), 
and Schwangerschaftsprotein 1 (SP-1). Aliquots of medium from 
subconfluent monolayers were assayed using standard radio­
immunoassay techniques in the routine laboratories performing 
these assays for clinical use. The levels of sensitivity for the 
assays were;- 0-HCG 3u/l, CEA 10u/l, SP-1 0.3ng/ml, and HPL 
0.05g/l, Immediately after removal of the aliquots for 
measurement, the medium was removed and measured, the cells 
harvested and counted. The results were expressed per million 
cells.
Oestrogen and progesterone receptors were assayed by the 
technique of Leake et al Briefly, cells were homogenised in
Hepes buffer, EDTA and 0.25mM DTT pH 7.4 and the cell pellet 
extracted by centrifugation. The cell pellet was washed in NaCl 
and hepes buffer. Aliquots were incubated for 18 hours at 4°C with
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3H 17£-oestradiol (concentrations 1,1,5,2,4,6,8,10xl0_1 °JD . Bound 
steroid in the cytosol fraction was calculated following addition 
of EDTA, hepes, dextran coated charcoal and Triton-toluene 
scintillant and counted at 25-30% efficiency in a liquid 
scintillation counter. The nuclear bound steroid was calculated 
following washing with normal saline and addition of toluene-PPO 
(5g/l) scintillant counted at 35% efficiency. Scatchard plots 
using at least 5 points were constructed and results compared with 
a known standard established by competition with known amounts of 
di-ethyl stiboestrol.
Approximately 10e cells were required for each assay. The 
oestrogen receptor contents of both the cytosol and pellet 
fractions were determined.
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Section 4 : Characterisation of the continuous cell lines
Tu 22-1, Tu 22-2, and Tu 31
4.1 Storage of cells
Cells from all cell lines were frozen at regular intervals from 
passage 4 onwards. Successful cultures have been achieved from 
all batches of frozen cells.
4.2 Cell morphology
Tu 22-1 and 22-2
Cells of both lines grew to confluence to give pavement-like 
monolayers (Figure 29), There was no contact inhibition and 
cells displayed considerable overlapping and layering if culture 
was continued beyond confluence.
Cells of the two cervical cell lines were not distinguishable by 
light microscopy. Figure 30a shows direct photography of growing 
Tu 22-1 cells to demonstrate their regular epithelial appearance. 
Figure 30b shows cells of Tu 22-2, fixed in situ. Figure 31, a 
high power view of Tu 22-1 cells, shows large, regular epithelial 
cells with pleomorphic nuclei containing numerous prominent 
nucleoli. The cytoplasm contained many organelles and 
mitochodria.
Transmission electron microscopy demonstrated the presence of 
tight desmosomes (Figure 32a) and intracellular tonofilaments and 
microvilli (Figure 32b) characteristic of squamous cells in both 
cell lines.
Cells have been in continuous culture for up to 15 months and 
have been passaged in excess of 50 times.
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FIGURE 29
Low power view (x 25) of subconfluent monolayer of Tu 22-1 cells, 
passage 24, in culture showing ‘pavement like* epithelial 
culture.
FIGURE 30a
Culture of growing Tu 22-1 cells, passage 34, showing typical 
epithelioid cells.
(x 40)
FIGURE 30b
View of Tu 22-2 cells, passage 38, fixed in situ, showing typical 
epithelioid cells of this line.
(x 40)
FIGURE 31
View of Tu 22-1 cells, passage 12, showing highly pleomorphic 
cells with multiple nucleoli.
(x 160)
FIGURE 32a
Electron micrograph of Tu 22-1 cells, passage 16, showing tight 
desmosome junction between two cells.
(x 12400)
FIGURE 32b
Electron micrographs of Tu 22-1 cells, passage 16, showing 
intracellular tonofilaments and microvilli.
(x 12400)
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FIGURE 33
High power view of early passage (passage 6) Tu 31 cells. Cells 
are fibroepithelial at this stage.
(x 100)
FIGURE 34
High power view of late passage (passage 46) Tu 31 cells showing 
now epithelial morphology.
(x 40)
FIGURE 35
Large pleomorphic cells of Tu 31, passage 34. Multiple nucleoli 
are seen,
(x 100)
TABLE 9
VIABLE CELL COUIT (S. D. )
TIKE TU 22--1 TU 22-2
(HRS)
lormal medium 10% serum Formal medium 10% serum EGF-
0 3.76x10s 4.00x10s 4.00x10s 4.00x10s 4.00x10s
24 4.37x10s 3.33x10s 2.72x10s 1.84x10s 2.12x10s
(0.32) (0.28) (0.18) (0.20)
48 6.4x10s 4.31x10s 2.47x10s 2.78x10s 3.25x105
(0.58) (0.36) (0. 17) (0.25)
72 1.09x10s 9.11x10s 4. 66x10s 3.69x10s 2.10x10s
(0.06) (0.87) (0.38) (0.40)
96 1.66x10s 1.35x10s 7.08x10s 6.30x10s 3.99x10s
(0.07) (0.13) (0.61) (0.56)
120 - - 1.19x10s 8.40x10s 7.09x10s
(0.08) (0.73)
144 1.60x10s 1.21x10s - 1.16x10s -
(0.12) (0.09) (0.09)
TABLE IQ
GRQVTH KIIETICS QF TU 22-1 CELLS II EGF DEFICIEIT MEDIUK
VIABLE CELL COUIT CKEAS OF 2 COUITS)
0
24
48
72
96
120
144
PASSAGE 1 
4.00x10s 
2.19x10s 
1, 35x10s 
2.10x10s 
3.99x10s 
5.88x10s 
6.86x10s
PASSAGE 2.
1.50x10s
1.78x10s
1.95x10s
2.02x10s
3.17x10s
3.33x10s
PASSAGE S
2.00x10s
1.80x10s
1.75x10s
1.80x10s
1.81x10s
1.76x10s
1.78x10s
TABLE .11 
GRQVTH KINETICS QF TU 31 CELLS
TIKE VIABLE CELL COUIT
(HRS? IQRKAL (S.,1?,.) 10% serum* 51 serum* 2% serum*
0 1x10s 5x10s 2.0x10s 2.0x10s
12 1.1(0.08)xl0s 4.7x10s
24 1.29(0.Il)xl0s 5.03x10s 1.8x10s 1.32x10s
48 3.03(0.31)xlOs 5.75x10s 3.4x10s 4.28x10s
72 6.42(0.60)xl0s 1.24x10s 4.74x10s 1.02x10s
96 9.75(0.89)xlOs 3.04x10s 1.94x10s 1.28x10s
120 - - 1.28x10s 2.81x10s
* mean of 2 counts
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Tu 31
In contrast to the cervical cell lines, early passage Tu 31 
cells retained a slightly fibro-epithelial appearance on direct 
microscopy (Fig. 33). Later passages however formed monolayers 
of large ovoid cells (Fig 34), seen in Figure 35 with large 
pleomorphic nuclei with many nucleoli and intracellular 
organelles. Cells left at confluence detached rapidly from the 
surface. Transmission electron microscopy showed highly active 
cells but no evidence of desmosome formation or intracellular 
tonofilaments as seen in the cervical cell lines.
The cells have been in continuous culture for up to 9 months and 
passaged in excess of 50 times.
4.3 Growth kinetics 
Subconfluent monolayers of Tu 22-1 passage 20 and 33, and Tu 22- 
2 passage 32 were used to establish the growth kinetics of the 2 
cervical cell lines. To observe the effect of EGF deficiency on 
Tu 22-1 cells, cells from this line were serially passaged 3 
times in the absence of EGF with cells harvested at 24 hour 
intervals. This experiment was performed in duplicate. Growth 
of Tu 22-2 in EGF medium and the growth characteristics of both 
lines in medium containing only 10% fetal calf serum were also 
studied.
The results are shown in Tables 9 and 10. Tu 22-1 cells had a 
doubling time in the logarithmic growth phase of 35.8 hours.
Vhen grown in EGF deficient medium, these cells exhibited a lag 
phase of 48 hours followed by a doubling rate of 31.5 hours. At 
second passage cells had a similar lag phase before dividing very 
slowly with a doubling time of 97.8 hours. On a subsequent 
passage the cells failed to divide, eventually ballooning and 
detaching from the plate surface. Later attempts to achieve EGF 
independence of the Tu 22-1 line followed this pattern with 
apparently normal growth at the first passage followed by slow 
growth and ultimate cell death on the third passage. In 10%
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fetal calf serum, cells had a doubling time similar to that of 
growth in standard medium, 31.2 hours.
Tu 22-2 cells had a doubling time of 33,5 hours following a 48 
hour lag phase in normal medium lacking EGF. In the presence of 
EGF there was a longer lag phase of 72 hours followed by 
logarithmic division and a doubling time of 27.3 hours. Growth 
in 10% fetal calf serum and EGF deficiency was impaired, with a 
doubling time of 40.5 hours.
Cells of the cell line Tu 31 grew rapidly in normal medium in 
the absence of EGF. They were readily subcultured. The growth 
kinetics of passage 16 cells were evaluated and the results shown 
in Table 11. Under normal growth conditions the doubling time 
was 20,7 hours. Growth in reduced fetal calf serum 
concentrations resulted in little change in growth kinetics, with 
the doubling times being 20.5 hours in 10% serum, 19.1 hours in 
5% serum and 30 hours in 2% serum, Tu 31 cells have never 
required EGF for continued growth.
4,4 Anchorage independent growth 
Attempts were made to demonstrate formation of cell colonies 
from single cell suspension in sloppy agar at passages 21, 23, 
and 47 of Tu 22-1 and at passages 21, 35 and 45 of Tu 22-2.
Cells of the Tu 22-1 cell line did not form discrete colonies 
even at very high plating densities and observation periods of up 
to 8 weeks. Cells of the Tu 22-2 cell line at passage 45 did 
form small colonies of 20-30 cells after 7 weeks (Fig. 36). Very 
few colonies formed and plating efficiency was therefore not 
calculated. Colonies formed only at plating densities of 5x10s 
cells per plate.
In contrast, Tu 31 cells readily formed discrete colonies from 
single cells in agar. Growth in sloppy agar was assessed using 
passage 48 cells. Numerous colonies developed at cell seeding 
densities of 1, 2 and 5x10s cells. These developed within 21 
days. Colonies were large,often exceeding 100 cells. A typical 
colony is shown in Figure 37.
FIGURE 36
Colonies in agar derived from single cell suspension of Tu 22-2 
cells, passage 45, plated at 5 x 10s cells per plate. One large 
colony and two very small colonies are shown here after 7 weeks 
in culture.
<x 25)
FIGURE 37
Typical colony in agar derived from single cell suspension of Tu 
31 cells at passage 48, photographed on day 19.
(x 40)
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4.5 Tumorigenicity in athymic nude mice.
Attempts were made on several occasions to produce tumours by 
subcutaneous injection of cells from both Tu 22-1 and Tu 22-2 
cell lines into the subscapular area of laboratory rodents.
Cells were from passages between 35 and 52. On no occasion was 
any detectable tumour produced despite observation periods of 4 
months. At autopsy, no animal had any evidence of tumour.
Vulval tumour cells from Tu 31 were highly tumorigenic in mice. 
Cells harvested from passage 47 were suspended in PBS at a 
concentration of lxlOe viable cells/ml. One ml. of this 
suspension was injected into the subscapular area of an athymic 
nude mouse. Vithin 21 days a palpable tumour of approximately 
2cm in diameter was detectable. One-half of this tumour was sent 
for histological analysis and the other half heterotransplanted 
into another mouse. The histology is shown in Figure 38, The 
tumour was a poorly differentiated squamous carcinoma. The 
second mouse developed a tumour in 4 weeks,
4.6 Karyotype analysis
Cytogenetic analysis was based on cells from passage 48 for Tu 
22-1, passage 51 for Tu 22-2, and passage 55 for Tu 31. Figures 
39 to 41 show representative karyotypes from the 3 cell lines. 
Chromosome distribution is shown in Figure 42.
Tu 22-1 cells had a wide distribution of chromosome number.
There was no modal number, with a range of 83-103 in 25 counts. 
The karyotype was essentially hypotetraploid with a large number 
of rearranged chromosomes. The distribution of individual 
chromosomes is shown in Table 12 and the putative origins of some 
the rearrangements in Table 13. It was not posible to assign 
with confidence many of the rearranged chromosomes. Tu 22-1 
cells consistently contained the rearrangements B, E, F, H, I, J, 
K, 0, Q, S, U, V, Y, Z, and the fragment 1C.
Tu 22-2 cells had a tighter chromosome distribution as shown in 
Fig 44. The modal number appeared to be 91-93, with a range of 
86-99 in 22 counts. The karyotype was hypotriploid with a large 
number of rearranged chromosomes, the distribution of individual
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FIGURE 39
Representative karyotype of Tu 22-1 cells, passage 48.
Chromosomes are trypsin-giemsa stained. Derivation of additional 
chromosomes is shown in Table 13.
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FIGURE 40
Representative karyotype of Tu 22-2 cells, passage 51.
Chromosomes are trypsin-giemsa stained. Derivation of additional 
chromosomes is shown in table 13.
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TABLE 12.
TflmTVTDIJAI. CHROMOSOME DISTRIBUTION IN TUMOUR CELLS
CHROKQSQIE TIKES REPRESENTED
TU 22-1 TU 22-2 TU 31
1 4  3 1-3
2 4 3 1-3
3 2 1 0 - 1
4 3 3 2,3
5 3,4 3,6 2,3
6 6 4 3,4
7 3,4 2,4 2,3
8 3 2,3 2,3
9 4-6 2,4 3
10 3,4 2,3 3
11 3 3 2
12 4 3,4 3
13 3,4 3 3
14 5 6 3
15 2 1»2 3,4
16 3,4 3 3
17 3 2 4
18 3 2,3 2,3
19 2 1*2 1#2
20 8,9 8 2,3
21 1 1-3 2
22 2-5 2,3 1,2
I 1,2 0-4 3
TABLE 13
PUTATIVE ORIOLE QF REARRANGED CHROMOSOMES IN TU 22
CELLS
A unknown, may be >2 chromosomes
B Chromosome 3 + unknown material added to long arm 
C Chromosome 1 with partial deletion long arm 
D possible isochromosome lq 
F Chromosome 20 + 7q 
H Translocation 14q:15q 
I Chromosome 1, deletion qll-»qter 
K 3p 
0 7q
S D or G derivative 
U Isochromosome 21q 
V Isochromosome lip
Rearrangements designated E, G, J, L, K, I, P, Q, R, T, V, I, Y, 
Z, and 1A-C not possible to characterise.
TABLE 14
ORIGIN OF CHROMOSOME REARRANGEMENTS IN 
TU 31 CELLS
A Host of chromosome 1 plus undetermined material on long 
arm.
B Host of chromosome 2 plus additional material on long 
arm.
C Translocation 3p: lq 
D Translocation unknown: 3q 
E Translocation 3p: unknown 
F Chromosome 1 with lp deletion 
fl Translocation lp:9q 
I Translocation 13:14 
J 5p- 
K 7p~
L 6q~
P Derived from chromosome 11 
R Isochromosome, origin unclear 
S Translocation unknown: 21 
V D or G group derivative 
X 21p-
Rearrangements designated G, II, N, 0, T, U, and V cannot 
be clearly assigned.
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chromosomes being shown in Table 12. Cells consistently 
contained the rearranged chromosomes A, B, F, I, J, L, M, 0, S,
U, X, Y, 2 copies of V, and the fragment 1C,
In both cervical cell lines there was consistent 
overrepresentation of chromosomes 6, 14, and 20. Relative to Tu 
22-1, Tu 22-2 cells consistently had fewer representatives of 
chromosomes 1, 2, 3, 6, 9, 10, 17, and 22. Tu 22-2 cells had 
more representatives of chromosomes 14 and 21.
A number of rearrangements were common to both lines, namely B, 
F, I, 0, S, U, the unclassified chromosomes J, N ,V, Y, Z, and 
the fragment 1C. Tu 22-2 cells contained the very distinctive 
chromosome A, which had material from more than 2 chromosomes and 
the rearrangements L and X not found in the parent line.
Tu 31 cells had a narrow chromosome distribution, 81 to 85 in 17 
counts. The modal number was 83. The distribution is shown in 
Figure 42, Cells were essentially hypotriploid with 22 or 23 
rearranged chromosomes, as shown in Table 12. The proposed 
origins of the rearrangements for this cell line are given in 
Table 14.
The majority of chromosomes were present in a triploid state. 
Chromosome 3 was consistently under-represented and frequently 
absent. Chromosomes 1, 2, 11, 19, 21 and 22 were consistently 
under-represented. Chromosomes 6, 15, and 17 were usually over­
represented. All cells studied were triple X, A high proportion 
of the identifiable rearrangements contained chromosome 1 or 3 
material. All cells studied contained 5 representatives of an 
unidentified isochromosome R.
4.7 Expression of oncofetal products and steroid receptors.
Medium from subconfluent monolayers of all cell lines was 
assayed.
The results are summarised in Table 15. Fresh cell-free medium 
containing EGF contained 21 iu/ml of measurable AFP but no other 
detectable oncofetal products. The amount of measurable AFP in 
medium taken from growing cells was therefore not significantly
TABLE A5l
EXPRESSION QF ONCOFETAL PRODUCTS AND STEROID
RECEPTORS IN  CELL-LINES
CELL
LINE
Tu 22-1
Tu 22-2
Tu 22-2 
<+EGF)
Tu 31
TU 31 
(+EGF)
AFP 0-HCG CEA HPL SP-1 Cytosol Cytosol Nuclear
oestrogen progesterone oestrogen 
receptor receptor receptor
40 520 <17 <90 <5
64 67 <17 <90 <5
48 69 <17 <90 <5
65 68 <17 <90 <5
n. d 
n. d.
n. d. 
n. d.
66 61 <17 <90 <5 n.d
n.d 
n. d.
n. d. 
n. d
n. d
n.d
n.d.
n. d. 
n.d.
n.d.
Results expressed as per 10e cells except receptor assays which are expressed 
as faol/ng protein for cytosol receptors and fool/qg DNA for nuclear 
receptors.
n.d. not detectable
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different from this. Tu 22 1 cells produced an 8—fold excess of 
0-HCG compared with Tu 22-2 cells and Tu 31 cells. Tu 31 cells 
were similar to the EGF independent sub-line Tu 22-2 in producing 
detectable 0-HCG only. Growth of Tu 22-2 or Tu 31 cells serially 
in the presence of EGF did not increase the production of £-HCG. 
Ho cell line had detectable oestrogen or progesterone receptors 
under normal growth conditions.
Section 5 : Analysis of cell line, tumour and control DIA
DHA was extracted, as described in chapter 2, from the tumour 
biopsies Tu 22 and Tu 27, from internal control myometrium Co 22 
and internal control vulval skin Co 27, and from harvested cells 
from cell lines Tu 22-1, passage 48, Tu 22-2, passage 36, and Tu 
31, passage 18.
5.1 Herpes simplex virus DHA probes
All DHAs were probed under stringent hybridisation conditions 
for the presence of HSV-2 DHA, cloned restriction fragments 
Hindi 11 a, e and h spanning the map units 0.28-0.72 which 
includes the regions Bglll j, c, and n, associated with 
morphological transformation in vitro (see Figure 2, page 79).
Figure 43 shows a Bam HI digest of cervical cell lines Tu 22-1 
and Tu 22-2, original tumour Tu 22 and control DHAs probed with 
HSV-2 HindiII a DHA. The reconstruction tracks demonstrate the 
typical pattern of Bam HI digestion of the Hindi 11 a region and 
size markers in kilobases are indicated. Ho hybridisation is 
demonstrable. The reconstruction at one copy per cell is poorly 
visualised in this exposure, but prolonged exposure confirmed no 
hybridisation at a level of one copy per cell. Figure 44 shows a 
similar digest probed with Hindi11 e DHA. There was no
5-8kb 
5kb
2 & k b  
2-2 kb
FIGURE 43
Bam HI digest of tumour, control and cell line DHAs probed with 
Hindi 11 a under stringent conditions.
The reconstruction tracks are lanes 1, 4 and 7 with 1, 5 and 10 
copies per cell respectively. Lane 2 contains DHA fron the 
original tumour 22, lane 3 DHA from internal control myometrium, 
and lanes 5 and 6, DHA from the cell lines Tu 22-1 and 22-2.
Size markers are shown on the right.
Hybridisation to the reconstruction lanes is seen at 5 copies per 
cell, and faintly on this exposure at 1 copy per cell. There is 
no hybridisation to tumour, control or cell line DHA,
I V. (M
C\i tV
4-2kb
3-5kb 
2-7 kb
FIGURE 44
Bam HI digest of D M s  from cervical tumour, control and cell 
lines probed with HindiII e under stringent conditions.
Lanes 3 and 6 are reconstruction at 5 and 1 copy per cell 
respectively. Lane 1 contains D M  from the original tumour 22, 
lane 2 D M  from internal control myometrium, and lanes 4 and 5, 
D M  from cell lines Tu 22-1 and 22-2. Size markers are shown on 
the right.
Hybridisation at a level of 1 copy per cell is seen in lane 6 but 
there is no evidence of hybridisation to tumour, control or cell 
line DMs.
FIGURE 45
Bam HI digest of cell line and control DHAs probed with Hindi 11 h 
under stringent conditions.
Lanes 1 and 2 are reconstructions with 5 and 1 copy per cell.
Lane 3 contains DHA from cell line Tu 22-1. Lane 4 contains DHA 
from an external control normal cervix and lane 5 plasmid DHA, 
included as on this occasion probe DHA was not excised from its 
vector. Size markers (kb) are on the right. Hybridisation at a 
level of 1 copy per cell is seen in the reconstruction in lane 2 
and there is hybridisation to plasmid DHA. Ho hybridisation is 
seen with cell line DHA or external control DHA.
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FIGURE 46
Bam HI digest of vulval tumour, control and cell line M A  probed 
with Hindi11 a under stringent conditions.
Reconstructions are in lanes 1, 2 and 5 at 1, 5 and 10 copies 
respectively. Size markers are on the right,
D M  from vulval tumour 27 D M  is in lane 3, from internal control 
skin 27 in lane 4 and from cell line 31 in lane 6. Lane 7 
contains D M  from an external control vulval skin biopsy, 
Hybridisation at a level of 1 copy per cell is seen in the 
reconstruction track in lane 1. Ho hybridisation is evident to 
tumour, control or cell line D M .
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demonstrable hybridisation to any tumour DNA at a sensitivity of 
less than one copy per cell. Figure 45 shows a digest of Tu 22- 
1 DNA only probed with HindiII h DNA. The reconstruction tracks 
show the pattern for a Bam HI digest of the HindiII h region. 
Track 5 contains plasmid DNA as on this occasion probe DNA was 
not excised from the vector. No hybridisation is seen in the 
cell line track or to external control normal cervix (NCx).
Similar hybridisations with cloned HSV probes were carried out 
on the vulval DNAs. Figure 46 shows a Bam HI digest of cell 
line Tu 31, original tumour 27 and control DNA, probed with 
Hindi 11 a DNA. The other track (lane 7) contains NY-1, DNA 
extracted from one of the normal vulval skin biopsies at 
postmortem. No evidence of hybridisation was detected in the 
vulval cell line or tumour with any of the HSV probes.
5.2 Probing of cell lines with human papillomavirus DNA
The DNAs above were probed under stringent and non-stringent 
conditions (see chapter 2, section 2) with cloned HPV-6, 11, 16 
and 18 DNA.
No hybridisation was seen with HPV-6, 11 or 18. Cross­
hybridisation between HPV-11 and HPV-16, and between HPV-16 and 
18 reconstruction tracks was noted in these experiments as 
previously discussed in Chapter 2. Figure 7 (page 84) 
demonstrated cross-hybridisation between HPV-11 and 16 in an 
experiment involving Tu 27 and Tu 31 cell line DNA, but even 
under non-stringent conditions there was no evidence of 
hybridisation to HPV-11.
Fig. 47 demonstrates the results of hybridisation experiments 
with HPV-16 DNA under stringent conditions for cell lines Tu 22- 
1, 22-2 and Co 22. Lanes 1 and 2 represented reconstructions at 
one and 5 copies per cell respectively. Lanes 3 and 4 contained 
Tu 22-1 and Tu 22-2 respectively and lane 5 contained Co 22 
myometrium. Both cell lines contained viral DNA in a similar 
configuration, with three distinct bands of different molecular
1 2 3 4 5
FIGURE 47
Bam HI digest of cell line and control D M s  probed with HPV-16 
under stringent conditions.
Reconstruction tracks are lanes 1 and 2, at 1 and 5 copies per 
cell. Lane 3 contains D M  from cell line Tu 22-1, lane 4 D M  
from Tu 22-2 and lane 5 D M  from internal control myometrium 22. 
The 8kb marker is shown on the right.
Hybridisation at 1 copy per cell is seen in lane 1. Both cell 
line D M s  hybridise to HPV-16 D M  in a similar configuration, 
with 3 major bands and one fainter low molecular weight band.
One of these major bands appears to comigrate with the 8kb 
reconstruction band.
1 2  3 4
FIGURE 48
Bam HI digest of vulval cell line and control D M  probed with 
HPV-16 under stringent conditions.
Reconstructions are in lanes 1 and 2, at 1 and 5 copies per cell. 
Lane 3 contains D M  from internal control skin 27 and lane 4 D M  
from vulval cell line Tu 31. The 8kb size marker is shown on the 
right. Hybridisation at 5 copies per cell is clearly seen in the 
reconstruction in lane 2. Tu 31 D M  hybridises at a level of 3 
copies per cell, with a single band colinear with the 8kb 
reconstruction D M ,  suggesting a single linear insert. A faint 
band is seen in lane 3, comigrating with the 8kb band, suggesting 
a linear insert of HPV-16 D M  in control skin. The presence of 
HPV-16 D M  in control 27 is more clearly demonstrated in lane 5, 
figure 9.
1 2 3 4
8kb
FIGURE 49
Bam HI digest of vulval tumour 27 probed with HPV-16 D M  under 
stringent conditions.
The reconstruction tracks are lanes 3 and 4, with 10 and 1 copy 
per cell.
Lanes 1 and 2 are a double loaded track containing Tu 27 D M .
The 8kb marker is on the right.
Hybridisation at a level of 1 copy per cell is seen in lane 4.
Tu 27 D M  hybridises to HPV-16 D M  at between 5 and 10 copies per 
cell. The pattern is of 3 bands, not colinear with the 8kb 
reconstruction.
•  '  ' j
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weight being identifiable. On much longer exposures, a fourth 
band of lower molecular weight, barely visible in this 
photograph in both tracks 3 and 4, was noted. One of these 
bands comigrated with the 8kb virion DM. This configuration 
suggested multiple insertion sites for viral D M  within tumour 
cell D M  and that this configuration had been conserved down 
both cell lines. As selection occurred at passage 8, it was 
likely that this pattern was present in the first subcultures. 
Unfortunately, D M  extracted from the original tumour 22 was 
extensively tested against all HSV probes and against HPV-6 and 
11 in the first instance in the early part of the study, prior 
to the availability of HPV-16 DM. Sufficient D M  remained to 
screen undigested D M  with HPV-16 under stringent conditions, 
confirming the presence of HPV-16 sequences comigrating with 
high molecular weight cellular DM. There was insufficient D M  
for detailed analysis. It seemed likely that this configuration 
of inserts was present in the original tumour, but it cannot be 
confirmed. No HPV sequences were detected in internally matched 
control tissue for these cell lines. HPV-16 D M  is present only 
in malignant cervical cells.
The vulval DNAs were similarly probed under stringent and non- 
stringent conditions with cloned HPV-6, 11, 16 and 18 DNA. 
Hybridisation was only seen with HPV-16. Figure 48 shows cell 
line Tu 31 and matched control DNA Co 27, digested with Bam HI 
and probed with HPV-16 under stringent conditions. Tu 31 DNA 
contained unit length HPV-16 homologous DNA which co-migrated 
with the reconstruction tracks. Viral DNA was present at around 
3 genome copies per diploid cell. Normal control DNA also 
contained unit length HPV-16 homologous DNA at a level of 0.1 - 
0.3 genome copies; seen here as a faint band at 8kb but present 
in longer exposures. Confirmation of the hybridisation of 
normal Co 27 DNA to HPV-16 DNA was shown in Track 5, Figure 9 
using undigested DNA.
Fig. 49 shows parent tumour Tu 27, loaded as a double track, 
and reconstruction tracks, digested with Bam HI and probed with
124
HPV-16 DNA under stringent conditions. Tu 27 DNA contained HPV- 
16 homologous DNA. This DNA was present as three distinct bands 
of different molecular weight. Undigested Tu 27 DNA 
demonstrates hybridisation to HPV-16 DNA which co-migrated with 
high molecular weight cellular DNA (see track 4, figure 12).
The complex pattern seen in the original biopsy differed 
substantially from that of both the derived cell line and
internally matched control tissue. This pattern suggested
multiple integration sites.
5.3 Other cervical cell lines probed with human papillomavirus 
DNA
For comparison DNA extracted from cells from three established 
cell lines derived from cervical carcinomas were probed with 
HPV-16 DNA.
HeLa cells 300 of strains RE and VS were grown under standard
conditions. Cells from the lines C4-1 and C33-1 331, stocks of
which were kindly provided by Dr L. Crawford, were subcultured 
under recommended conditions and DNA extracted as previously 
described.
DNA from the two HeLa cell strains showed no detectable 
hybridisation with HPV-16 DNA under stringent hybridisation 
conditions. Similar findings were reported by Boshart et al 
(1984) 133 who described HeLa cells as containing HPV-18 
homologous DNA.
Figure 50 shows the results for C4-1 and C33-1 cell DNAs. 
Reconstruction tracks for HPV-16 are in lanes 1 and 2, and for 
HPV-11 in lanes 5 and 6, again demonstrating cross-hybridisation 
even under stringent conditions. Lane 3 contained C4-1 DNA, and 
a faint band was visible (as indicated) at around 9kb at less 
than one copy per cell. C4-1 cells have subsequently been shown 
to contain HPV-18 sequences 3:70 and this could represent cross 
hybridisation between HPV-16 and 18, as previously noted in 
Chapter 2. C33-1 cells (in lane 4) did show a faint signal on
prolonged exposure but it was not certain if this was
1 2 3 4 5 6
FIGURE 50
Bam HI digest of cervical cell line DNAs probed with HPV-16 under 
stringent conditions.
Lanes 1 and 2 are reconstruction experiments containing 1 and 10 
copies per cell HPV-16. Lanes 5 and 6 are reconstruction tracks 
containing 1 and 10 copies per cell HPV-11, Lanes 3 and 4 
contain DNA from cell lines C4-1 and C33-1. The 8kb marker is on 
the right. Hybridisation to HPV-16 at 1 copy per cell is shown 
in lane 1. Hybridisation is also evident to HPV-11, lane 6 
confirming cross-hybridisation between HPV-16 and 11 under 
stringent conditions. There is no evidence of hybridisation in 
lane 4 (C33-1) but a faint band is seen at around 9kb in lane 3 
(C4-1), as indicated.
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significant. It is thought that this cell line does not contain 
detectable HPV.
Section 6 : Properties of cell lines
6.1 Derivation of cell lines Tu 22-1 and 22-2
These cell lines derived from a single biopsy from a moderate to 
poorly differentiated squamous carcinoma in a young woman prior 
to definitive surgery. Most existing cell lines, derived prior 
to the apparent increase in genital wart virus infection, were 
obtained from older women although CaSki 33‘7 and SKG-III 330 
were derived from women aged 40 and 38 years respectively. Two 
of the lines derived by Kelland et al (1987) 331 were from women 
of a similar age to those described here. Cell lines from 
younger women could be important as it has been suggested that 
such tumours could behave differently from those in older age 
groups although recent data has disputed this 3S,S.
Cell selection plays an important role in the establishment of 
continuous cell lines. It was interesting to note the behaviour 
of the tumour in this woman. Radical hysterectomy with pelvic 
lymphadenectomy was carried out in view of the localised nature 
of the tumour and the young age of the patient. Such surgery 
allowed conservation of ovarian function, ovarian metastases 
being rare in cervical carcinoma. The tumour from which the cell 
line was derived, however, did result in a large ovarian 
metastasis within a relatively short space of time The
tumour was to some extent atypical. Few reports of other lines 
gave sufficient detail of patient outcome. The CaSki cell line
387 derived from a mesenteric metastasis 1 year after primary 
treatment. KE-180 33A was similarly derived from an omental 
metastasis and the patient died within 3 months. The line EC-50
388 was derived from ascitic fluid obtained shortly before d e a t h  
in a w o m a n
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who presented, with advanced disease but who deteriorated rapidly 
despite radiotherapy. The patient from whom one of the earliest 
cell lines, OG 332, was derived, presented with terminal disease 
four years later. Only the patients from whom Kelland et al 
(1987) 331 derived their cell lines remained well although 
stated follow up time was short. Continuous cell lines might not 
necessarily be repesentative of the biology of the majority of 
cervical cancers and this must be taken into account in the 
interpretation and extrapolation of experimental data from 
established cell lines.
6.2 Tu 22-1 and 22-2 are new continuous cell lines
The cell lines were derived by primary explant culture similar 
to SiHa, CaSki and Cx 106 . se®. They retained the
characteristics of squamous cells on electron microscopy. Cells 
from both lines have been subcultured through over 50 passages 
over 12 months and were rescuable from frozen stocks. On this 
basis they would appear to be established continuous cell lines. 
However, despite repeated attempts it was not possible to produce 
tumours in immunocompromised rodents, unlike any of the other 
cell lines. Fogh et al (1977) 333 have suggested that the 
production of tumours in nu/nu mice was the only sure way of 
differentiating that the cultured cells were derived from tumour 
cells and not from non-malignant cells within the tumour biopsy. 
Neither cell line would classify as a new established cell line 
under these criteria.
Normal cervical squamous cells have not been passaged to this 
degree, with or without feeder layers 3-:re»3:7'3 . These cells 
were undoubtedly squamous cells, were aneuploid and behaved 
otherwise as tumour cells. Tu 22-2 cells were capable of 
anchorage independent growth. They also retained the viral DNA 
present only in the parent tumour.
This behaviour was comparable with in vitro transformation data. 
HPV-16 transformed human cells were not tumorigenic although 
exhibiting anchorage independent growth and aneuploidy 1'70
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Human ectocervical cells transformed by HPV-16 or 18 were 
immortalised but were not tumorigenic 1 In rodent cell
transformation by HPV-16, it is thought that development of the 
full oncogenic phenotype could be a progressive process1 
A similar multistep pathway to full tumorigenicity was noted in 
HSV-2 transformation systems These in vitro studies have
been supported by the work of Schneider-Maunory et al (1987)*-01, 
who have developed a cell line derived from a vulval carcinoma in 
situ. Initial cultures contained high copy episomal HPV-16 DITA 
and were not tumorigenic in mice. At passage 20, amplification 
of a cellular region containing an integrated single copy of HPV- 
16 DFA was noted and these cells were tumorigenic in mice.
It is attractive to propose that Tu 22 cells demonstrate this 
phenotype. However, these cell lines were derived from an '
invasive tumour which has subsequently demonstrated a capacity 
for metastatic spread. As Tu 22 cells were immortalised cells, 
aneuploid and as the subline formed colonies in agar, it was
therefore felt appropriate to define these cultures as 
established cervical cell lines.
6.3 Comparison of properties of Tu 22-1 and 22-2
Both cell lines derived from the same explant culture plate. 
Attempts were made to wean early passage cells from EGF for 
purely fiscal reasons. This was possible at a critical passage 
number and later attempts to grow established Tu 22-1 cells in 
the absence of EGF resulted in the growth patterns seen in Table -■* 
10. The cells were otherwise indistinguishable morphologically. 
They did exhibit interesting differences in their behaviour, in 
their chromosome distribution and in the secretion of £-HCG sub­
unit.
The EGF independent sub-line produced small colonies from single 
cell suspensions in agar. Repeated attempts with Tu 22-1, even 
at late passage and at high seeding densities, failed. The 
Inability of Tu 22-1 cells to form colonies in agar and tumours 
in athymic mice could be related to its EGF dependence. However,
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EGF, in cervical cultures, has been shown to increase plating 
efficiency and to result in increases in colony size 
Continued supplies of EGF were required to maintain the ability 
of this line to subculture although cell replication could occur 
in its absence. This difference in the 2 lines might be of value 
in the investigation of the role of EGF in the growth of cervical 
cells and tumours.
The karyotypic differences were inversely related to the degree 
of differentiation of the 2 lines. The EGF independent Tu 22-2 
cells had a much tighter chromosome distribution at late passage 
compared with the parent line which retained a wide scatter of 
chromosome number. Both lines exhibited a tighter chromosome 
distribution than other recent cell lines 
The quantitative difference in £-HCG production demonstrated 
could reflect subtle changes in the cells of each line. This 
difference was not due to the presence of EGF as it was not 
abolished by growth in EGF of Tu 22-2 cells. A similar range of 
production was seen in both EGF independent cell lines, Tu 22-2 
and Tu 31. The coding sequences for £-HCG are located on 
chromosome 16 but there were no dosage differences in this 
chromosome between the 2 lines. A number of other cervical cell 
lines have been reported as producing £-HCG 387-39°. Patillo 
et al (1977) 3<3'7 demonstrated the presence of £-HCG in the serum 
of the patient, Nozawa et al (1983) 330 also demonstrated the 
presence of SP-1 in the SKG-IIIa cell line (a passible 
adenocarcinoma cell line). Bo evidence of SP-1, CEA or AFP 
secretion was detectable in the Tu 22 cell lines. The 
differential production of fl-HCG in cell lines derived from the 
same tumour might allow examination of this hormone in cervical 
cancer.
6.4 Properties of the vulval cell line Tu 31
The cell line Tu 31 was derived from a well differentiated 
squamous cancer of the vulva. Cell selection occurred at two 
levels. Cells were initially passed through an athymic nude
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mouse. Intraperitoneal injection was performed as the primary 
tumour appeared infected at the time of surgery, confirmed by 
gross Pseudomonas contamination of the primary explant cultures 
within 48 hours. Ascitic fluid from the animal provided the 
first source of cells, but secondary selection occurred by 
replating epithelial cells growing in suspension. The 
characteristics of the Tu 31 cells could reflect this selection 
process.
The parent tumour itself behaved in an atypical manner.
Normally, the prognosis for a locally invasive node negative 
tumour would be expected to be excellent. This patient died of 
recurrent disease within 12 months. The LT-2 vulval cell line 
3S>A derived from a groin node secondary deposit. Although the 
tumour was more advanced clinically than that presented here, and 
treatment was by radiotherapy, the patient died within 15 months 
of presentation. Bo details of the clinical course of the tumour 
from which the A431 line derived, other than age (85 years),
were available. Results from cell lines derived from tumours 
whose biological behaviour is at the poor prognostic end of the 
clinical spectrum might not be representative of that tumour, and 
extrapolation of results to clinical practice might not 
necessarily be valid.
The Tu 31 cell line exhibited all the characteristics of a fully 
oncogenic continuous cell line. The cells were rapidly growing 
(doubling time = 20 hours), aneuploid cells which showed 
anchorage independent growth and were tumorigenic in athymic 
mice. Morphologically they retained an epithelial appearance 
although the electron microscopic characteristics of squamous 
epithelial cells have been lost. This could be a reflection of 
the complex selection process, in particular the selection of 
cells capable of viability in suspension.
The karyotype of this cell line again exhibited a tighter 
chromosome distribution than other vulval lines . Oncofetal 
products produced were similar to the EGF independent Tu 22 2 
cell line. LT-2 cells also produced significant quantities of £-
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HCG 3S*A and produced CEA in early passage. Early passage Tu 31 
cells have not been examined for CEA production.
Tu 31 represents a new continuous cell line derived from a 
squamous carcinoma of the vulva.
131
CHAPTER 5
IBTERACTIQH OF VIRAL AJD EHVIRQFMESTAL FACTORS IJT THE 
PROGRESSIOR OF GERITAL ¥ART VIRUS IffFECTIQF TQ 
CERYICAL IRTRA-EPITHELIAL BEOPLASIA 
Section 1 : Introduction
The evidence implicating human papillomavirus in cervical 
carcinogenesis, described in Chapter 1, does not answer the 
question of what may influence the development of cervical intra- 
epithelial neoplasia in some women with genital wart virus 
infection but not in others.
The reported incidence of overt genital (mainly vulval) warts 
increased dramatically in recent years (PHLS 1986) and although 
the incidence of cervical pre-malignant disease also increased, 
the majority of women with genital warts did not develop CIB. 
Other factors must therefore be involved in cervical HPV 
infection and the progression of such infection to pre-malignant 
disease. The clinical studies were aimed at approaching this 
problem in pre-invasive disease in the same geographical area as 
the invasive cancer studies.
Colposcopic examination of women presenting with genital warts 
revealed that 30% will already have established histological 
evidence of CIS at first assessment A°3 . However the
precise risk to the other 70% who did not have CIB at initial 
screening and which other factors could modify any risk were not 
known. In Walker et al*s study 3 of 22 women,initially
normal, developed colposcopic abnormalities within 6 months, 
although it was not clear whether this was CIB or cervical wart 
infection. Franchesci et al (1983) retrospectively examined
women with genital warts and normal smears. Ten percent of these
132
women, in whom subsequent cervical cytology was available, had an 
abnormal smear at a mean of 3 to 4 years later.
There are clearer data on the subsequent risk of CIB in women 
with established cervical HPV infection. Short follow up studies 
have indicated that colposcopic HPV progressed to CIB within 6 
months in some women ‘ao:3. Longer term studies have now clearly 
established this progression. Mitchell et al (1986) AOJ& 
undertook a 6 year follow up of women with cytological evidence 
of HPV infection only. 13.4% of such women developed CIB, 
confirmed by histology. Syrjanen and colleagues have undertaken 
longitudinal studies of a large group of women with cervical HPV 
infection, histologically confirmed 21 e . These women were 
followed for a mean of 25 months and assessment has involved 
colposcopy, cytology, DBA studies and assessment of HSV and 
chlamydial status. 14.1% progressed, 11.9% to carcinoma-in-situ. 
Sixty percent of lesions persisted in this study. Bevertheless, 
a significant proportion of women with cervical HPV infection 
either did not develop CIB or the viral infection resolved 
without treatment. Extraneous factors influencing these events 
are poorly understood.
zur Hausen (1984) AC,G has proposed synergism between HSV and 
HPV, with HSV being an initiator of the chain of events leading 
to malignant transformation and HPV having a promotor role. As 
discussed in the introduction other viruses^such as CMV, could be 
involved. Potential environmental agents were oral contraceptive 
steroids and cigarette smoking. There was substantial evidence 
suggesting a role for these two factors in cervical cancer and it 
might be that their role was in association with HPV.
Viral type itself could be an important factor. It has been 
conventionally accepted that HPV-16/18 represented a high risk 
viral group in comparison to HPV-6/11 and there was evidence that 
lesions containing HPV-16 were more likely to progress *<>.*. 2 1  
The relationship between HPV and cervical cancer is therefore 
likely to be complex. At any stage other factors, such as local 
immunity, hormonal milieu, other viral infection or other 
carcinogens may accelerate or reverse the progression. If
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factors are identifiable which allow clinicians to determine 
which women are at significant risk of CIB following viral 
infection of the vulva or cervix then this will allow a more 
rational approach to screening, treatment or immunisation.
As the previous studies had identified that both cervical and 
vulval invasive disease contained a high prevalence of HPV-16 in 
our geographical area and an invasive model system has been 
evolved for both these tumours, it seemed appropriate to examine 
groups of women with papillomavirus infection and pre-invasive 
disease. Others s:os later have indicated that CIB lesions of 
all grades in this area contain a very high proportion of HPV-16 
and 18.
Clinical studies were designed to compare the occurrence of 
known associated factors in women with vulval HPV infection, 
cervical HPV infection and CIB. The first study examined cross 
sectional data to elucidate differences in associated cofactors 
in women with normal cervices, cervical HPV infection and CIB.
It was felt that this might determine which of these factors were 
important in influencing the progression from cervical HPV 
infection to CIB. In the second study women with vulval warts 
with colposcopically normal cervices were studied prospectively 
to determine factors influencing progression of disease after 
primary treatment for clinical warts and to identify differences 
between women with existing CIB at initial assessment and those 
without. These studies could firstly establish whether there was 
any clinical evidence of potential interaction between HPV and 
other factors and secondly at which stage in the progression 
these factors operated.
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Section 2 : Study methods
2.1 Cross sectional study
Criteria for entry
Vomen referred to the Colposcopy Clinic, Western Infirmary, 
Glasgow for assessment of abnormal cervical cytology were 
eligible for inclusion into the study groups. Cervical cytology 
was classified as normal, suspicious, or malignant only and was 
not expressed in classes nor was there any attempt to correlate 
the cytology with possible histology. Vomen with suspicious 
cervical cytology would include those with histological mild 
inflammatory atypia through to CIB 3.
Data on age, parity, socio-economic class, current contraceptive 
usage, and current smoking habit were obtained.
Microbiological data
Bacteriology swabs were obtained from the urethra, posterior 
vaginal fornix and endocervix. These were transported in 
Stuart's medium (Oxoid) to the laboratory and plated onto blood 
agar (aerobic and anaerobic), sensitivity blood agar, MacConkey 
agar, Thayer and Martin medium and Robertson's meat broth fluid 
medium, with subculturing if necessary. Endocervical swabs were 
obtained for chlamydial culture. These were transported in 2 SP 
medium and inoculated into monolayer culture of McCoy cells 
without prior feeding as described by Harper (Harper et al 1982) 
Lugol's iodine was used to stain the cultures 3 days after 
inoculation. Endocervical swabs were taken for isolation of 
herpes simplex virus. These were transported in BHK 21 medium 
(Gibco Europe Ltd) and cultured in BHK C13 cells in transport 
medium supplemented by 10% fetal calf serum. Cultures were 
examined for the typical cytopathic plaques of HSV types 1 or 2.
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A diagnosis of infection with Trichomona vaginalis was made by 
direct visualisation on cervical cytology.
Venous blood was withdrawn for estimation of complement fixing 
antibodies to CMV and HSV and for estimation of antibodies to C, 
trachomatis. Chlamydial antibodies were estimated using the 
method of Thomas '*°IS.
Colposcopic assessment
All women were assessed colposcopically, Vith the patient in 
the lithotomy position, the cervix was visualised with a Cusco's 
speculum. A cervical smear was taken using an Ayre's spatula and 
spread and fixed immediately. The cervix and upper vagina were 
inspected directly. Five percent acetic acid was then applied to 
the cervix and the cervix again inspected. Colposcopically 
abnormal areas were directly biopsied using Eppendorf biopsy 
forceps. Vomen with unsatifactory colposcopy or suspicious 
findings underwent knife cone biopsy of the cervix at another 
time.
Study groups
From the referral population, three groups were delineated based 
on the histological diagnosis:
Group la 116 women with histological evidence of CIB alone,
Group lb 84 women with evidence of CIB and HPV infection,
Group 2 36 women with histological evidence of HPV
infection alone.
Histological criteria for HPV infection were based on those of 
Dyson et al (1984>AO£*. Diagnosis and grading of CIB was based 
on the criteria of Buckley et al (1982) -*10.
Control group
A group of women with normal cervical cytology were recruited 
from gynaecological inpatients and outpatients over the same time
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period. These women had normal cervical smears, no history of 
previous treatment to the cervix and were undergoing treatment or 
investigation for non-malignant disease. One hundred women were 
recruited, matched as a group for age, parity, social class, and 
current genital infection rate with C.trachomatis and T.vaginalis 
with women with CIB. Twenty-four of these women consented to 
undergo colposcopic examination. All were normal.
Vomen with histologically proven CIB and some women with HPV 
infection alone underwent local ablative treatment of the 
cervical transformation zone when appropriate with the carbon 
dioxide laser and were reviewed colposcopically at 4 and 12 
months.
2.2 Prospective study
Criteria for entry
Fifty-nine women with overt vulval warts referred from 
Gynaecology, Dermatology, and Genito-urinary Medicine clinics for 
assessment and treatment of their warts, agreed to participate in 
a prospective study into the natural history of wart infection 
after treatment. They gave fully informed consent to colposcopic 
examination and to cervical punch biopsy.
A full history was obtained to include data on age, parity, 
marital status, contraceptive practice, smoking habit, age at 
first coitus, and number of sexual partners.
Colposcopic examination
All women underwent colposcopic examination, A cervical smear 
was obtained under direct vision using a modified Ayre's spatula 
and immediately fixed. The cervix was visualised and any overt 
papillomata on the cervix or vagina noted. Three percent acetic 
acid was then applied to the cervix and upper vagina. If a
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colposcopic abnormality was visualised, then a directed biopsy 
was taken using Epppendorf biopsy forceps. If no colposcopic 
lesion was visible, then 2 biopsies were taken from the centre of 
the cervical transform! ation zone on the upper and lower cervical 
lip.
The vulva was inspected to assess the extent of the overt warts. 
Representative papillomata were removed by avulsion or excision 
after injection of local anaesthetic agent (1% plain lignocaine). 
This tissue was snap frozen in liquid nitrogen after appropriate 
labelling.
Treatment and follow up
All women were offered treatment of the warts with podophyllin 
solution, Efudex (5-fluoro-uracil) cream, or electro-diathermy 
under general anaesthesia if necessary. The cervix of women with 
histological evidence of CIB or cervical HPV infection
was, in addition, treated by local ablation using the Semm Cold 
Coagulator ‘al1 . All women with cervical histological 
abnormality were followed annually at the Cervix clinic,
BinewelIs Hospital and underwent repeat colposcopy at that visit, 
Vomen with normal findings were advised about seeking 
examination of their regular partners, and about barrier 
contraception if their partners were unwilling to seek medical 
advice. They were invited to attend for a repeat assessment at 1 
and 2 years.
2.3 Viral DBA analysis
DBA was extracted from snap frozen vulval wart tissue as 
described in chapter 2 except that high volume lysis buffer (30 
ml. per sample) was used, digestion times were up to 24 hours and 
the RBAse treatment was omitted.
The suspended DBA was sent in a single batch to Dr. D. McCance, 
Dept of Microbiology, United Medical and Dental School, Guy's
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Campus, Guy s Hospital. The DBAs were numbered and the cervical 
histology was not available at the time of DBA analysis.
The DBA was probed for the presence of HPV-6, 11 and 16 using 
the technique described by McCance et al (1983) lso. One-third 
of each sample was digested with the bacterial restriction 
endonuclease Pst 1. The reaction was stopped with edetic acid 
and the DBA fragments precipitated at -70°C with 0. 1 volume 
5mmol/I ammonium acetate and 1 volume of isopropanol. Samples 
were redissolved in loading buffer (10ml TRIS HC1 pH 7.5; lmmol/1 
EDTA; 50% sucrose and bromocresol green ) and run on a horizontal 
0.8% agarose gel in trometamol-acetate buffer (40mmol/l TRIS HC1 
pH 7.5; 5mmol/l sodium acetate; lmmol/1 EDTA) for 16-18 hours at 
1 volt/cm. The gels were washed in 0.5mol/l BaOH and lmol/1 BaCl 
for 1 hour to denature the DBA and then neutralised by washing 
for 1 hour in lmol/1 TRIS, 3 mol/I BaCl. The DBA was then 
transferred to nitrocellulose filters by the method of Southern
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The filters were baked at 80°C under vacuum and then washed for 
2-4 hours at 68°C in 6 x SSC, 0.2% ficoll, 0.2%
polyvinylpyrrolidone, and 0.2% bovine serum albumin. The filters 
were transferred to hybridisation solution containing the above 
and 400pg/ml single stranded salmon sperm DBA, 0.1% SDS and nick 
translated 32P labelled papillomavirus DBA. The method of nick 
translation was that of Rigby 3G1 and was described in chapter 
2. The DBA was labelled to specific activity of 1-3 x 10s cpm/pg 
DBA. The hybridisation was carried out at low stringency (Tm- 
40°C), the filters washed 3 times at room temperature for one 
hour in 0. 1 x SSC, and 0.1% SDS then washed at low stringency and 
again at room temperature before exposure to Fuji X ray film for 
5-7 days. The filter was then washed at high stringency (Tm-10°C) 
and at room temperature and re-exposed.
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2.4 Statistical methods
Continuous variables were compared using Student's t test. 
Numerical groups were compared using a x2 test with Yates 
correction where appropriate. Social class distributions were 
compared using Vilcoxon-Mann-Vhitney non-parametric testing.
Crude relative risks were obtained from odds ratios calculated 
for unmatched case-control studies and the confidence intervals 
calculated using the logit method
Section 3 : Results from cross sectional study
3.1 Characteristics of study and control groups
There were no statistically significant differences in age, 
parity, or social class between the study groups or between the 
study groups and the control group. The data are shown in Table 
16. The relatively low proportion of women with CIB 3 reflected 
the referral pattern to the clinic. Vomen could be referred with 
only one atypical cervical smear.
Bacterial culture results are shown in Table 17. There were no 
differences in Chlamydia or T. vaginalis, the isolation rates 
being as high in cytologically normal women as in the study 
groups with abnormal cervical histology. Herpes simplex virus 
was not isolated from any patient or control. There were some 
minor differences in the bacterial flora isolated in the study 
groups, Vomen with CIB had a higher rate of colonisation with 
Gram-negative entero-bacteria and enterococci than the control 
normal group (all Coliforms/enterococci x2=9’497 p<0.01, CIB 
compared with controls; x2=3.948 p<0.05, CIN+HPV compared with 
controls). Yeasts were not isolated in any case where HPV 
infection of the cervix was present without CIB.
TABLE 16
DEMOGRAPHIC CHARACTERISTICS II CROSS SECTIQIAL STUDY
IORKAL CONTROLS
AGE (YRS) 29.6
S.D. ±8.05
PARITY 1.9
S. D. ±1.6
SOCIAL CLASS 1 3
2 22
3 36
4 13
5 10
6 16
CII 1 
CII 2 
CIV 3
CII OILY CII+HPV HPV OILY
29.8 28.8 29.8
±6.4 ±6.05 ±9.2
1.7 1.8 1.2
±1.6 ±1.6 ±1.6
3 0 0
26 17 5
36 26 10
23 12 13
8 4 1
20 25 7
27 18
50 47
39 19
Social class 6 = never worked, unemployed >3years.
IABLEJLZ.
lOUi/fllQJ in VfJM.
IORKAL COHTROLS CII OILY
■ni<
CII+HPV HPV OILY
Chlamydia trachomatis 10 12(10%) 12(14%) 4(11%)
Herpes simplex virus 0 0 0 0
T. vaginalis 12 10(8%) 4(5%) 1
I.gonococcus 0 0 1 0
Group £ streptococci 2 2 2 0
Streptococci (other) 8 5(4%) 4(5%) 1
Gardnerella vaginalis 2 4(3%) 1 1
Yeasts 11 8(7%) 5(6%) 0
Coliforms 2 11(9%) 5(6%) 5(14%)
Enterococci 6 14(12%) 8(10%) 5(14%)
E. Cali 1 4(3%) 3(4%) 0
Bacteroides sp. 1 2 3(4%) 0
S.albus 2 10(8%) 5(6%) 3(8%)
S. aureus 2 2 1 0
Xixed anaerobes 1 1 2 0
TABLE 18 
SERQPQSITIVITY II STUDY GROUPS
COITRQL IORKAL
ALL HSV POSITIVE 63(63)
(%)
ALL CKV POSITIVE 32(32)
(%)
ALL CHLAKYDIA
POSITIVE (%) 13(13)
HSV OILY 32
CKV OILY 7
CHLAKYDIA OILY 3
HSV+CHV POSITIVE 20
ALL POSITIVE 5
CII OILY CII+HPV HPV OILY
84(72) 63(73) 26(72)
49(42) 36(42) 18(50)
24(21) 18(21) 9(25)
36 28 7
5 5 1
6 4 1
30 20 12
12 11 4
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Evidence of past infection was sought using serology. As up to 
20% of genital isolates may be HSV type 1 4,3 and HSV type 1 is 
capable of morphological transformation, type common antibody to 
HSV was determined. Vomen were scored for the presence or 
absence of significant antibody titres using the normal 'cut-off' 
values for the individual laboratories. A 'positive' HSV titre 
was above 1 in 8, a 'positive' CHV titre above 1 in 8, and a 
'positive' chlamydia titre above 1 in 16. The data are given in 
Table 18. No differences were apparent in past infection with 
HSV or Chlamydia between the study groups or between the study 
groups and the normal group. Previous CHV infection was 
significantly more common in both the HPV only (x2=3.492, p<0.1) 
and total CIN group (x2=5.296, p<0.05) than in the normal 
control group, but there were no significant differences between 
the study groups. The crude relative risk of CIN for previous 
CHV infection was 1.57 (95% C.I. 0.8-2.6).
3.2 Contraception
Contraceptive usage is shown in Table 19. No information was 
obtained for duration of use of contraceptive steroids or type of 
preparation used. Vomen were asked if they had ever used oral 
contraception in the past if they were not current users. There 
were significantly less users of barrier contraception in the 
CIN+HPV group compared with the normal group (x2=6.297, p<0.02) 
although the numbers in each group were small.
A significantly greater proportion of women with CIN were ever 
users of oral contraceptives compared with the normal group 
<X2=7.5, p<0.01, all CIN cf controls; Odds ratio 2.0, 95% C.I. 
1.54-2.60 for CIN for ever pill use). The proportion of ever 
users in the HPV group was higher than the control group, though 
this did not reach statistical significance. Although the odds 
ratio for HPV infection for ever users was 1.7, the confidence 
interval was 0.76-3.83. It would appear that ever use of oral 
contraceptives imparted an increased risk of CIN. It could also 
impart an increased risk for HPV infection.
TABLE 19
CQITRAGEPTIYE USAGE
COFTROL FORMAL CIM OILY CII+ HPV HPV OILY
BARRIER METHODS 14 10 2 3
IEVER PILL 51 45 33 15
EVER PILL 35 61* 49+ 18
* = p < 0.05 
t = p = 0.02
TABLE 20
PATIEIT CHARACTERISTICS BY PILL USAGE
CII(ALL) COFTROL FORMAL HPV OILY
EVER IEVER EVER IEVER EVER IEVEI
PILL PILL PILL PILL PILL PILL
AGE(±S. D) 27.8 31.8 29.7 30.2 27.8 31.4
±5.6 ±7.0 ±6.8 ± 9.2 ±7.7 ±11.4
PARITY 1.6 2.2 1.4 2.1 0.8 1.5
<±S.D.) ±1.6 ±2.1 ±1.2 ±1.7 ±1.2 ±2.0
CII 1 23 19
2 57 35
3 30 24
HSV +ve 75 59 20 33 13 12
CMV +ve 44 33 16 15 7 10
Chlamydia
+VE 28 14 4 6 4 6
SMOKIIG
FOIE 29 30 18 26 8 3
<10/day 18 7 4 4 5 5
>11/day 63 41 13 21 5 7
Excludes barrier contraceptive users
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Table 20 compares the characteristics of women with CIH,
CIH+HPV, HPV, and the normal group by use of oral contraceptive 
steroids. Vomen using barrier methods were excluded from this 
analysis. Vomen with CIH exposed to oral contraceptive steroids 
tended to be younger (t=4.444, p<0.001> and have had less 
pregnancies (t=2.239, p<0.05) than women who have never used this 
form of contraception. The effect of parity was seen in the 
control group, but the effect of age was not. There was a trend 
in the HPV group but this never achieved any statistical 
relevance. Ho differences in serology, severity of CIH, or 
smoking habit were seen within the histological groups.
The data could suggest that oral contraceptive usage resulted in 
the development of CIH at an earlier age than would occur in the 
absence of such exposure although severity was not affected. The 
increase in parity in the never users could be an age effect, or 
it could be speculated that these women had different sexual 
behaviour, exposing them to other risk factors (e.g. different 
viral types). The lack of any significant difference in 
contraceptive habit between women with CIH and those with 
cervical HPV alone suggested that oral contraceptives did not 
influence the progression from HPV to CIH. If oral 
contraceptives have a role, as suggested here, then it was in the 
transition from normal to abnormal.
3.3 Smoking
Smoking habit is shown in Table 21. There were highly 
significant differences in smoking habit between the normal 
cytology group and all other groups, the normal group having a 
higher proportion of non-smokers. The crude relative risk for 
CIH (all CIH) for smokers was 2.57 (95% C.I. 1.47-4.49). The 
crude relative risk attributable to smoking appeared to be 
relatively constant in both CIH groups and in the HPV alone group 
( 2.51, 2.66, 2.56 respectively for CIH, CIH+HPV, HPV). For CIH, 
the relative risk appeared higher for the heavier smokers (2.75 
compared with 1.97) although the confidence intervals were wide,
TABLE 21
SMDKIIG HABTT
COITROL IOEKAL CII OILY CII+HPV HPV OILY ALL •
IOI-SMOKERS 53 36+ 25** 11* 71
SMOKE < 10/day 11 13 12 11 25
SMOKE>ll/day 36 67 47 14 114
* = p < 0.02 
«  = p < 0.01 
t = p < 0.001
TABLE 22
PATTKTT CHARACTERISTICS BY SMOKTIG HABTT 
IORMAL COFTROL ALL CII HPV OILY
101- <10 >11 101- <10 >11 101- <10 >11
AGE(YRS) 31.2 25.2 26.7 30.9 27.2 29.8 27.4 33.1 26.1
(±S. D. ) ±8.5 ±2.0 ±7.5 ±7.3 ±5.3 ±5.9 ±10.7 ±9.7 ±5.5
PARITY
<±S. D. ) 1.7 2.7 1.7 2.2 2.1 1.8 0.9 2.8 0.5
±1.5 ±2.0 ±1.8 ±2.1 ±2.1 ±1.7 ±1.6 ±2.2 ±0.9
HSV +VE 31 8 25 45 19 81 6 8 11
CHV +VE 15 5 12 25 8 49 2 5 9
Chlanydia
+VE 6 2 5 9 6 26 2 2 6
EVER 17 4 13 28 15 61 8 6 6
PILL
IEVER 36 7 23 33 10 53 3 5 8
PILL
CII 1 16 7 20
2 28 14 55
3 17 4 39
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suSgesting a possible dose effect. This difference was not 
apparent in the group with HPV alone.
Examination of differences between women with CIN and those with 
HPV alone demonstrated a highly significant difference in smoking 
habit between the CII only group and the HPV only group 
<X2=7.275, p<0.02). There seemed to be a similar proportion of 
non-smokers ( 31% cf 30.5% ) in each group but amongst those who 
smoke, women with CIN were heavier smokers than women with HPV 
alone. There were similar differences between the HPV group and 
the CIN+HPV group, although these did not reach statistical 
significance. The general similarities between the two CIN 
groups in all parameters studied suggested that they behaved as a 
homogeneous group. Comparison of the all CIN group with HPV 
confirmed the difference in smoking habit. The odds ratio for 
CIN compared to HPV only for smoking >ll/day was 1.47 <95% C. I. 
0.52-4.12). This could suggest that smoking imparted a risk of 
abnormality, but the severity was dependent on the extent of 
cigarette consumption. Unfortunately, no data were available on 
total life consumption. Smoking could therefore act at two 
separate levels.
A detailed analysis of the smoking groups by histological 
diagnosis is shown in Table 22. Vithin each histological group 
there were few differences. Control women who were non-smokers 
tended to be older compared with those who smoke but there were 
no differences in parity or serology. In particular there were 
no significant differences in pill usage associated with smoking. 
Vithin the CIN group the moderate smoking group were younger than 
both control and heavy smoking groups. There were no other 
differences and no difference in the severity of CIN with 
increasing cigarette consumption. These findings were likely to 
be a statistical aberration. A similar phenomenon was seen with 
parity in the HPV group, the difference in age not achieving 
statistical significance.
This analysis suggested that the differences in smoking habit 
between control and study groups and between CIN and HPV groups 
were independent of other confounding factors in the data set and
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reflected an effect of cigarette smoking in the aetiology of CIN. 
The differences between CIN and HPV groups were particularly 
interesting and could suggest that smoking plays a role in 
promoting the development of CIN once cervical HPV infection is 
established.
Section 4 : Results of prospective study
4.1 Patient characteristics
The patient data are presented in Tables 23 to 25. The women 
were grouped by initial histological diagnosis. Of the 59 women 
referred, 17 already had established histological CIN. Seven 
women had CIN 1, 7 had CIN 2 and 3 had CIN 3. Twelve women had 
histological evidence of cervical HPV infection in addition to 
overt vulval warts. Thirty women had no cytological, colposcopic 
or histological abnormality of the cervix at initial assessment.
Five of the 12 women with cervical HPV infection were reported 
to have normal cervical cytology at the time of diagnosis. Seven 
of the 17 women with CIN, including 2 of the 3 with CIN 3, were 
reported to have normal cervical cytology at initial diagnosis.
Comparison of the 3 histological groups is shown in Table 26. 
There were no differences in age or parity between the groups 
although the women with CIN were slightly younger than both the 
HPV and normal groups. No differences in sexual behaviour were 
demonstrable between the groups.
The majority of women in all groups took oral contraceptive 
steroids. Vomen with an initial diagnosis of CIN used oral 
contraceptives for a significantly shorter time than either the 
HPV group ( t=2.548, p<0.02 ) or the normal group ( t=2.067, 
p<0.05 ). As only 8 of the 59 women however did not have 
exposure to oral contraceptive steroids, the significance of the 
differences in duration of use were difficult to interpret.
TABLE 23
AGE PARITY AGE 1ST NO,PARTNERS
k u i i l m  II i n w i n  n i rin
SMOKING PILL OTHER
,01 HO'
HPV
oc.joriE.nt i
HISTOLOGY
COITUS (PACK (yrs)CONTRA- TYPE
YRS) CEPTION
1. 26 1 + 1 17 <5 1 2 IUCD 6b CIN2 + HPV
2, 21 0+0 17 <5 none 3 - 6d CIN2
3, 18 0+0 16 <5 2,5 - - - CIN1 + HPV
4. 24 0+1 18 <5 4 - - 6d CIN2 + HPV
5, 17 1+0 15 <5 2,25 - - - CIN2
6, 21 0+0 16 <5 none 1 - 6d CIN3
7, 20 1+0 16 >5 4 2 IUCD 11 CIN1 + HPV
8, 19 0+0 18 <5 none 2 - n/s CIN2
9 17 0+0 16 <5 none 1 - - CIN1 + HPV
10, 37 0+0 18 <5 none 2 - 6d CIN1 + HPV
11. 21 0+0 18 <5 none 3 - 6d CIN + HPV
12, 23 3+2 16 <5 7 - IUCD - CIN2
13. 38 1+7 21 <5 none 5 - - CIN + HPV
14, 22 0+1 19 <5 none 3 - - CIN1 + HPV
15, 19 0+1 16 <5 2,25 1 - 6d CIN3
16, 22 1+0 16 <5 3 2 - - CIN3 + HPV
17, 21 0+0 19 <5 none 2 - - CIN2
TABLE 24
CHARACTERISTICS OF WOMEN WITH CERVICAL HPV AT FIRST ASSESSMENT
AGE PARITY A6E 1ST NO,OF SMOKING PILL OTHER HPV 
COITUS PARTNERS (PACK (YRS) CONTRA- TYPE
YRS) CEPTION
18, 23 0+0 18 >5 6 6 - 6d
19, 21 0+0 16 <5 3,75 6 - -
20, 25 0+0 16 <5 7,5 9 - 6d
21, 21 0+0 18 <5 3,75 4 - n/s
22, 21 1 + 1 14 >5 3,75 2 - -
23, 19 0+0 16 <5 2 6 - -
24, 24 0+0 19 <5 none 5 - 6a
25, 28 4+1 18 <5 10 1 Tubal lig, -
26, 33 2+2 18 <5 none - IUCD 6d
27, 26 2+0 18 <5 none 3 IUCD 6d
28, 19 0+0 16 <5 3 2 - -
29, 24 3+0 16 <5 3 2 - 6d
n/s insufficient for DNA extraction
IflfiLE 25
CHARACTERISTICS DF WOMEN WITH NQRHftL CERVIX AT FIRST ASSESSMENT
AGE PARITY AGE 1st
COITUS
NO. OF 
PARTNERS
SMOKING 
(PACK YRS)
PILL
(YRS)
OTHER HPV 
i CONTRA- TYPE 
CEPTION
30, 21 0+0 20 <5 none 2 - 6d
31. 36 3+2 17 >5 6 2 Tubal lig n/s
32, 20 1+0 17 <5 none 1 - -
33. 20 0+0 16 <5 7 6 - -
34. 42 1 + 1 19 <5 40 5 Tubal lig -
35 18 0+0 18 <5 none - - -
36 44 2+0 20 <5 30 2 Tubal lig 6d
37 17 0+0 16 <5 none 2 - 6a
38 37 1+0 18 <5 10 10 - 6d
39 20 0+0 18 <5 3,75 3 - -
40 32 2+0 20 <5 16 6 Barrier 6d
41 19 0+0 17 <5 none 1 Barrier -
42 47 2+0 18 <5 none - - -
43 22 0+1 18 <5 none 5 - -
44 20 0+0 19 <5 none 1 - 6d
45 24 0+0 18 <5 3,75 13 - -
46 21 0+0 18 <5 none 3 - -
47 24 0+0 19 <5 0.6 5 - -
48 20 0+0 18 >5 none 2 - 6d
49 17 0+1 16 <5 1.5 1 - 6d
50 21 0+1 19 <5 none 2 - 6d
51 23 0+0 21 <5 none - Barrier -
52 25 3+0 17 <5 4 1 - -
53 42 3+1 21 <5 10 4 Tubal lig -
54 33 1 + 1 16 <5 none 4 - 6d
55 18 1 + 1 15 <5 none 1 - 6d
56 23 0+0 21 <5 none 2 - -
57 21 1+0 19 <5 none 1 -
58 20 0+0 18 <5 none 2 - 6d
59 20 0+0 17 <5 3 3 - 6d
TABLE 26
DEMOGRAPHIC DATA BY HISTOLOGICAL GROUP
CII SPY IOBXAL
<n=17> <n=12> <n=30>
AGE(TBS)±S.D. 22.7±6.04 23.7±4.0 25.7±9.1
PARITY (±S.D.) 1.1±2.2 1.3±1.8 1.1±1.3
AGE 1ST COITUS 
(±S.D.) 17.1±1.5 16.9±1.5 18.1±1.6
SEXUAL PARTIERS
<5 16 10 28
> 5 1 2 2
DURATIOI PILL
USE(TBS) 1.7±1.4 3.8±2.6 3.0±2.9
SHOEIIG
JCEAI PACK YRS 1.5±2.1 3.6±3.1 4.5±9.3
IOI-SMDKERS 9 3 18
SMOKERS 8 9 12
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The smoking data highlighted the difficulties in defining risk 
in this complex situation. Vomen with CIJT appeared to be the 
least exposed to cigarettes yet had a higher proportion of 
smokers than the normal group. Examination of the control group 
revealed that those who smoked were very heavy smokers. The wide 
range of cigarette consumption resulted in there being no 
statistical difference in the mean pack years consumed between 
the 3 groups. If the data were analysed to give a relative risk 
of cervical abnormality attributable to smoking, then this was 
2.13 although the confidence limits were very large (0,4-6.0).
It was not clear how such data should be interpreted, other than 
with caution. It was more supportive of risk being a function of 
smoking or non-smoking, rather than a dosage related phenomenon.
Bo clear picture emerged on differences between those 
histologically normal or abnormal at initial diagnosis and larger 
numbers would be necessary to unravel these relationships.
4.2 DBA analysis
Sufficient DMA was extracted for analysis in 56 of the 59 
samples. The distribution of viral type is shown in Table 27. 
There were no differences in the proportion of HPV positive 
samples in the different groups. Ho DBA sample had detectable 
HPV-16.
The DBA labelled HPV-6d was a probable variant of HPV-6.
Samples containing this DBA hybridised with HPV-6 DBA under 
stringent conditions. However, the pattern of DBA fragments 
produced after restriction enzyme digestion with the enzyme Pst 1 
differed from the profile of the known HPV-6 subtypes. Figure 51 
demonstrate samples of vulval wart DBA digested with Pst 1 and 
hybridised against HPV-6 under stringent conditions. Lane 3 
showed the typical pattern of HPV-6a. Lanes 2, 4, and 5 
contained no hybridisable sequences. Lanes 1 and 6 demonstrated 
another pattern not corresponding with any known pattern of HPV-6 
subtypes. This particular pattern was noted in a large number of 
samples.
1 2 3 4 5 6
3.8
1.7 
1.4
1.0
&. (
FIGURE 51
PstI digest of vulval wart DIAs probed with HPV-6 under stringent 
conditions.
Lanes 1 to 6 represent DHAs extracted from 6 different wart 
samples. Size markers are shown on the left.
Ho hybridisation with samples 2, 4 and 5 is seen. The sample in 
lane 3 shows a pattern consistent with the presence of HPV-6a,
The samples in lanes 1 and 6 show a different pattern, not 
consistent with known HPV-6 types. This pattern has been 
labelled HPV-Dundee and was seen in other samples.
TABLE 27
DEIBCTIQI QF VIRAL DIA - TYPE BY 1IITIAL HISTOLOGY
HPV-6a
CII
0
HPV
1
IORIAL
1
HPV-6b 1 0 0
HPV-6d 6 5 12
HPV-11 1 0 0
HPV-16 0 0 0
HO DETECTABLE DIA 8 5 16
IISUFFICIEIT DIA 1 1 1
HPV~6d see text
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It is possible that some of these alterations could be due to 
degradation of DNA samples, as extraction from wart tissue was on 
occasions difficult with long digestion periods. However, this 
could not account for the consistent pattern seen in lanes 1 and 
6 of figure 51, and which was found in other samples. It was 
felt that this was likely to be a geographical variant of HPV-6 
(HPV-6 Dundee).
4.3 Follow up studies
All women diagnosed as having histological evidence of CIN, 
whatever the grade, were treated by local ablative therapy using 
the Semm cold coagulator. They were seen annually thereafter.
One woman treated for CIN 1 was found to have CIN 3 at 1 year
follow up and was re-treated. She was normal at further follow
up.
Of the 12 women with cervical HPV at first visit, 8 were seen at 
1 year. Six were normal, 1 had persistent cervical HPV and 1 
woman had an abnormal cervical smear but no colposcopic 
abnormality. Of these 8 women, 4 were seen at 2 years. In 
addition 2 who did not attend at 1 year, attended at 2 years.
Two women did not attend for any follow up. Of the 6 women seen
at 2 years, 2 had developed CIN 1 and the woman with abnormal
cytology had a persistently abnormal smear but again normal 
colposcopy.
In the normal group, 18 attended for 1 year follow up. One had 
developed CIN 1 and 1 cervical HPV. Ten of the 18 were seen at 2 
years and 4 women who had not attended at 1 year attended at 2 
years. Of this group, 1 had developed CIN 1 and 1 CIN 3. One 
other woman had abnormal cytology but normal colposcopy. Full 
data on follow up is shown in figure 52. In all 8 women received 
no follow up at 1 or 2 years.
Thus 3 women with initially normal cervices who had treatment 
for vulval warts developed CIN within 2 years of presentation.
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Follow up of women with vulval warts
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Section 5 : Discussion of methodological problem
5.1 Cross-sectional study
The major methodological problem in the first study was the lack 
of detailed data on sexual variables. As discussed in Chapter 1, 
controlling for differences in sexual behaviour could 
dramatically alter the conclusions of any study on the aetiology 
of cervical cancer.
The decision not to collect this data was a conscious one. Data 
were being obtained from women attending for investigation for 
abnormal cervical cytology. The normal management protocols were 
in operation. Sequential visits for diagnosis, treatment and 
review were required, to ensure optimal management. Such a 
clinic therefore relied heavily on patient trust in the 
clinician. It was felt that potentially embarassing questioning 
on aspects of sexual behaviour might result in poor compliance 
with follow up. For this reason it was elected not to collect 
this type of data.
It was felt that indirect evidence of sexual behaviour could, in 
part, be obtained by bacteriology and viral serology. Exposure 
to chlamydia has been suggested as a potent indirect method of 
assessing sexual behaviour Positive virological assessment
of 2 sexually transmissible viruses could add to this indirect 
assessment.
No substantive differences in bacteriological flora isolation 
rates were demonstrated be tween the CIN and control groups.
Although no differences in prior infection with HSV or chlamydia 
were demonstred statistically, the prior infection rates with 
chlamydia in the study groups (25% for HPV only, 21% for all CIN) 
were sufficiently different from the control population (13%) to 
urge caution in comparing the study with the control group in the 
field of sexual behaviour. This caution was reinforced by the 
findings for CMV exposure.
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The data proposing a role for this virus in cervical cancer were 
discussed in chapter 1. Although the data from this study- 
suggested a relative risk of 1,57 for CIN in women exposed to 
CMV, the confidence interval was large. The finding could be 
spurious. The rate of seropositivity for the control group was 
lower than expected. Using ELISA assays, Hart et al 233 found 
seropositivity rates of 51 - 67% in the age range 18 - 41 years. 
The comparable findings using complement fixing antibody were 58% 
in a large series of pregnant women**1 **, using a similar 1 in 8 
titre cut-off value. The mean ages of women in these two 
studies were comparable. There was no clear explanation for the 
low values obtained in this study, but it did cast some doubt on 
the 'normality1 of the control group.
Validating the 'normality' of this group was a major problem. 
Cytological and colposcopic normality did not necessarily equate 
with absence of intraepithelial neoplasia of HPV infection 
histologically. Biopsy was not performed, although in the 
prospective study 30 colposcopically and cytologically normal 
women were biopsied; none having CIN or HPV on histology. Others 
have described similar negative results in larger patient 
groups203 although Cox et al 3SS found that 6 of 17 
cytologically and colposcopically normal cervices had histlogical 
CIN at biopsy. There must therefore remain some uncertainty 
regarding the absence of pathology from the control group.
There was less reservation in interpreting differences between 
the CIN and HPV groups. Although the same difficulties arose 
with the lack of sexual parameters, it was likely that these 
groups were comparable. Bacterial isolation rates and prior 
exposure rates were comparable between these two groups. Others 
**1S have established that women with cervical HPV infection 
without established CIN were indistinguishable from those with 
CIN in terms of sexual behaviour, therefore comparisons between 
these groups in the cross-sectional data were valid.
The problems of appropriate serological assessment of prior HSV 
infection in women with cervical cancer have been discussed. In 
this study complement fixing antibodies to HSV were measured.
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This method did not distinguish between HSV-1 and HSV-2 
infection. Therefore considering the high background rate of 
HSV-1 infection in local populations (88%), even a study of this 
size might not necessarily show a significant difference. There 
was justification for such an approach. Early reports ^ 1 
suggested that genital infection with HSV-1 was rare and that 
methods which differentiated the 2 viral types would distinguish 
genital from oro-facial infection. Data from Edinburgh A13, 
geographically close to the area from which our patients were 
drawn, suggested a rate of up to 40% for genital HSV-1 infection. 
It was felt unjustified to limit serology to one viral type.
The data were cross-sectional. This limited the interpretation 
of both pill and smoking data as no data were collected on 
duration of use or extent of exposure. This was a major flaw but 
the published literature was not consistent on the effect of 
either of these two variables. Duration of pill use was 
consistently reported as a factor =:i=*o .=><=»i . , =><=».* .^e
threshold duration at which the risk becomes significant varied. 
For smoking, the early studies 233»303•3oe suggested a dosage 
effect. Of the 2 major recent studies, Lyon et al (1983)303 
were unable to demonstrate any dosage effect whereas Trevathan et 
al (1983)303 did demonstrate a linear response. There were wide 
variations in the actual relationship between dosage and relative 
risk. The precise relationships of prolonged low exposure and 
short high exposure have not been adequately studied. In this 
study it was elected to differentiate current smoking behaviour 
on the arbitrary basis of heaviness of current smoking habit 
rather than on averaged pack years. Further difficulties in 
interpreting average smoking and pill exposure are discussed 
below.
5.2 Prospective study
The major problems with this study related to study size. 
Patients were self selected on the basis of initially referring 
for treatment of their lesions and secondary self selection then
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ensued on the basis of consent to colposcopy and biopsy.
Although 59 women were recruited to the study, this reflected 
only a small proportion of women attending the various clinics 
with genital warts. Colposcopy was an invasive procedure and 
recruitment was difficult. The sample size made any statistical 
comparisons difficult and follow up data were confounded by the 
high drop out rate. This loss was to be expected in the study of 
sexually transmissible disease.
In contrast to the first study, it was felt justifiable in women 
presenting with genital warts to ask specific questions regarding 
sexual behaviour as advice regarding sexual behaviour and 
treatment of partner were offered. Data on duration of pill use 
and total cigarette exposure were also collected in this study. 
There were thus more detailed data in this smaller study. The 
data demonstrated no differences in sexual behaviour in the 
different histological groupings.
Another criticism was the lack of DNA analysis of the cervical 
tissue. It could be argued that DNA analysis of vulval warts did 
not necessarily correlate with DFA type in the cervix. This 
detracted from the major aims of the study which were to 
determine the differences between women with vulval warts who had 
cervical disease and to follow the course of those women who did 
not have cervical disease at presentation. The study had a 
practical aim, that of determining whether there were any 
criteria by which a clinical decision on the management of women 
with vulval warts could be individualised rather than the blanket 
approach suggested by Singer et al (1985) A1G. There were data 
from a number of studies which have looked at DNA types within 
individuals to suggest that the viral type in the external 
genital region would be that found in the cervix 1 3 1  * 3 & 0
It was felt that viral typing of the vulval lesions would reflect 
viral type on the cervix. The role of viral types will be 
discussed more fully in chapter 6 .
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Section 6 : Risk to women with treated vulval warts.
The second study confirmed the risk of CIN in women presenting 
with vulval warts and reinforced the argument for screening these 
women at presentation. The mode of screening is controversial.
To screen all women presenting with vulval warts by colposcopy 
would require considerable resource input for clinics in genito­
urinary medicine. Logistically it would be easier to screen all 
by cervical cytology. However this study demonstrated a 
substantial false negative rate in women having smears of known 
abnormality under colposcopic control. Others have voiced 
concern over the false negative rate for cervical cytology and it 
could be argued that in such an obviouly high risk group, 
colposcopy would be more effective. Nevertheless, colposcopy is 
a traumatic experience for women ■*17\ Many of the lesions of 
the cervix will be mild. There has been some recent disquiet4*1 & 
over a blunderbuss approach to mild atypia and CIN 1 4*1G, The 
decision on which screening procedure will ultimately be based on 
local, financial and political factors.
And what of those women treated for vulval warts and who have no 
cervical abnormality at presentation ? There are no guidelines.
In the second study, it was alarming to find that 3 women cured 
of their vulval lesions, given specific advice about partners and 
who were aware of the potential risks, still developed CIN within 
2 years. Even if all non-attenders were assumed to have remained 
normal, 10% of this group developed CIN in a very short time 
span. The numbers were inadequate to draw conclusions on 
particular risk factors which might identify those at particular 
risk. On the basis of such results annual cytological screening, 
similar to that recommended for women with treated CIN, would 
seem appropriate. Larger studies of such women, probably based 
on genito-urinary medicine clinics with colposcopy facilities, 
are urgently required to determine follow up policies.
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CHAPTER 6
DISCUSSION ; THE RQLE ,QF VIRUS Iff  GENITAL CAffCER
Section 1 : The significance of human papillomavirus sequences 
in cervical carcinoma
1.1 Significance of viral type
HPV-16 DNA sequences are almost invariably found in invasive 
squamous cervical cancers (10/14) whereas HPV-18 is present in 
only one tumour. The ubiquity of HPV-16 in this geographical 
region is confirmed by Millan et al (1986) =2°^ , who found 
evidence of HPV-16 DMA in 7 of 16 biopsies from CIN 2/3, 
including 1 case without histological evidence of HPV infection. 
Three biopsies from this group contain HPV-18 DMA.
Subsequently, Murdoch et al (1988) 203 describe the presence of 
HPV-16 DMA in 14 of 21 biopsies of CIN. Only 1 case of CIN in 
these two studies contains HPY-6/11. Histological or 
cytological evidence of HPV infection is present in most of the 
CIN samples in both studies, and Cassidy et al (1988) -A1S* 
describe the presence of HPV antigens in a proportion of CIN 
biopsies with histological evidence of HPV infection. HPV-16 
appears to be predominant in our geographical area in 
premalignant and malignant cervical tissue with little evidence 
of HPV-6/11. HPV-18 is rarely identified in invasive tissue: no 
more frequently than HSV-2 DNA. A significant role for this HPV 
type in our area cannot be substantiated on this data.
Other U.K. studies investigating malignant cervical disease 
show a high prevalence of HPV-16 (ref.225 5/6; ref.201 12/13; 
ref.229 27/42) in squamous cell carcinoma of the cervix. 
Similarly, although McCance et al (1983) 190 initially describe 
a number of cases of CIN with HPV-6 DNA present, other
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studies from different areas of the U.K. 201 *2°3 have 
infrequently identified HPV-6/11 in biopsies from CIN of all 
grades.
In two of these areas 190,201 * a z o  predominant wart virus 
infecting the vulva remained HPV-6.
The HPV types 16 and 18 are associated with malignant change 
and progression from mild to severe premalignant disease appears 
to be more likely if these viral types are present in the 
initial mild lesion =*c>a,:2 i=* Despite the high frequencies of 
high risk viral types, there is no evidence that cervical 
precancer or malignant disease behaves atypically in this 
country. The mortality from cervical cancer is comparable with 
other countries. There do not appear to be differences in age 
or stage at presentation. The cure rates from local ablative 
therapy in premalignant disease are comparable with other 
geographical regions ^ .
Such data raises some questions on the role of particular viral 
types in the genesis of genital neoplasia. It is agreed that 
women with vulval warts are at considerable risk of CIN 
■*oz,ao3 and the data presented in chapter 5 confirms this. 
Vulval warts generally contain HPV-6 or 11 1 9 0 • 19 A »201 • A:zc> 
although HPV type 16 is being increasingly recognised in overt 
condylomata 11 ^  • 131 • 1 99 *2203 * 21 °-212, It is argued that the 
viral type in vulval lesions may not reflect that of the 
cervical lesion or that mixed infections are common. Thus the 
cervix will be more susceptible to the more oncogenic viral 
types. Mixed infection does occur in a proportion of cases 
, rzoe. cervical HPV and in CIN.
There are marked differences in the proportions of the 
different HPV types found in cervical wart virus infection.
HPV-16 is present in up to 40% of cervical HPV infection in the 
area from which the first study groups are drawn 
Other studies looking at DNA types in cervical HPV infection 
indicate that 35 - 63% of these lesions contain HPV-6 or 11 
1 31 . 2 oe. 2 1  e Only in Schneider's study 20G is the frequency 
with which HPV-16 is present in such lesions greater than that
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of HPV-6/11. Studies examining DNA type within individuals with 
cervical and vulval lesions find a 60-90% concordance in viral 
type 131 . xhe majority of non-concordant samples contain 
mixed types. It therefore appears that a DNA type identified in 
vulval wart will be reflected in any pre-malignant lesion higher 
in the lower genital tract.
There is little doubt that HPV-16 and 18 predominate in CIN 3 
i si . zoi , 2 o a , zo-7. zoe. zi a although this is not the case in 
premalignant tissue locally Nevertheless, in many
studies a significant proportion of biopsies from CIN contain 
HPV-6/11 2 0 2 .2 oe, 2 ie including those from women with CIN 3. 
HPV-6/11 has been identified in malignant cervical tissue 
i s»a . i 3©, i S3. A 2 2  Progression and persistence of CIN is more 
likely if the original lesion contains HPV type 16 or 18 
20i* *213 although a significant proportion of HPV-6/11 
containing lesions do progress = ie>,zie,2 is Syrjanen's 
group, who have the longest experience in the follow up of 
cervical HPV infection, emphasise that HPV-6/11 identification 
in mild lesions does not mean that these lesions are to be 
regarded as low risk 21G . Local experience suggests that 
despite the very high prevalence of 'high risk' HPV types in 
both premalignant and invasive tissue, the cure rates and 
recurrence rates are comparable with other clinical centres. 
Follow up of women with invasive disease for up to 4 years does 
not demonstrate any differences in prognosis imparted by the 
presence or absence of viral DNA in tumours (see chapter 2, 
section 4). The significance of 'high risk' types remains 'not 
proven'.
From experimental studies, it was initially felt that HPV-6 or 
11 could not bring about in vitro morphological change, either 
as whole virus or using only the E6/7 ORFs even in the
presence of activated oncogenes. This may be related to 
differences in RNA processing as suggested by Scheidei Gadicke 
et al (1986) 4*2S or differences in behaviour within the lcr 
A 2 e^  However, Kasher and Roma (1988) were able to
transform rodent cells using an HPV-6b variant cloned from an
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invasive vulval cancer. HPV-6 is then capable of in vitro 
transformation.
Even if a proportion of the geographic variation is due to 
interlaboratory variation the inconsistency of these data
and the geographic variation in viral types identified in viral 
infected, pre-malignant and malignant cervical tissue despite 
the relatively consistent biological behaviour argues against a 
specific role for particular viral types in the genesis of 
cervical squamous cancer.
The putative role of viral type is further complicated by 
recent data on adenocarcinoma. Traditionally thought to be 
uncommon, it now appears to be occurring with increasing 
frequency and tumours of mixed squamous and adenomatous
elements are probably underdiagnosed 2;3e\ CIN is associated 
with these lesions ^3°. There is no evidence of any link 
between sexual behaviour or sexually transmissible disease and 
these tumour types. Oestrogens may however be implicated 4*31 as 
may oral contraceptive steroids Jt3:z.
In the study of viral type, only one adenocarcinoma is 
included, and it contains HPV-16 DNA. Others also describe HPV- 
16 in adenocarcinoma However, other groups suggest
that non-squamous tumours contain a higher proportion of HPV-18 
22A.232,233> Tase et al (1987) 2:33, examining a large group 
of non-squamous tumours using in situ hybridisation, demonstrate 
that, of 17 adenocarcinomas containing HPV DNA, only one 
contained HPV-16, the remainder having HPV-18. Of the 16 
adenosquamous tumours positive for HPV DNA, 50% contain HPV-18 
DNA. None of the squamous carcinomas examined by this group 
contained HPV-18 DNA. It therefore seems that histology plays a 
role in the relative frequencies with which HPV types are found.
The presence of HPV DNA in tumours of non-squamous origin 
itself requires explanation. HPV conventionally requires 
differentiating squamous’ cells to allow viral replication 
although vegetative virus may exist in basal layers. Its 
presence in columnar epithelial cells and in cancer subtypes
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thought to have no relationship with sexual transmission raises 
many questions regarding the role of HPV in carcinogenesis and 
in the ability of the virus to infect different tissues. The 
finding of apparently integrated HPV-16 DNA in both endometrial 
adenocarcinomas studied is interesting. Although not confirmed 
in a subsequent study by Bergeron et al (1988) de Villiers
et al (1986) did identify HPV DNA in endometrial tissue.
Endometrial adenocarcinoma is not related to sexual behaviour, 
indeed the opposite is true, the tumour being more common in 
nulliparous women. There is no explanation for these findings 
and further work is needed to interpret the significance of HPV 
DNA in non-squamous malignant tissue.
The findings of this study, as in others, that HPV type 16 DNA 
is detectable in a high proportion of invasive cervical tissue, 
does not per se assign an aetiological role for this viral type. 
The weight of evidence, both in vivo and in vitro, is highly 
suggestive of such a role. There are, however, a number of 
epidemiological, biological and molecular biological 
contradictions which require more critical appraisal before a 
definitive causal relationship can be established. There is 
insufficient evidence to attribute higher risk to particular HPV 
DNA types and extreme caution is necessary in predicting the 
clinical course of pre-invasive disease from molecular 
biological data,
1.2 Significance of the state of viral DNA within tumour cells
In contrast to the conflicting studies into the cellular 
localisation of HPV DNA in pre-neoplastic biopsies, it is 
reasonably clear, using combined histology and in situ
hybridisation with tritiated probes » "that HPV
genomes reside in neoplastic cells within invasive tissue 
2 3 3 .3 &r £S discussed earlier, the demonstration of
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concordant HPV DNA in secondary deposits and primary tumour 
biopsies2 0 2 * 2 2 3 * 2 3 2  re-inforces the likelihood that tumour 
cells contain the detected sequences. It remains unclear whether 
the state of the viral DNA itself within the cell is a 
significant factor in oncogenesis.
Vide variation in copy number and DNA pattern are reported by 
all groups studying the prevalence of HPV in genital cancer, It 
is conventionally thought that viral sequences are maintained as 
free episomes in pre-invasive tissue and that integration occurs 
in invasive tissue. Thus as HPV- 6  and 11 are rarely integrated 
into cellular DNA, they represent a lesser risk of malignant 
progression.
This overview is controversial; the statement initially being 
based on the analysis of HPV-16 DNA in 2 mild dysplasias and 2 
bowenoid papuloses of the vulva Invasive tumours contain
only integrated sequences and the original sequences from which 
HPV-16 derives existed as 50% integrated and 50% oligomeric 
sequences. Although some groups confirm the impression that 
HPV-16 sequences exist in episomal form in CIN and integrated in 
invasive cancers 2 0 1  0ther groups are less clear 112.
Others 2 1 3 ' 2 ' 7  detect integration in all grades of pre-invasive 
disease and the presence of episomal DNA in invasive lesions. 
Meanwell et al (1987) 2 2 9  describes the vast majority of 
invasive tumours as containing free episomal DNA whereas Choo et 
al (1987) A3G suggest that all invasive tumours have integrated 
DNA, Smotkin and Vettstein (1986) A 3 2  demonstrated the presence 
of HPV transcripts from a primary tumour and its nodal metastasis 
containing episomal HPV-16 DNA. Local data • -'••-• ° is strongly 
suggestive that both HPV16 and 18 DNA can exist as integrated 
sequences in pre-invasive cervical biopsies.
In this study, hybridisation with HPV-16 under stringent 
conditions using undigested DNA (e.g.Figures 9 and 12) indicates 
that hybrid!sable sequences comigrate with high molecular weight 
cellular DNA. This suggests that HPV DNA is present either in 
concatemeric form or is integrated into host cell DNA. Analysis
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of digested DNAs indicated that many specimens contained unit 
length 8 kb viral DNA of varying copy number (e.g. Figure 10, Tu 
34). It is presumed that as these sequences comigrate with 
cellular D M  in undigested hybridisations, they represent 
integration of tandem full length viral D M  into cell DM. Other 
tumours (e.g. Figure 8 , Tu 24; Figure 49, Tu 27) contain 
additional fragments not colinear with cloned linear HPV-16 DM, 
some of which are larger than intact form III linear viral DM.
It is thought that these sequences represent integrated viral 
sequences at varying locations within cellular DM. High 
molecular weight fragments probably indicate viral D M  and 
associated junction fragments. The copy number in this study 
varied from 1 to over 100 (Tu 28). Only one tumour in this 
series has undergone detailed analysis of a genomic library, the 
vulval carcinoma in situ Tu 28 A 3 Q 4 Viral D M  in this tumour 
appears to be present as a head-to-tail dimer in an episomal 
configuration. Cloned inserts are 16kb, suggesting that exactly 
two genomes are present. Detailed restriction enzyme analysis 
also suggests that there may be a small deletion within the non­
coding region (see Figure 1). This region is known to contain 
the origin of DNA replication and transcriptional control 
sequences.
The presence of complex patterns, not colinear with virion D M  
following restriction endonuclease digestion, in conjunction with 
migration of hybridisation with high molecular weight cellular 
DNA following probing of undigested DNA, does not necessarily 
infer that sequences are integrated into cellular DNA.
It therefore appears that viral DNA sequences can be integrated 
or episomal in both pre-invasive and invasive tumour biopsies, 
and that episomal DNA present in invasive biopsies can be 
transcribed. It seems unlikely, on existing data, that 
integration is a necessary prerequisite of malignant change.
Other papillomaviruses are known to function as autonomous 
episomes within transformed and tumour cells liAS. It may be 
that small defects within these episomes may result in 
alterations in function or expression sufficient to promote
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cellular transformation. The deletion in the lcr of the HPV-16 
episomes detected in Tu 28 may be interesting in this regard. 
Others describe alterations in the lcr in HPV- 6  isolates from 
atypical ly aggressive tumours . 3Ae. *3S, and the HPV-6 b used 
in the transformation of NIH 3T3 cells had insertion 
sequences within the lcr region.
More detail of the precise state of viral DNA is required from 
both malignant and pre-malignant biopsies, It is possible that 
switch on of viral transforming genes could be achieved either by 
integration or by alterations in the lcr region in episomal viral 
DNA. Detailed analysis of invasive lesions with non-integrated 
HPV DNA might clarify this controversial issue.
1.3 Human papillomavirus DNA in histologically normal tissue
The previous discussion suggests that neither the type of HPV 
nor the state of viral DNA within the neoplastic cell are 
necessarily important factors in the genesis of neoplastic change 
in genital cancer. Is then the presence of papillomavirus alone 
in genital tissue necessary for malignant transformation ? To 
address this aspect it is necessary to examine the frequency with 
which HPV DNA is present in neoplastic and appropriately 
controlled non-neoplastic tissue,
HPV-16 sequences were present in one sample from a 
colposcopically and histologically normal cervix. These 
sequences comigrated with high molecular weight cellular DNA in a 
manner similar to that found in tumour DNA.
Such findings are consistent with other early studies
although Boshart et al (1984) 1 did not detect 
viral DNA in 15 normal samples tested. More recent larger 
studies using southern blot hybridisation confirm the impression 
that around 10% of normal cervices harbour detectable HPV DNA 
se qu e nee s ^ ^  The availabilty of filter in situ
hybridisation allows studies of larger populations.
Schneider et al (1985) 200 indicate 2.7/* of normal cervical
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smears as harbouring HPV-16 sequences. With more detailed 
cytological and colposcopic data Toon et al (1986) 2 0 3  describe 
HPV-16 DNA in 9 of 104 normal samples, Other small studies tend 
to show similar findings The largest population study to
date describes HPV DNA in 9% of women with normal cervical
cytology.
The significance of such findings is unclear. DNA positive 
women may represent a high risk sub-group within the normal 
population. Even so, if 9-10% of all women smeared harbour HPV 
genomes, only a small percentage of these will develop CIN, This 
would suggest that other factors may be as important in 
determining progression to malignancy. Long term surveillance of 
these apparently normal women will be required to answer this 
question. Alternatively, the finding of viral genomes in normal 
tissue may simply represent the false positive rate of 
hybridisation techniques. This is an aspect of the 
circumstantial evidence which has not been rigorously tested. In 
many studies, including this study, the numbers of tumours 
available for testing does not warrant statistical testing to 
exclude random chance association. Only the studies of De 
Villiers (1987) 23°and Schneider et al (1985) 2 0 0  lend 
themselves to such analysis.
Few studies of invasive disease systematically attempt to 
compare the frequency of HPV detection in women with invasive 
cervical cancer and normal women in sufficient number to warrant 
statistical comparison. Meanwell et al (1987) ;z:zs> found that 
6 6 % of tumours to contain HPV-16 DNA. 30% of cytological ly, 
colposcopically and histologically normal control samples also 
contained HPV-16 DNA. Statistical analysis suggests that this 
does not represent a significant difference. If the groups are 
corrected for age then there are no differences in the HPV-16 DNA 
detection rates. Such data seriously questions the signifance of 
HPV DNA in cervical cancer tissue. Fuchs et al (1988) 20,r found 
HPV-16 DNA in 9 of 102 normal biopsies, 1 of 33 biopsies of CIN 
1, 12 of 43 biopsies of CIN 2, 64 of 140 biopsies of CIN 3 and 21
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of 44 invasive carcinomas. There is no difference between the 
prevalence of HPV-16 in normal and CIN 1 tissue. There is a 
statistical difference in the prevalence between CIN 2 and normal 
tissue, although the 95% confidence interval of this difference 
includes an odds ratio for infection with HPV-16 of only 1.5.
Much has been made of the poor control for sexual behaviour and 
other demographic variables in epidemiological studies of 
cervical cancer and HSV-2. There are no studies where the 
frequency of detection of HPV DNA in pre-malignant or malignant 
tissue has been compared with that of an appropriately matched 
normal control group. Recent data using the highly sensitive 
polymerase chain reaction to detect HPV sequences in cytological 
specimens from women with CIN and normal women, has suggested 
that 70 to 84% of entirely normal women have detectable HPV-16 
DNA in cervical cells This is at a level which would
argue that HPV was a commensal organism rather than a pathogenic 
virus. If this is confirmed, then the role of HPV will require 
complete re-assessment.
It has always been difficult to recruit appropriate control 
women in studies where matching for sexual behaviour is 
necessary. One alternative is to examine tumour and normal 
tissue within patients. The patient then controls for all 
confounding variables. Few studies examine this approach in 
genital cancer. Lehn et al (1985) 3SG state that non-malignant 
tissue from 2 cervical tumours, positive for HPV-16 DNA, do not 
contain viral sequences. Tsunokawa et al (1986) 3 3 - 7 collected 
internal control tissue for cervical tumours comparable with this 
study. Three tumours contain HPV-16 sequences. One of the 
control samples also contains HPV-16 sequences. The marked 
difference in copy number between tumour and control tissue led 
them to conclude that this might represent contamination. In the 
current study, collection criteria are more rigid, avoiding 
potential contamination. In some instances, internal control 
tissue from tumours having low copy number DNA are positive.
This makes contamination unlikely. In one instance (Tu 27 and
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Co27), ‘the restriction pattern of viral sequences differ. The 
most comparable study is that of Di Luca et al (1986) 2 1 7  who 
examined both cervical and vulval tumours. No details are given 
as to the precise site of the internal control tissue, although 
it appears to have been normal tissue adjacent to the tumour. 
Internal control tissue is available from only 2 cervical tumours 
but from 6  vulval tumours. None have detectable viral DNA,
The data presented in the current study clearly demonstrates 
that although HPV-16 DNA is frequently present in invasive 
cervical and vulval cancer tissue, it is present in normal tissue 
from all but three patients. It can only be concluded that HPV- 
16 DNA is more likely to be present in DNA extracted from any 
tissue in women with cervical or vulval cancer than in women 
without cancer. HPV-16 DNA is detectable as frequently in non- 
malignant tissue as in malignant tissue. An aetiological role 
for HPV-16 in genital cancer is not substantiated by this study. 
Even if all studies of invasive disease where internal control 
tissue is available are grouped together, no statistical 
difference can be demonstrated between the detection rate of HPV- 
16 DNA in malignant and non-malignant tissue in the same women.
The data suggests only that women with lower genital tract 
malignany are more likely to harbour HPV DNA in their tissues 
than unmatched women without such disease.
More information is available from pre-invasive disease as it is 
simpler to collect adjacent normal tissue for comparison.
Ferenczy et al (1985) 2 1 1  demonstrate that recurrence of 
condy1 omata is more likely if viral genomes are detectable in 
histologically normal tissue adjacent to the treatment margins. 
Such DNA is detectable in 45% of 20 cases. These findings raise 
many questions regarding treatment of papillomavirus lesions. 
Follow up of women in this study does not detect any increase in 
tumour recurrence amongst those with viral sequences distal to
the primary tumour.
Nevertheless other groups demonstrate that a high
proportion of histologically normal tissue adjacent to both CIN
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and VIN contain HPV DNA. In neither of these studies are the 
samples strictly paired for comparison. Murdoch et al (1988) 
2°3 , describe paired biopsies from colposcopically normal and 
abnormal areas of the cervix. Although only 15 of the 27 
'control' biopsies are histologically normal, 9 of these contain 
HPV-16 DNA. It is not possible to precisely pair these results 
but HPV-16 DNA is detected in 17 of the 27 colposcopically and 
histologically abnormal tissues.
It therefore appears that viral DNA sequences are as commonly 
found in tissue adjacent to and distal to pre-malignant and 
malignant tissue as in the neoplastic tissue itself. Viral 
infection alone is insufficient to evoke morphological change.
Such changes may require focal breakdown of local immune 
response within a field of viral infection as proposed by Reid et 
al (1987) 131. Abnormalities in local immmune response have 
been noted within pre-invasive cervical disease and
recent data proposes that exposure to cigarette smoking may be an 
aetiological factor in these alterations 3 1  s.
The high frequency with which HPV genomes are detected in 
tissue distal to invasive disease, especially when such tissue is 
thought not to be permissive for papillomavirus infection, is 
however, not explainable by such a hypothesis. The conclusion 
from this study does not support a specific role for HPV-16 in 
invasive genital cancer. It was almost 20 years before 
appropriately controlled sero-epidemiological studies finally 
demonstrated that women with cervical neoplasia were not exposed 
to HSV-2 infection more commonly than normal women 
Appropriately controlled studies of the prevalence of HPV DNA in 
women with pre-invasive and invasive disease and women with 
histologically normal cervices are still awaited some time after 
the initial demonstration of an apparent link between HPV and 
cervical cancer. Experimental data at molecular level, discussed 
further in section 3 , however detailed, does not necessarily 
confer aetiological status to HPV. There is a wealth of 
molecular data on the oncogenicity of HSV in culture systems but
163
it appears unlikely that it is a significant factor in the 
aetiology of cervical cancer.
Section 2 : The significance of human papillomavirus DIA 
sequences in vulval cancer.
80% (8/10) of vulval tumours demonstrate hybridisation to HPV-16 
DNA. Seven of these are invasive squamous cancers, the eighth an 
in-situ cancer. This latter tumour also shows evidence of
hybridisation to HPV-18 DNA. There are no comparable local data
of pre-malignant vulval disease and no other studies of invasive
vulval carcinoma in the U.K. McCance et al (1985) 3SO in their
analysis of 5 cases of multifocal genital neoplasia, describe 
combined infection with both HPV- 6  and 16 in all areas of vulval 
intra-epithelial neoplasia positive for viral DNA. These data 
suggest that HPV-16 is present in high frequency in vulval 
tumours in the U.K.
The data on prevalence of viral type in vulval cancer is more 
varied than that for cervical cancer. European studies 
i i , i , i sc., find HPV-16 DNA infrequently in invasive 
vulval cancer and HPV-18 DNA is absent. HPV-16 DNA is however 
frequently identified in pre-invasive biopsies 2 1 7  * 2 2 0  * sss 
Previously, only Beaudenon et al (1986)22e have reported the 
isolation of HPV-16 DNA in invasive vulval cancer in Europe in 
any frequency (63%). The current study reports the highest 
prevalence of HPV-16 in invasive vulval cancer.
North American studies have given more conflicting results. It 
appears that HPV-16 predominates in pre-invasive disease 
i3 i ,2 ii .2 2 2 f HPV-18 has been rarely identified as the sole 
HPV type in either pre-malignant or malignant tissue except in 
the large study of Kaufman et al (1988) 33e. More importantly, 
HPV- 6  is identified frequently in high grade pre-malignant and in 
invasive tissue i 3 3  • ' 3S2. Variant HPV- 6  DNAs have been
cloned from atypically invasive vulval tumours . ^ 3 3  and
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one of these ■a-2 '7  is capable of oncogenic transformation of 
rodent cells.
Reference has already been made to the state of viral DNA in 
genital cancer. There is little data on this for vulval lesions. 
It appears that hybridisation to vulval tumour DNA migrates with 
total cellular DNA (see Figure 12) in this study, suggesting 
integration. As previously discussed, detailed analysis of the 
in situ cancer, Tu 28, indicates that viral DNA is in episomal 
form.
All internally controlled tissue studied contains HPV sequences. 
Reference has already been made to the frequency with which 
normal tissue adjacent to pre-invasive vulval neoplasia is found 
to contain HPV sequences 1 3 1  ' 2 1  1 * 33e
The same problems in interpretation of the significance of HPV 
DNA sequences elucidated in cervical cancer, namely viral type, 
state of viral DNA, and presence of sequences in internal control 
tissue, apply to vulval cancer. It does appear at least that the 
HPV type commonly associated with vulval warts, can be found with 
reasonable frequency in neoplastic vulval tissue, although this 
is not the finding of this study.
It is attractive to speculate, in light of the finding of 
similar high prevalences of HPV-16 in cervical and vulval cancer 
within one geographical area, of common mechanisms bringing about 
morphological change. Vulval cancer has a different epidemiology
from cervical cancer; it is not thought to be sexually
transmitted, although there are associations with sexually 
transmissible factors (see chapter 1, section 10.1). The 
differing epidemiology and the differing distributions of HPV 
types found in vulval neoplasia advise caution in the 
interpretation and extrapolation of molecular data obtained from 
studies involving cervical carcinoma. The age distribution in 
vulval cancer strongly suggests that other and possibly different
cofactors may act with HPV of varying types to produce
premalignant and malignant change. In one interesting 
experimental model in the rodent Kastomys natalensis,
papillomaviral genomes persist, untranscribed, in various
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tissues. The genome copy number increases with age. Invasive 
tumours of the skin appear with ageing and this correlates with 
the onset of viral transcription. Chronic treatment with tumour 
promoter accelerates this process. Such a system is a close 
model for vulval cancer but must involve different mechanisms to 
those interacting with HPV in the genesis of cervical cancer. It 
may be that HPV is capable of prolonged persistence in vulval 
skin and that varying tumour promoters, possibly including HSV, 
may either activate E6/7 transcription directly or cause 
alterations in the non-coding control region such that cellular 
suppression of viral expression is overcome.
TABLE „2&
HPV IHFQRMATIQH IE CERVICAL CELL LIKES
NAME TYPE CHROMOSOME DNA ARRANGEMENT/ RNA TRANSCRIPTS PROTEIN
SITE INTEGRATION SITE SYNTHESIS
HeLa 18 5,8,9,22
756 18 12
C4-1/II 18 8
M e 180 18
MS751 18
SKG-T 18 
SK6-II
HT-3 none detected 
C33-1 none detected 
CaSki 16 8,12,20
SiHa 16
SKG-III 16
QG-U 16
QG-H 16
Cxl06 16 
Hxl5 1 c 16 
HxlSSc 16 
H x 156c 16 
Hxl60c 16
13
Deletion E2/4/L2 Multiple,E6/7/L1 £6,E64,
El ,E7
Probable genome Multiple,E6/7/L1 E6,E64
E2 integration E!,E7
Deletion E2/4/L2 Multiple,E6/7/L1 E6,E6*
El ,E7
<1 copy per cell None detectable
Deletion E2/4/5/ Single l,5kb
Ll/2
Probable entire Lcr,E6/7,Ll/El
Integration E2/4/5
Tandem repeats 
Entire genome 
Integration E2 
Head to tail, 
IntegrationE2/4 
E2 deleted 
Deletion E2/E4 
E5/L2/E1 
Entire genome 
Integration E2/4/5 
Entire genome 
Integrat ionE4/5/L2
Deletion El/2 
Complex pattern 
Complex pattern
E2,E6/7 +others E4,E6,E7
E6/7+others
Mainly E6
Multiple
Multiple
Multiple,E6/7 
Multiple,E6/7 
Multiple,E6/7 
Multiple,E6/7
E4,E6,E7
E6
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Section 3 : Human papillomaviral sequences in cell lines derived 
from genital cancers.
3.1 Viral DNA in continuous cell lines
Much of the difficulty in establishing the role of HPV in 
genital cancer might be alleviated by examination of the 
interplay between viral sequences and cellular function in model 
systems.
Many of the existing cervical cell lines have been examined for 
the presence of HPV DNA 1 ^ , ass, Table 28 summarises
the main findings. In all, only 2 cell lines, 33-1 and HT-3 3 - 7 1  
do not contain identifiable HPV DNA, although it has been 
suggested 3::ro that C33-1 cell DNA does faintly hybridise with a 
combined HPV-16/18 probe. In these studies, on long exposures 
there is a similar suggestion of faint hybridisation to HPV-16 
(see Figure 50). This cell line may contain an unrelated HPV 
type. Of 19 other cervical carcinoma cell lines, 11 have 
identifiable HPV-16 DNA and 8 HPV-18 DNA. In all cases DNA is 
thought to be integrated into cellular DNA. The quantity of 
viral genomes present in these lines varies from 1 - 2 0 0 0  genome 
copies per diploid cell. The integration pattern of viral DNA 
varies from single copy intact inserts ( e.g.CaSki, ref. 370) to 
multiple insertions on different chromosomes ( e.g.Hela, refs. 
372,446).
Only the A431 vulval cell line has been examined for the 
presence of viral sequences and none were found 371. A 
keratinocyte cell line derived from a bowenoid papulosis, a 
premalignant vulval lesion, which is tumorigenic in nude mice is 
described as containing integrated HPV 16 sequences and these are 
expressed ■a ° 1 . Many of these cell lines are being used 
extensively to determine the function of viral DNA in genital 
malignancy.
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As outlined in chapter 4, there are several potential 
difficulties in the use of existing cell lines and further, 
better defined lines were derived.
Both the derived cervical and vulval cell lines described 
contain DNA homologous to HPV-16 DNA. Tu 22-1 and 22-2 cells 
contain viral DNA in an similar complex pattern with bands at 
molecular weights greater than intact viral DNA, suggesting 
viral-cellular fragments. These cell lines are derived from the 
same biopsy and it is interesting that the pattern of viral 
integration is so similar in each. Two other cell line groups 
are derived from a single biopsy, the C4-1 and 2 lines 3 0 1  and 
the SKG 111a and b lines :33°. The C4 cell lines contain HPV-18 
DNA in an identical pattern and the SKG 111 lines, though 
morphologically quite different, contain HPV-16 DNA in identical 
configuration. Evidence of hybridisation of HPV-16 to DNA 
extracted from the C4-1 cell line is seen (see Figure 50). In 
the main study some cross hybridisation of HPV-16 and 18 occurred 
even under stringent conditions (see figure 13b). This may be the 
explanation in this instance.
The significance of viral DNA in established cell lines requires 
confirmation before data obtained from these are extrapolated to 
intact tumours. No existing cell line has parent tumour tissue 
or normal tissue from that patient for comparison. The cervical 
tumour (Tu 22) contains HPV-16 sequences but unfortunately the 
amount of DNA extracted is insufficient for detailed analysis of 
the integration pattern. However HPV-16 DNA is present only in 
malignant tissue in this case as no detectable viral DNA is 
present in normal tissue from this woman. Expression of viral 
function in the Tu 22 cell lines may be more confidently assumed 
to be related to carcinogenesis than in existing cell lines even 
if of low passage 3°r3.
Viral DNA in the vulval line Tu 31 appears to be as a single 
insert of intact DNA. This configuration differs from that in 
the parent tumour DNA where three molecular weight bands are 
seen. The significance of this difference is unclear.
Matlashewski et al (1987) describes a similar phenomenon in
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3T3 cells transformed by HPV-16 DNA linked to a heterologous 
retroviral promoter. The pattern of viral DNA integration in the 
initial transformed lines and tumours produced by injection of 
these cells into nude mice differs. The cell lines contain 
integrated single original insert DNA plus rearranged viral- 
cellular DNA fragments of varying molecular weights. Tumours 
produced from the cells contain only original single insert DNA. 
However, Morgan et al (1988) 1 in transformation experiments 
with rodent C127 fibroblasts demonstrate similar complexity of 
integration pattern in cell line and tumour DNA. Some type of 
cell selection will have occurred in vitro but it appears that 
selection or rearrangement of viral sequences has also occurred 
during the selection process. Such selection in viral DNA 
configuration may suggest that the analysis of the sites of 
integration and the inferences from the configuration of ORFs in 
cell line DNA may not necessarily be applicable to an in vivo 
tumour and that results so obtained must be regarded with 
caution.
3.2 Integration of viral DNA in cell lines
Detailed restriction fragment analysis of integrated viral DNA 
has suggested that common to all cell lines studied, DNA 
fragments containing the intact open reading frames (ORFs) of the 
E6  and E7 genes, the non-coding long control region (lcr) and 
usually the complete ORF of the LI region are conserved 
372,448-460 This applies to both HPV-16 and 18 containing 
cell lines. In cell lines where the site of integration has been 
determined, disruption of the El, E2 or E4 ORFs is consistently
reported 3 7 0  • 37A * * ° 1 ' •
Similar analysis of intact tumour tissue is less conclusive.
Lehn et al (1985) 3se examined the site of viral integration in 
4 HPV-16 containing tumours. The opening site for viral 
integration was different in all 4 tumours (namely 
El; E4/5;L2;E5), suggesting random integration. Matsukura et al
(1986)3eA cloned viral DNA from a cervical cancer biopsy.
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Restriction fragment analysis demonstrates that cellular DNA 
interupted the viral DNA within the El ORF and that E2,4,5 and 
part of L2 are deleted. Smotkin and Vettstein (1986) x t 3 7  
describe gene expression in a tumour biopsy, but viral DNA is not 
integrated in this tumour. The significance of viral products in 
this case remains unclear. Entire genomic HPV-16 DNA is found in 
a number of tumours AS1, Detailed analysis of 6  tumours 
containing HPV-16 DNA AZ3ie- demonstrates that, although 
integration patterns were all different, 1 1 of 14 integration 
sites lay within the El/2/4/5 ORFs. The E2 region is invariably 
lost. The E6/7 and LCR regions are invariably retained.
No consistency has been demonstrated in the site of integration 
into the cellular genome. Integration of HPV-18 in HeLa cells 
appears to occur in chromosomes 5, 8 , 9, and 22 AJte whereas it 
occurs at a single site on chromosome 12 in SV756 and on 
chromosome 8  in C4-1 cells j^g chromosome location of
HPV-16 in SiHa cells is 13 whereas CaSki cells have
multiple sites on chromosomes 8 , 12 and 20 AS3. Interestingly, 
human fibroblasts with a specific deletion of the short arm of 
chromosome 1 1 , can be transformed to anchorage independence by 
HPV-16 alone, without retroviral promoters This re­
inforces the possibility of gene products from this chromosome 
being involved in genital malignancy as acquisition of a single 
normal copy of chromosome 1 1 is known to suppress the malignant 
phenotype of HeLa/fibroblast hybrids This suggests that at
least one of the cellular control mechanisms may be located on 
this chromosome. Karyotypic analysis of the cervical cell lines 
Tu 22-1 and 2 shows trisomy of this chromosome and the normal 
complement is present in Tu 31 cells. The integration pattern is 
not known.
It therefore appears that random integration into a number of 
chromosomal sites may occur in both HPV—16 and 18 containing cell 
lines. Some of these sites in some cell lines, notably the HPV- 
18 containing HeLa and C4-1 lines, are related to known proto- 
oncogene positions in the genome •AS3. It has been shown that 
there is elevation of c—myc transcription in these cell lines
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compared to those where the integration site is on different 
chromosomes. Overexpression of c-myc in cervical cancer has been 
linked to poorer prognosis although there is no apparent
relationship between c-myc expression and either HPV type or copy 
number in tumour biopsies it is interesting to speculate,
in view of the co-operative effect of proto-oncogenes and HPV in 
transformation experiments, that chromosomal sites of integration 
may not necessarily be as random as they appear.
The relative uniformity of viral integration site, and the 
almost invariable retention of the E6/7 ORFs and lcr does suggest 
that particular configurations may be required to allow 
expression of the E6/7 transforming region or to allow 
alterations in its control by cellular or extraneous factors.
3.3 Viral expression in continuous cell lines
In all cell lines examined except ME180 line, irrespective of 
the type of viral DNA present, RNA is transcribed. Transcipt 
size varies although commonly includes a 1.5kb transcript.
Analysis of RNAs produced has shown that the major transcripts 
derive from the E6 , E7, and LI genes
3 7 2 .3 7 3 , 425, 4 3 7 ,44e, Abo, 4 Bi with E7 transcripts being 
quantitatively greatest. Other ORFs are transcribed in some 
lines. Again data from tumour biopsies is less convincing. Lehn 
et al (1985) 3se detected HPV-16 transcripts in only one of four 
tumours. Smotkin and Vettstein (1986) A 3 7  were able to detect 2 
major transcripts in a cervical cancer recurrence which coded for 
the E2, E6  and E7 ORFs although the transcripts do not co-migrate 
with the transcripts from the CaSki cell line. Takebe et al
(1987) has shown that E6 transcripts are present in cancer
tissue but other regions are transcribed. Tsunokawa et al (1986) 
3 0 7  detected poly-A transcripts in 2 of 4 HPV positive tumours 
although they state that RNA degradation may have been a problem 
in the 2 negative tumours. Di Luca and colleagues could not
detect E6 polypeptide in invasive or preinvasive lesions.
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The major polypeptides coded by the putative transforming region 
have been characterised. Smotkin and Vettstein (1986) 
identified the E7 protein of HPV-16, a cytoplasmic phosphory1ated 
protein of short half-life frequently associated with other 
proteins suggesting a regulatory function. This protein is
detectable by immunoprecipitation from both the CaSki and Si Ha 
cell lines, known to contain HPV-16 sequences, and not from the 
HeLa cell line. These polypeptides are also present in cervical 
biopsy material. The E6 protein of HPV-16 101 is detectable in 
the same two lines and in an HPV-16 transformed line Banks
et al (1987) describe the presence of an HPV-18 specific 16
protein in HeLa cells and of an antigenically distinct HPV-16 
derived E6 protein in SiHa cells. A number of studies have now 
confirmed the presence of E6 and/or E7 in HPV-16 containing cell 
lines 373 * * A63 and the presence of E6 protein in HPV-18 
containing lines 3es• Some other polypeptides have been
identified in some lines 
Despite the similarities in DNA sequence, it is clear that the 
putative transforming proteins of HPV-16 and 18 are different.
It has been suggested that the E6 and E7 proteins of the varying 
papillomaviruses have evolved from a common 33 amino-acid peptide 
by duplication AG-A . Throughout the sequence there are regular 
repeats of a Cys-X-Cys-X-Cys tetrapeptide. This and other 
structural considerations has led these workers to conclude that 
these different proteins may form nucleic-acid binding domains. 
Grossman et al (1988) have subsequently demonstrated that
the E6 protein of HPV-18 is a small lysine-arginime rich 
polypeptide capable of DNA binding. This binding is non-specific 
and they note the poor conservation of this protein in different 
HPV types. It is therefore likely that there nay be a group of 
proteins of similar properties linked to transformation, and this 
may explain the differing ORFs involved in transformation by BPf,
HPV-8, and HPV-16 and 18.
Recent studies have demonstrated that specific inhibition or 
down—regulation of HPV transcription in cancer cells will alter 
cellular growth , Inhibition of transcription of the
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E6/7 ORFs reduces the detectable E7 protein in the HPV-18 
positive C4-1 cell line, using transfection with plasmids 
containing antisense E6/7 RNA, and is associated with a reduction 
in cellular proliferation and clonal growth in agar. This 
suggests a direct effect of a viral protein in driving cell 
proliferation in a long established cell line. Suppression of 
HPV-18 transcription in non-tumorigenic HeLa/keratinocyte hybrids 
using DNA methylation inhibition, results in cessation of 
cellular growth. Similar cessation of growth is seen in 
keratinocytes immortalised by HPV-16. However, no effect of this 
treatment is noted in established SiHa cells or tumorigenic HeLa 
hybrids. There is therefore direct evidence that alterations in 
HPV transforming functions will affect cell growth in genital 
cancer cells.
3.4 Summary of evidence
In summary, examination of existing continuous cell lines has 
shown that virtually all contain HPV DNA sequences. These are 
transcribed and the predominant RNA species appears to be that of 
the E6/E7 region. Polypeptides coded by these sequences have 
been identified in cell lines.
There appears to be consistency regarding the viral break point 
at which sequences are integrated into cellular DNA although the 
site of integration in cellular DNA varies widely. Sequences 
equivalent to the E6/E7 and lcr regions appear to be retained.
Finally, selective alteration in expression of HPV transcripts 
in HPV DNA containing cell lines is associated with alterations 
in cellular growth and cell division. The case for a direct 
aetiological role at the molecular level would seem to be 
watertight.
Nevertheless, there are a number of inconsistencies which make 
such claims currently uncertain.
The proportions of cell lines containing HPV-16 and 18 differ 
substantially from those found in biopsy specimens. As discussed 
previously, HPV-18 is associated more closely with adenocarcinoma
173
of the cervix than with squamous carcinoma and a relationship of 
this tumour type with sexual behaviour sufficient to implicate a 
sexually transmissible virus in its aetiology remains to be 
shown. Conclusions extrapolated from data on HPV-18 containing 
cell lines may not necessarily apply to squamous carcinoma in 
vivo.
Equivalent data from tumour biopsy material is less conclusive 
for integration site, viral break points and viral expression and 
it cannot be assumed that cell line conclusions can be directly 
transferred to a clinical situation.
The atypical biological behaviour of tumours from which cell 
lines are derived (discussed in chapter 4) further restricts the 
confidence with which in vitro results can be translated to in 
vivo.
Much is made of integration site and common break points in 
viral DMA. However there is no consensus that such integration 
is a prerequisite for oncogenic change, as discussed in section 1 
of this chapter. Many invasive lesions contain episomal DMA and 
preinvasive lesions integrated DNA 2 17-22®.437,
Finally, there remains a lack of appropriate control data. The 
studies presented in chapter 4 represent the only attempt to date 
to derive cell lines where the state of viral DNA is known in 
both normal and tumour tissue in the parent individual. Under 
these circumstances the demonstration of different integration 
patterns in Tu 31 cells compared with Tu 27 tumour biopsy serves 
to emphasise the problems in interpretation of cell line data.
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Section 4 . Herpes simplex virus and human cytomegalovirus in 
genital cancer
This study confirms the paucity with which HSV DNA sequences are 
identified in cervical cancer using southern blot methods 
©«=». n s - i  The sequences identified are similar to those 
previously noted as the HindiII a region includes the Bglll n 
sequences. The frequency of such sequences is consistent with 
the larger study of Rotola et al (1986) 1 1 ® who identified the 
Bglll n fragment in 6  of 64 cervical tumours. Subsequently, Di 
Luca et al (1989) ‘ase have described the detection of sequences 
homologous to the Bjlll n or BamHI e region in 29% of invasive 
cervical cancers.
This study is the first to describe the finding of HSV specific 
DNA sequences in vulval cancer 1:zo, again identifying the region 
Hindi 11 a (0.512-0.718). Subsequently, Manservigi et al (1986)
119 have demonstrated the presence of the Bglll n and Bglll o 
(0.38-0.42) regions in 2 of 4 invasive cancers of the vulva.
These two regions appear to be linked within the same cellular 
DNA fragment. This group also detected DNA homologous to Bglll n 
and part of the Bglll o region in one of two vulval dysplasias.
Although rarely found in either malignancy, sequences identified 
consistently correspond to those associated with malignant 
transformation of rodent cells in vitro Viral antigens
encoded within the Bglll o and j regions have been identified in 
a number of genital tumours 1 i os, sse, 3 3 7 -, Where
comparative study of polypeptide expression by HPV and HSV has 
been carried out the ICP10 protein (encoded within the
MTRIII region, 0.42 - 0.58) is identified more frequently than 
either HPV-16 capsid antigen or E6 polypeptide. However, the 38K 
polypeptide identified within the MTRII region, and which 
represents the small subunit of ribonucleotide reductase, has not 
been identified in tumour biopsy material using immunoperoxidase 
staining los, A polypeptide of this molecular weight has been
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immunoprecipitated from the sera of women with cervical cancer 
^°. This polypeptide, however, is not the small subunit 
previously identified. In situ hybridisation detects RNA 
sequences consistent with the Bglll o and j regions in the 
majority of biopsies where hybridisation is detected 
Toe, 109.-i-i i ( Hybridisation to sequences from the Bglll n 
region is infrequently seen and when present is at very low 
levels 1 03.
Transformation of rodent cells in vitro is not associated with 
retention of detectable viral DNA at high copy number and in 
some instances viral DNA is not detectable by DNA-DNA 
hybridisation although intact virus may be recovered by 
superinfection with temperature sensitive mutants 
Nevertheless these transformed cells form invasive and metastatic 
tumours which are fatal to laboratory rodents. Although it is 
attractive to find that a particular virus transforms a normal 
cell, is retained within the transformed cell and is functionally 
required to maintain the transformed phenotype as is the case for 
SV40 and Ad2, such a system is not invariable. The highly 
oncogenic virus adenovirus 12 does not necessarily maintain its 
DNA in tumour cells BPV-4 is required for oncogenic
change in the bovine alimentary tract yet is absent from 
malignant tissue
The development of pre-malignant and malignant change is the 
end result of complex actions and interactions. All cervical and 
vulval cancers are not necessarily the result of infection with a 
single virus family.
The effect of each viral type on different genital sites must be 
different as the epidemiology of the two tumours is markedly 
different. The metaplastic epithelium of the cervical 
transformation zone may be susceptible to malignant change by any 
sexually transmissible virus which is capable of transforming 
cells, Thus although infection with HPV may be the predominant 
event in the majority of tumours, a similar end point could be 
reached by infection by HSV-2 or by HCMV. Although we did not 
identify HPV and HSV DNA within the same tumour biopsy,
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suggesting a role for HSV perhaps in HPV-free tumours, others 
have identified both DNA types within single tumours. 
Similarly in vulval carcinoma in-situ, Kaufman et al (1988) 
demonstrated the presence of putative HSV polypeptide and HPV DNA 
in the same biopsies, although there is no DNA data on HSV 
available.
Serological studies in pre-malignant disease suggest a slight 
risk attributable to previous CMV infection. It is interesting 
that the finding of DNA from the putative transforming region of 
CMV in CIN biopsies reported by Fletcher et al (1986) should
occur in women attending the same colposcopy clinic in which a 
small relative risk of CIN due to previous CMV infection was 
seen. Despite the paucity of support for CMV as an aetiological 
agent in cervical cancer described in chapter 1, section 8.1, a 
role for this virus cannot be excluded within the population 
presented in the current studies.
The possible mechanisms by which herpesviruses may bring about 
oncogenic change are described fully in chapter 1, section 4.2.
The potential effects of herpesvirus infection on cellular 
control mechanisms by way of biological mutagenesis, 
amplification of cellular DNA sequences, and quantitative 
alterations in host protein synthesis may in themselves promote 
oncogenic change, or produce a cellular milieu in which other 
carcinogens, viral or environmental, may finally produce 
uncontrolled cellular proliferation. These effects may differ in 
different epithelial sites.
Although viral nucleic acid is infrequently retained in invasive 
genital cancers, and prospective sero-epidemiological studies 
have shown no association between previous infection with 
herpesvirus and the development of cervical cancer, a place in 
the cascade of events required to transform benign squamous 
epithelial cells into invasive malignancies cannot be excluded. 
Recent molecular biological data ASS and epidemiological data 
demand that it is not excluded from the scene.
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Section 5 : Non viral factors in genital cancer
It is clear that not all women infected by HPV of whatever type 
develop genital cancer. Even at the experimental level, HPV-16 
and 18 alone are insufficient to induce full oncogenic change in 
human cells. Other factors are therefore likely to be of equal 
importance.
5.1 Oral contraceptive usage
Differences in oral contraceptive usage are apparent in the 
cross sectional study. Both CIN groups have a higher proportion 
of ever users than the control group, with the HPV group 
occupying an intermediate position. The relative risk of CIN for 
ever pill users is 2.0 compared with never users. This is 
similar to the risk described by Peritz et al (1977) 230 who 
also used previous genital infection as an indirect assessment of 
sexual behaviour. It is also comparable to the relative risk 
stated by Harris et al (1980) :zs:3, 1.75, for exposure of 5-9 
years and this study controlled for a number of sexual variables. 
No data are available in the cross-sectional study for duration 
of pill use and sexual behaviour has been inferred from indirect 
measures.
Although the proportion of ever users in the HPV group does not 
differ significantly from either the CIN or normal groups, the 
relative risk of cervical HPV for ever users is 1.7. The odds 
ratio comparing pill use and CIN or HPV is virtually unity 
(1.17). Oral contraceptive usage therefore imparts risk of 
histological cervical abnormality, both established CIN and HPV 
infection. The association is not strong given the confidence 
intervals but the lack of difference between HPV and CIN groups 
in the study would argue that these steroids are more likely to 
be involved in promoting or establishing cervical infection with 
HPV rather than affecting the progression from HPV to CIN.
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This speculation is partly supported by examination of the 
age/pill associations. Detailed assessment of pill usage 
demonstrated an age difference between women with either CIN or 
HPV infection who are ever users and those who were never users. 
This age difference does not occur in the control group. There 
are similar differences in parity but this difference also occurs 
in the control group. There are no other differences and in 
particular no differences in the distribution of severity of CIN. 
Histological change occurs in many women never exposed to oral 
contraceptives. It may be that such exposure might allow earlier 
establishment or persistence of HPV in the cervices of young 
women.
With a working hypothesis that oral contraceptive steroids may 
predispose the cervix to HPV infection, the second study, 
analysing in more detail the differences between women with and 
without histological change in the cervix after known exposure to 
external HPV, may be expected to demonstrate marked differences 
in pill usage. The contrary is true. Those women with 
established CIN at first assessment have the least exposure to 
oral contraceptive steroids in terms of mean duration of use.
Even if all women with histological change are combined, there is 
no difference in the mean duration of pill use (3.1 cf 3.0 
years). Precise conclusions from this information are difficult. 
Of the 59 women enrolled into the study, only 8 had never used 
oral contraceptives. These are evenly distributed between the 
three histological groups. Women with abnormal histology are 
significantly younger in this study compared with the initial 
study. Although there is a wide standard deviation in age 
results, there is a 3 year age difference between women with CIN 
and those with a normal cervix at initial examination. Between 
all histological abnormalities and the normal group there is a 2 
year difference (mean 23.8). Thus the mean age at which oral 
contraceptive steroids were commenced may be different in the 
abnormal and normal groups. The small size of the study 
precludes any meaningful conclusion, but such a difference in the 
mean age at start of exposure may be critical. The cervix may be
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more susceptible to the changes brought about by oral 
contraceptives at a younger age. Similar durations of use 
commencing at different ages may result in different changes or 
time course of changes, thus subtly altering the ability of the 
cervix to deal with HPV infection once established.
How such interaction occurs is speculative. Older experimental 
data suggests that oestrogens alone could induce cervical 
changes. Morphological changes induced by oral contraceptive 
steroids may produce a situation conducive to HPV infection.
At the molecular level, there are now some data to support 
interaction between steroid hormones and HPV DNA. The lcr region 
of HPV-16 contains sequences with a large degree of homology to 
the consensus glucocorticoid-responsive element sequence A'3ro. 
These sequences are responsive to dexamethasone. Subsequently, 
Crook et al (1988) A:23 demonstrated that the combination of HPV- 
16, its own promoter region and the activated oncogene, EJ-ras, 
can only achieve oncogenic transformation of primary rodent cells 
in the presence of either dexamethasone or progesterone.
Continued cell growth is possible only in the continued presence 
of these hormones. These results have been confirmed separately 
by Pater et al (1988) who were unable to transform under
similar conditions using HPV-11, which has similar functional 
hormone responsive sequences.
A role for progesterone has not been proposed in cervical cancer 
although Kaminetsky (1966) has suggested that progesterones
can cause the development of cervical tumours in mice pre-treated 
with chemical carcinogens. Most early studies suggest a 
protective effect in experimental animals 2i‘7e. Neither of the 
cervical cell lines described in these studies contain detectable 
progesterone receptors *
Notwithstanding the molecular studies, epidemiological data 
remains unconvincing. Early work is plagued by poor control for 
differences in sexual behaviour between the groups (see ref.285) 
and those studies controlling partly or fully for such variables 
are unable to demonstrate any significant differences 
Recent studies suggest a dosage effect of the pill in
1 8 0
CIN and the most recent analysis of the long term RCGP oral 
contraceptive study supports this hypothesis.
One other possible relationship requires further investigation. 
It appears that adenocarcinoma of the cervix in increasing in 
frequency A23, especially in the younger age groups There
have been suggestions that this is pill related A22. HPV-18 
appears to be more strongly associated with cervical 
adenocarcinoma 12:3:3 and it may be that this viral type interacts 
with these steroids in a predictable fashion.
The analyses presented here serve to demonstrate the 
difficulties in assessing exposure to oral contraceptives, 
although suggesting that its action may be in allowing 
establishment of HPV infection. The relationship between oral 
contraceptive steroids and CIN, if it exists, is likely to be 
complex and mean age at exposure as well as gross exposure may 
need to be taken into consideration.
Further detailed work at both epidemiological and molecular 
level is required to clarify these issues. Epidemiological 
studies must take cogniscence of morphological effects of these 
steroids and the possible effect of exposure by age. Further 
studies into the role of progesterone and oestrogen in the 
modulation of HPV gene function will be required to complement 
those epidemiological studies proposing a role for oral 
contraceptive steroids.
5.2 Cigarette smoking
There are significant differences in the relative proportions of 
non-smokers and smokers in the CIN and HPV groups in the cross- 
sectional data compared with women with normal cervical cytology, 
53% of women with normal cytology are non-smokers compared with 
just over 30% of the other groups. Although there are no 
differences in the proportions of smokers and non-smokers between 
the two main abnormal groups, women with CIN who smoke are 
significantly heavier smokers than those with HPV alone who 
smoke.
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Aon smokers tend to be older than smokers, except within the HPV 
alone group. No differ ences are evident in serology, pill usage 
or severity of CIN between smokers and non-smokers within groups.
The crude relative risk of CIIST attributable to smoking in the 
cross sectional study is 2.57. There is some suggestion of a 
dosage effect, with the risk for heavier smokers being 2.75 and 
for light smokers, 1.97. This order of risk is confirmed in the 
initial data collected during the prospective study, with the 
crude relative risk of abnormal histology in smokers being 2.13 
for women presenting with vulval warts. These data are 
consistent with the relative risk stated by Harris et al 
(1980)233, of 2 for smoking over 15/day. No real difference in 
the relative risk occurred in heavier smokers. In the two other 
important studies, Trevatham et al (1983) 303 indicated a higher 
relative risk, of the order of 2.4-3.6 and did demonstrate a 
dosage effect with the relative risk of carcinoma-in-situ being
2.4 with 1- 4 pack years exposure and 12.7 with 12 or more pack 
years exposure using a logistic regression model. Lyon et al 
(1983) 303 indicated a relative risk of 3 for CIN 3 but could 
not show any dose relationship. All of these studies controlled 
for sexual behaviour and the first two for oral contraceptive 
usage. This study has used indirect indices of sexual behaviour 
to control this aspect.
There are no available data on the relative risk of cervical HPV 
in smokers. This study suggests that smoking is a risk factor 
for cervical HPV without CIN (odds ratio = 2.56) and this is 
comparable with the risk of CIN. The differences in smoking 
habit between the HPV and CIN groups are interesting, with the 
CIN group being heavier smokers, although the relative risk of 
CIN compared with HPV for smokers is only 1.47 (C. I. 0.52-4.12). 
However it suggests that smoking may act at two levels, allowing 
establishment of HPV infection and in the promotion of HPV 
infection to preclinical neoplasia.
These relationships are complex, as indicated by the two methods 
of analysis of the second study. With strict comparison of mean
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exposure, in terms of pack years, women with histological
abnormality at initial assessment are less exposed to cigarettes
than those with a normal cervix. But there is wide variation in
smoking habit in these small numbers with women with normal
cervical findings amongst the heaviest individual smokers.
Comparison of relative risks give the opposite result as a higher
proportion of the abnormal group smoke. It is impossible to
speculate on the differences to the cervix in women smoking 5/day
for 10 years compared to 20/day for 2fc years, both of whom will
have an exposure of 2.5 pack years. All three women who
progressed to CIN were non-smokers.
These studies support the view that it is the presence or
absence of exposure that is critical rather than the level of
exposure. A dosage threshold cannot be ruled out, although if
present it may be at a fairly low level.
The difficulties in unravelling the relationships between the
factors involved in cervical cancer are highlighted in the recent
RCGP update on oral contraceptives and cancer'*-71 . Close
analysis of the data shows that the relative risk of CIN 3
decreases with increasing cigarette consumption in pill users,
from a relative risk of 4.8 in non-smokers to only 1.3 in those
smoking over 15 per day.
It is not surprising that these two factors interact. Smoking
has been associated with oestrogen deficiency states such as
early menopause and osteoporosis and it appears that menstrual
disturbances and impaired fertility are more common in smokers
A:73. There is biochemical evidence that nicotine may increase
2-hydroxylation of circulating oestradiol, resulting in reduced
bio-availability of active oestrogens From this
information, combined with the known concentration of nicotine
and cotidine in cervical mucus from normal and pre-neoplastic
cervices s , si ^  direct interaction at cellular level is
possible. It can be speculated that reduction in the
availability of oestradiol due to smoking may result in
potentiation of the effects of other local hormones such as
progesterone on cells containing HPV, thus linking with molecular
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biological evidence of a role for this hormone in transformation 
experiments.
Cigarette smoking may therefore have three possible modes of 
action. It may interact with sex steroid hormones at a cellular 
level as discussed above, it may be directly carcinogenic as 
suggested by the description of mutagenic cervical mucus 31 or 
as others have proposed, it may alter local immune response.
There is evidence both, that impaired immune response, as occurs 
in immunosuppressed women, results in an increased incidence of 
cervical precancer, and that smoking can induce alterations in 
immune response Nicotine has been shown to result in a
reduction in local immune response if present in high 
concentrations in cervical mucus Local populations of
Langerhans' cells, an antigen presenting cell, are depleted in 
both normal and preneoplastic cervical epithelium in current 
smokers 31 s . Furthermore, these cells appear to be depleted in 
HPV-16 or 18 containing CIN tissue compared with internally 
controlled paired normal tissue Therefore there are
potential mechanisms which may allow infection by, persistence of 
or abberant response to HPV, mediated by cigarette smoking.
How this can result in oncogenic transformation is still 
unknown, but it may provide one step on the pathway. There is 
experimental evidence that tobacco products might alter the 
ability of DNA viruses to undergo normal lytic infection allowing 
persistence of non-replicating virus ■av'G\ This group studied 
the effect of tobacco products on the lytic cycle of HSV-1. 
Addition of nicotine or n-nitrosamines to infective cell cultures 
of HSV-1 results in persistence of the virus in a non-replicating 
form. Inhibition of the normal lytic cycle is a prerequisite of 
cellular transformation by HSV in rodent cell systems. Thus it 
is conceivable that similar effects could be brought about in 
HPV.
There is therefore considerable epidemiological and experimental 
data which might suggest a direct or indirect role for cigarette 
smoking in cervical cancer. The studies presented support such a 
role and suggest that this role, although likely to act at the
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time of cervical HPV infection, could act at two separate points
in the carcinogenic cascade.
Section 6 : Conclusions
6. 1 Summary of results
1. HPV-16 DNA is frequently identified by Southern blot DNA-DNA 
hybridisation in DNA extracted from biopsies of invasive 
carcinoma of the cervix and vulva.
2. Other viral types, HPV-18 and HSV-2, are infrequently 
identified by these techniques in both tumour types.
3. Normal tissue from women with cervical and vulval malignant 
disease frequently contains identifiable HPV-16 DNA.
No significant difference is demonstrable between the 
frequency of this viral type in malignant and non-malignant 
tissue.
4. HPV-16 DNA is identified in DNA extracted from endometrial 
carcinoma biopsies.
5. Immortalised cervical cell lines have been derived from a 
squamous carcinoma of the cervix. HPV-16 sequences are 
present in the original tumour biopsy but not in internally 
matched tissue. Both cell lines contain detectable HPV-16 DNA 
in a similar pattern.
6. A continuous cell line has been derived from a squamous 
carcinoma of the vulva. HPV-16 sequences are present in the 
original tumour biopsy and are present in low copy number and 
in a different pattern in internally matched control tissue. 
The cell line contains HPV-16 DNA as a single insert, a 
different configuration from that seen in the tumour biopsy.
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7. Clinically based studies carried out within the same 
geographical area suggest a role for both oral contraceptive 
steroids and cigarette smoking in the development of pre- 
invasive cervical cancer. Cigarette smoking may confer a risk 
of both pre-invasive disease and cervical HPV infection.
There may be a dosage effect in the progression from cervical 
HPV to cervical intra-epithelial neoplasia. Oral 
contraceptive steroids confer a risk of cervical intra- 
epithelial neoplasia only. There may be a relationship 
between age at exposure to oral contraceptives and risk of 
histological abnormality.
8. A small risk for cervical intra-epithelial neoplasia is 
demonstrable for previous exposure to human CMV but not to HSV,
9. No relationship between the presence of HPV-16 sequences in 
invasive or normal tissue and subsequent prognosis is seen.
No relationship is demonstrable between the presence of 
detectable HPV sequences in genital warts and the presence or 
development of cervical histological abnormality.
10. A novel subtype of HPV-6 is present in the majority of vulval 
warts in the Tayside region of Scotland.
6.2 Does genital virus infection cause malignancy ?
The DNA studies presented do not support a specific role for HPV 
in genital tract malignancy. Although a single HPV type, HPV-16, 
is present in the majority of cancers, it is as likely to be 
present in internally matched control tissue. The presence of 
viral DNA sequences alone does not appear to confer malignant 
potential. The other major HPV type, HPV-18, implicated by 
others in genital malignany, is rarely identified in these 
studies, HSV-2 DNA being as frequently identified.
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The DNA studies emphasise the importance of appropriate control 
tissue in molecular biological studies. Studies which have 
examined internally matched tissue for viral nucleic acid support 
the conclusion of this study, that the presence of viral DNA does 
not alone result in malignant change. Its presence in both 
myometrial and endometrial tissue, as described here, strengthens 
this statement.
If HPV alone does not cause morphological change, then which 
other factors interact with it to bring about such change ? 
Epidemiological evidence implicates bath smoking and oral 
contraceptive steroids and there is now increasing experimental 
evidence of how the effects of these may be mediated. The 
studies here support this view. Nevertheless, caution is 
required in interpreting epidemiological data. There is no clear 
consensus on the importance of duration of contraceptive use or 
amount of smoking. The studies presented here serve to emphasise 
the difficulties in interpreting simple statements of pill years 
and pack years. More attention to the age at which both commence 
is needed and to the precise relationship between duration of 
smoking and numbers consumed daily is needed. It has not really 
been appreciated within the oncological literature that smoking 
has an effect on sex steroid metabolism, and the relationships 
between virus, steroids and smoking may be even more complex than 
predicted.
It is felt that many of these questions and inter-relationships 
can only be examined at cellular or molecular level. Continuous 
cell lines, in which viral DNA has associated with tumour cells 
in vivo, are attractive model systems for examining the role of 
HPV in cancer. Much information has already been derived from 
these studies. Reservations on the usefulness of this data have 
already been discussed and the new cervical cell lines described 
in this study may offer a sounder base for such studies. The new 
vulval cell line will allow similar studies to be carried out for 
vulval cancer.
187
It is also clear that neither the presence of HPV in tissue, 
the viral type, nor integration of viral DNA into cells is 
sufficient to induce oncogenic change in human cervical or vulval 
cells. Data on integration and viral expresssion obtained from 
continuous cell lines may therefore not be relevant to tumours in 
vivo.
Different factors may result in the same end point in different 
populations. HSV may play a role in some tumours or may interact 
with HPV. The studies presented here in conjunction with DNA 
hybridisation data suggest that CHV may have a role within this 
population.
As stated earlier, over a decade passed before appropriate 
epidemiological studies demonstrated that previous exposure to 
herpes simplex virus was not a risk factor in cervical cancer.
It is now essential that studies are undertaken into the 
prevalence of HPV in women with cervical neoplasia and control 
populations matched for those confounding variables known to be 
important in this cancer. The data becoming available from 
sensitive PCR techniques on the prevalence of HPV DNA in normal 
tissue emphasises the need for such studies. Only by this 
approach can both the relative importance of HPV as an 
aetiological factor be assessed, and the molecular mechanisms 
clarified.
Separate studies will be required to examine vulval cancer as 
data obtained in vivo or in vitro cannot be translated between 
two such clinically and epidemiologically diverse cancers.
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